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Abstract 
Chronic neuropathic pain occurring after an operation is a common problem, 
however little data is available describing the nature or prevalence of acute 
neuropathic pain following surgery. In this thesis, I explore the measurement 
scale properties of a commonly used neuropathic pain screening tool, and use 
this tool to describe the prevalence of acute and chronic neuropathic pain 
following thoracic surgery. I also explore how best to diagnose acute 
neuropathic pain with a Delphi survey of expert opinion and confirmatory 
observational cohort study. The results show that the Leeds Assessment of 
Neuropathic Symptoms and Signs (LANSS) neuropathic pain screening tool 
demonstrates acceptable fit to the Rasch measurement model in the chronic 
postoperative pain population, but only has reliability consistent with use at a 
group level. Using this tool, I demonstrate that 8% of thoracic surgery patients 
experience acute neuropathic pain an average of 3 days after surgery, with 
22% developing neuropathic pain by 3 months. Experiencing acute neuropathic 
pain significantly increased the odds of developing chronic neuropathic pain 
(odds ratio 7.7 [95% confidence interval 1.5-39.7]). A Delphi survey of 
specialists identified 9 items considered important in the diagnosis of acute 
neuropathic pain, and suggests that unlike diagnosis in the chronic pain 
population, a poor response to opioid medications was an important indicator of 
neuropathic pain. Preliminary results from a matched cohort study confirm this, 
by demonstrating that verbal descriptors of neuropathic pain are significantly 
more common in patients with poorly controlled postoperative pain despite 
strong opioid use. 
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1 Introduction 
1.1 Acute pain following surgery 
The history of surgery, anaesthesia and pain management are inextricably 
linked together through developments in medicine that have occurred during the 
last two centuries. The discovery in the mid nineteenth century, that the 
sedative gases ether, chloroform and nitrous oxide could relieve the suffering 
associated with surgery and childbirth coincided with a shift away from the 
prevalent philosophy that pain and suffering were inevitable, or that pain was 
inflicted by God to strengthen faith.1 As these advances in medicine facilitated 
the practice of ever more complex surgery, the acceptance that the relief of 
bodily pain was a positive good grew. At the same time as these advances in 
anaesthesia and surgery were occurring, pharmaceutical and technical 
advances meant that the availability of analgesics steadily increased. In the 
early nineteenth century, Morphine was first derived from opium and 
subsequently manufactured by the pharmaceutical company Bayer. The 
development of the hollow syringe in the mid nineteenth century made the 
administration of morphine simple, and it’s potent analgesic properties mean it 
is still the mainstay of postoperative pain relief regimes today.1 Aspirin was 
released in the early twentieth century, and there followed a proliferation of 
analgesic drugs and techniques over the subsequent century. During this time, 
acute postoperative pain management has become increasingly recognized as 
a vital part of modern medical practice. However, despite advances in our 
understanding of the pathophysiology of acute pain, and a burgeoning variety of 
pain management techniques and medications, many people still experience 
significant pain following surgery. One reason why this may be so is explored in 
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this thesis, however first it is necessary to establish some important definitions 
regarding the nature and extent of pain in this context. 
The most prevalent definition of pain results from the International Association 
for the Study of Pain (IASP) workforce on taxonomy 2: 
“An unpleasant sensory or emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage.” 
Traditionally, pain has been sub-classified in a number of ways, for example by 
diagnosis (malignant/non malignant), by timescale (acute/chronic) or by 
mechanism (nociceptive/neuropathic).  
1.1.1 Acute Pain – definitions 
Acute pain has been defined in a number ways, but with common themes that 
include a usually time limited physiological response to an identifiable injury. 
Interestingly, the terms “acute pain” and “chronic pain” do not appear in the 
IASP taxonomy of pain terms, nevertheless these terms are in widespread use 
in both clinical practice and pain research.2 The absence of a consensus 
definition, does however mean that subtle variations in meaning exist 
throughout the literature. The following are common examples of such 
definitions: 
“Pain of recent onset and probable limited duration. It usually has an identifiable 
temporal and causal relationship to injury or disease.” 3 
“The normal, predicted physiological response to an adverse chemical, thermal 
or mechanical stimulus….associated with surgery, trauma and acute illness.” 4  
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“Pain that is present in a surgical patient after a procedure. Such pain may be 
the result of trauma from the procedure or procedure related complications.” 5 
The temporal nature of pain symptoms is also commonly used to distinguish 
acute from chronic pain, with arbitrary chronological markers of between two 
and six months historically used as cut off points for the progression of acute to 
chronic pain.6 There are obvious conceptual issues with defining pain as acute 
one day and chronic the next according to a temporal cut off point, with expert 
opinion acknowledging that pain associated with new tissue injury may last less 
than one month, but at times greater than six months.2 Therefore in recent 
years there has been a move towards describing acute pain according to both 
time and physical pathology, with acute pain tending to last a limited period of 
time, and remitting once the underlying pathology resolves.6  
In the case of postoperative pain therefore, we can conclude that acute pain 
represents the ‘initiation phase’ of a cascade of pathophysiological events 
triggered by tissue injury, which generally resolves as the injury heals, although 
this may take a variable length of time, and in some individuals progress to 
chronic pain even when the underlying surgical insult has resolved.7 As well as 
unpleasant sensory phenomena, pain after surgery is also related to unpleasant 
emotional and mental experiences.8 
1.1.2 Acute pain – epidemiology 
Despite progressive improvements in the understanding and options available 
to treat acute postoperative pain over the last sixty years, the evidence 
suggests that many patients still experience an unacceptable degree of pain 
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after surgery. Table 1.1 outlines the incidence of poorly controlled postoperative 
pain since early studies on this topic were published in the 1950’s.  
Since the development of early acute pain services in the 1980’s there have 
been many national and international attempts to improve postoperative pain 
control. These include attempts to improve assessment (for example by 
highlighting pain as the “fifth vital sign”), treatment (for example by developing 
practice guidelines), and widespread promotion of the deficiencies in acute pain 
management (such as the IASP “Global year against acute pain 2010-2011).5, 9 
Nevertheless, a significant proportion of patients still experience moderate to 
severe pain following their operation, and this has seemingly remained 
unchanged from 1950 through to the present day. The reasons behind such a 
lack of progress are likely to be multifactorial. Proposed causes include under 
measurement of pain, deficiencies in the education and training of healthcare 
workers, poor compliance with guidelines and underuse of effective analgesic 
techniques.10-13  
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Reference Incidence of moderate or severe 
pain or insufficient analgesia (%) 
Papper et al., (1952)14 33 
Lasagna et al., (1954)15 33 
Keeri-Szanto et al., (1972)16 20 
Cronin et al., (1973)17 42 
Banister (1974)18 12-26 
Tammisto (1978)19 24 
Cohen (1980)20 75 
Donovan (1983)21 31 
Owen et al., (1990)22 37 
Apfelbaum et al., (2003)23 70 
Sommer et al., (2008)24 41 
Maier et al., (2010)25 29.6-55 
  
Table 1.1 The incidence of moderate or severe acute postoperative pain or insufficient analgesia 
1950 to 2010 (modified from the ‘Report of the working party on pain after surgery’ 26). 
 
1.2 Neuropathic pain 
Although the classification of pain into ‘acute’ or ‘chronic’ is ubiquitous both in 
pain literature and also clinical practice, over the last two decades a more 
fundamental, mechanism based classification of pain has emerged. This 
‘mechanistic’ approach led to the classification of pain into that related to tissue 
damage (nociceptive pain) or pain related to nervous system injury or 
dysfunction (neuropathic pain).27 
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Neuropathic pain has been formally defined by the International Association for 
the Study of Pain (IASP) as: 
“Pain caused by a lesion or disease of the somatosensory nervous system.”2 
In contrast, nociceptive pain is defined as: 
“Pain that arises from actual or threatened damage to non-neural tissue and is 
due to the activation of nociceptors.”2 
In contrast to neuropathic pain, nociceptive pain implies pain that occurs as a 
result of a normally functioning nervous system. Importantly, although these 
definitions are widely accepted, they do not represent diagnostic criteria. 
Although this mechanistic approach to pain classification is a relatively modern 
construct, there are many historical references to neuropathic pain. One of the 
earliest descriptions of peripheral neuropathic pain depicts symptoms akin to tic 
douloureux in the distribution of the radial nerve as a result of a musket ball 
injury during the Spanish Peninsula War.28 By the 20th century, neuropathic pain 
caused by lesions of the central nervous system was well described, with the 
term ‘central pain’ coined by Behan in 1914.29 For most of the 20th century, pain 
regarded as arising from a damaged or dysfunctional nerve was termed 
’neuralgia’, with the phrase ‘neuropathic pain’ first appearing in the 1980’s. 
Since the first edition of the IASP taxonomy of pain in 1986, the term 
‘neuropathic pain’ has become widespread in both pain research and clinical 
practice.30  
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1.2.1 Neuropathic pain – epidemiology 
Neuropathic pain is a relatively common symptom of a variety of disorders that 
affect both the peripheral and central nervous systems. Table 1.2 shows the 
prevalence of neuropathic pain among individuals with different medical 
problems. 
Condition Neuropathic pain prevalence % 
Diabetes31 11-26 
Cancer32, 33 18-39 
HIV34, 35 35-53 
Back Pain36 37 
Infection37 10-25 
Stroke38 8 
Spinal cord injury39 75 
Multiple Sclerosis40 58 
 
Table 1.2 The reported prevalence of neuropathic pain in specific medical conditions 
 
It is clear from the table that neuropathic pain plays a role in the experience of 
pain symptoms for a wide variety of disparate medical conditions. Importantly, 
neuropathic pain is not only associated with diseases of the nervous system, 
where we would perhaps expect pain to be of a neuropathic nature, but also 
disease processes where a mixed pathology is more likely. For example, 
neuropathic pain is surprisingly prevalent amongst cancer pain patients.32 In a 
recent international study of over 1000 cancer patients 79.7% were given the 
clinical diagnosis of nociceptive pain, and 16.9% considered to have 
neuropathic pain.41 Of note, up to 39% of cancer pain patients may have a dual 
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pain mechanism, both nociceptive and neuropathic, a common feature of other 
conditions such as lower back pain.33, 36 
The prevalence of neuropathic pain in the general chronic pain population is 
approximately 17%, demonstrating that a neuropathic pain component is 
commonly seen amongst chronic pain patients.42 Perhaps more surprising is 
the prevalence of neuropathic pain in the general population, with an estimated 
prevalence of 6-8% when using screening questionnaires.42, 43 
In general, neuropathic pain seems to be associated with particularly poor 
health related quality of life, with mixed neuropathic pain having a similar impact 
on the EQ-5D as NYHA Class IV heart failure.44 Patients also seem to suffer 
greater pain intensity, and report greater impact on daily living compared with 
nociceptive pain.45 Even when controlling for pain intensity, neuropathic pain 
patients seem to suffer more mental and physical health problems, implying that 
the nature, and not simply the intensity of neuropathic pain is contributory.46 
The impact of neuropathic pain on quality of life is in part likely to reflect the 
chronic nature of such pain in many conditions. Although there is a paucity of 
longitudinal data describing the natural history of neuropathic pain, for some 
conditions such as diabetic peripheral neuropathy, symptoms are unlikely to 
improve with time (with 77% continuing to have pain problems 5 years after 
diagnosis in one study).47 In contrast, where the initiating disease or lesion 
resolves, such as post herpetic neuralgia, symptoms may be more likely to 
improve over time.48 
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1.2.2 Neuropathic pain – pharmacological management 
A mechanistic approach to classifying pain is important, as there are differences 
in the approach to managing neuropathic compared to nociceptive pain. In 
terms of pharmacotherapy, traditionally conditions thought to be associated with 
a predominantly nociceptive pain component, such as arthritis, have been 
treated with analgesics such as paracetamol, non-steroidal anti-inflammatory 
drugs (NSAIDS) and weak or strong opioids.49 Similarly, this approach has 
been the cornerstone of analgesic management of cancer pain for over two 
decades following the publication of the WHO analgesic ladder.50 
In contrast, neuropathic pain tends to be managed with entirely different types 
of medications, designed to act as pharmacological modulators of nerve pain. 
The most commonly used classes of drugs for neuropathic pain are the 
antidepressants (including tricyclic antidepressants and serotonin and 
noradrenaline reuptake inhibitors [SNRI]), and the anticonvulsants (including 
the gabapentinoids and older drugs such as carbamazepine). Antidepressant 
drugs act by enhancing the descending inhibitory pain pathways from the brain 
to the spinal cord. Anticonvulsants have a variety of mechanisms including 
blockade of sodium and calcium channels in the central nervous system. 
Current National Institute for Clinical Excellence (NICE) guidance for the 
management of neuropathic pain includes tricyclic antidepressants, 
gabapentinoids and SNRI medications as first and second line management.51  
Although these medications are relatively efficacious for managing neuropathic 
pain, they seem to have little benefit in conditions where nociceptive pain 
predominates. For example, a recent Cochrane systematic review of the 
efficacy of antidepressants in inflammatory arthritis concluded it was not 
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possible to draw firm conclusions about the efficacy of these drugs.52 Similarly, 
six unpublished trials investigating the efficacy of gabapentin for the treatment 
of nociceptive pain failed to show a benefit, although this has not been widely 
publicized by the drug manufacturers, and the full trial details are not 
available.53  
The evidence therefore suggests that antidepressant and antiepileptic 
medications are effective for neuropathic pain, but not effective treating 
nociceptive pain. It should be of no surprise therefore, when these drugs are 
used in populations where there are high levels of mixed pain (such as cancer 
pain) systematic reviews demonstrate that such adjuvants are helpful, although 
the effect size is much smaller than that seen in patients with non-cancer 
neuropathic pain.54 
Interestingly, some analgesics commonly used to treat nociceptive pain are also 
effective treating neuropathic pains. For example, tramadol, with its dual mode 
of action (opioid agonism and enhancing descending inhibitory pain pathways) 
is considered a third line anti-neuropathic agent by NICE, and is commonly 
used to treat nociceptive pain.51, 55, 56 Similarly, strong opioids such as morphine 
or oxycodone also show efficacy in treating neuropathic pain, although outside 
the cancer pain population are rarely considered first or second line agents due 
to the potential for adverse effects.46 
Neuropathic and nociceptive pain are therefore discrete pain entities, with 
differing health impact and responding to different modes of analgesia. 
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1.3 Neuropathic pain following surgery 
The pathophysiology of postoperative pain is complex, and includes elements 
of nociceptive (generated by the noxious stimulus of surgery), and inflammatory 
(resulting from tissue injury and immune cell activation) pain processes.57 There 
is also evidence from research into the mechanisms of postoperative pain that 
support the hypothesis that part of the postoperative pain experience may be 
neuropathic.  
There appear to be a number of mechanisms by which surgery may result in 
neuropathic pain. Broadly, these include direct nerve injury (including by 
mechanisms other than obvious nerve trauma), and perhaps more 
controversially, via the process of central sensitization. 
1.3.1 The pathogenesis of postoperative nerve injury 
Signs of nerve damage are well documented in a number of surgical 
procedures where nerves cross, or are in close approximation to the surgical 
field. This includes chest wall surgery (both thoracic and breast surgery), hernia 
surgery and mandibular osteotomy.58-61  
During thoracic surgery, nerve damage can occur during the dissection of the 
muscle layers, intercostal muscle incision, rib retraction or suturing of intercostal 
muscles during thoracotomy.62 Rib retraction causes allodynia in animal models 
of post thoracic surgery pain, and some patients exhibit objective signs of nerve 
damage such as loss of superficial abdominal reflexes, and changes to 
neurophysiological studies.63-65 Maguire et al., (2006) investigated intercostal 
nerve damage at the time of operation with nerve conduction studies, and 
demonstrated two patterns of nerve injury.66 They suggest this may reflect 
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different mechanisms of injury; neuropraxia resulting from pressure related to 
rib retraction and damage caused by traction on the nerve.66 More recently, 
detailed quantitative sensory testing of patients six months following 
thoracotomy revealed nerve injury to be a common phenomenon.67 
Inguinal hernia repair similarly risks damage or disruption to major peripheral 
nerves including the ileoinguinal, ileohypogastric and genitofemoral nerves.68 
Quantitative sensory testing demonstrates that sensory disturbance following 
surgery is common, implicating that nerve damage around the time of surgery 
has occurred.68 As well as direct damage to nerves at the time of hernia 
surgery, an inflammatory response to implanted mesh has also been implicated 
in postoperative nerve damage.69, 70 
Breast surgery is also linked to high levels of post-operative sensory 
disturbance. In patients who have had breast surgery to treat cancer, the 
prevalence of sensory disturbances range from 31% to 85%, depending on the 
treatment received, with axillary lymph node dissection a particular risk factor.71 
This is perhaps unsurprising given the close proximity of the intercostobrachial 
nerve to lymph nodes in the axilla. However, a number of studies have tried to 
define the role of this nerve in the generation of chronic pain following breast 
cancer surgery, with mixed results.72-76 Methodological problems probably 
account for this result, with none of the studies using objective measures such 
as quantitative sensory testing.71 Sensory changes are also common following 
cosmetic breast surgery, with one questionnaire based study revealing 75.8% 
of respondents had sensory changes over the breast, a mean of 31.8 months 
following breast augmentation surgery.61 
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Although less common, sensory changes or other evidence of nerve damage is 
present following many other types of surgery. For example, a minority of hip 
surgery patients experience femoral neuropathy (0.1-2.4%) as a complication of 
surgery.77 Interestingly, although quantitative sensory testing of patients with 
chronic pain following hip arthroplasty revealed hyperalgesia over the operation 
site, intact thermal sensation suggests nerves with cutaneous innervation over 
the hip are not implicated, rather the findings may reflect damage to deeper 
tissues (such as muscle).78 
This conclusion is interesting in light of other recent findings, which suggest that 
mechanisms other than overt, major peripheral nerve damage may be 
implicated in the generation of neuropathic pain following surgery. The 
suggestion that the sensory hyperalgesia present following hip arthroplasty may 
be a result of muscle or deep tissue damage is supported by experiments 
investigating ‘neuropathic muscle pain’ in animal models.79 Alvarez et al provide 
experimental evidence that persistent muscle hyperalgesia is present in animal 
models of painful neuropathy.79 This suggests that neuropathic pain arising 
from muscles may be a greater clinical problem than is generally appreciated, 
and may contribute to the development of neuropathic pain following surgery.80 
The preceding evidence suggests that overt peripheral nerve injury following 
surgery is possible, and that damage to other tissue such as muscle can also 
trigger changes associated with nerve damage and neuropathic pain. There is 
also evidence that the skin incision alone may be enough to trigger nervous 
system changes normally seen with injury to peripheral nerves.81  
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Hill et al., (2010) demonstrate that in animal models, skin incision can induce 
expression of nerve injury and regeneration associated genes.81 Specifically, 
they demonstrate that nerve regeneration related genes (such as activating 
transcription factor 3) that are normally absent from dorsal root ganglion 
neurons, but present following peripheral nerve injury, are also induced by skin 
incisions.81 Skin tissue contains resident nerve axons, and it seems injury to 
these may be enough to trigger expression of neuronal injury/regeneration 
genes. This may represent a further mechanism by which neuropathic pain 
changes can be triggered following surgery; however to what extent this 
contributes to clinical symptoms and signs remains unknown. Certainly, the size 
of skin incision alone does not appear to affect acute pain following total hip 
arthroplasty.82 Dorr et al compared a minimally invasive surgical approach with 
a more conventional approach to hip arthroplasty, yet with the same skin 
incision size.82 They demonstrated significantly less postoperative pain in the 
minimally invasive group where underlying muscles were preserved.82 In a 
complementary study, there was no difference in postoperative pain when 
different skin incision lengths were compared (with the same degree of deep 
tissue injury).83 
The immune response to surgery has also been implicated in the pathogenesis 
of postoperative nerve damage.84 Staff et al., (2010) report a series of patients 
who developed postoperative neuropathy with an inflammatory rather than 
mechanical cause.85 Patients presented following a variety of procedures with 
focal, multifocal or diffuse neuropathies, with pain a common feature of 
presentation. An inflammatory cause was confirmed by nerve biopsy, which 
typically showed axonal degeneration and focal fibre loss with increased 
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epineural perivascular lymphocytic inflammation. Patients also had abnormal 
MRI changes, demonstrating increased T2 signal and nerve enlargement in the 
implicated roots, plexus or peripheral nerve. The authors note that some cases 
of inflammatory neuropathy clinically mimic mechanical postoperative 
neuropathies, and that inflammatory causes of postoperative nerve damage are 
probably under-recognised (the prevalence of this condition is unknown).85 
Interestingly, chronic pain following a thoracotomy for lung transplant is much 
less prevalent than following thoracotomy for other reasons (5% and >40% 
respectively.86 One potential reason may be the immune suppression received 
by transplant patients. 
In addition to nerve injury caused by direct trauma from a surgical incision, or 
inflammatory response, perioperative neuropathy may arise as a complication 
of the need for anaesthesia. In a retrospective analysis of over 380,000 surgical 
cases performed at a single institution over a 10 year period, Welch et al (2009) 
discovered 112 episodes of perioperative nerve injury that were not a direct 
complication of the surgery itself.87 Upper limb injuries were more common, as 
were primarily sensory symptoms (rather than motor dysfunction).87 They also 
reported a significant association between nerve injury and hypertension, type 
of anaesthetic and surgical specialty.87 The overall frequency of nerve injury 
was 0.03%, lower than studies performed in the 1970’s (0.14%) and late 1980’s 
(0.11%).88, 89 
A variety of factors have been implicated in the aetiology of ‘anaesthetic’ nerve 
damage, including patient positioning, and direct damage from regional or 
neuraxial anaesthetic procedures. Surgical positions, such as the lithotomy 
position, have been implicated in obturator, lateral femoral cutaneous, sciatic 
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and peroneal nerve damage following surgery, with nerve strain and increased 
compartment pressures potential causes.90-92 Other nerves, such as the ulna, 
are prone to damage because of their prominent and superficial location.93  
Nerve damage may also occur as a result of regional anaesthetic techniques. 
This may result from direct needle trauma, injection into the nerve or from 
neurotoxic drugs or chemicals used in the procedure.94 Long term nerve 
damage is rare, confounding attempts at reliably measuring its prevalence (0.5-
1% in retrospective studies), although transient symptoms of neuropraxia may 
be more common (8-10%).94-96 
In summary, there are a number of different processes by which nerve damage 
may occur in the perioperative period. They include damage to skin, muscle or 
nerve by the surgical incision or retraction, anaesthetic related factors and 
inflammatory processes. It is useful to review how such nerve damage may 
result in neuropathic pain, and how the complex processes involved in 
neuropathic pain generation differ from those driving the nociceptive pain 
experience. 
1.3.2 The pathophysiology of neuropathic pain 
A number of physiological processes occur following nerve injury. Some of 
these processes are regarded as maladaptive, and demonstrate the plasticity of 
the nervous system in response to an insult such as surgery. These 
maladaptive processes are complex, but help us explain the clinical features of 
neuropathic pain following nerve injury. 
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Spontaneous pain 
Spontaneous pain that arises without stimulus is a feature of neuropathic pain. 
A number of mechanisms by which spontaneous pain may be generated have 
been discovered. When a nerve is injured, ectopic action potential generation 
can occur at the site of the neuroma, at the injured nerve’s dorsal root ganglia 
and in neighbouring uninjured primary sensory neurons.97  
Spontaneous firing of action potentials occurs as a result of increased 
expression or altered trafficking of voltage gated sodium channels, both in 
injured and uninjured neurons.98, 99 Exactly which subtype of sodium channel is 
implicated is not clear, mainly because there are no animal models of 
spontaneous pain.97 As an example of the difficulties investigating this process, 
Nav1.8 sodium channels are thought to have an important role in generating 
neuropathic pain, however Nav1.8 ‘knockout’ mice do not exhibit reduced 
neuropathic pain behaviour, and Nav1.8 seems to be down regulated following 
axonal injury.99-102 The dorsal root ganglion may have a role in regulating this 
ectopic activity, with the hyperpolarization-activated cyclic nucleotide-modulated 
channel (HCN) implicated in raising membrane excitability.103 Further changes 
in the dorsal root ganglion alter the responsiveness, transmission and survival 
of sensory neurons.104  
Distal to the nerve injury, denervated Schwann cells help generate molecules 
such as cytokines and growth factors, which increase axonal sensitivity by 
increasing sodium and TRP channels. Inflammatory mediators, (such as TNFα), 
which gather around the injured neuron further increase ectopic activity.105-107 
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Gene transcription appears to have a major role in driving the processes that 
signal nerve injury and the resulting production of local mediators.97 
A further generator of spontaneous pain following nerve injury may be body 
temperature.97 Following nerve injury, TRPV1 channels in nerve axons, which 
are normally triggered by noxious heat, may have their thresholds for triggering 
reduced to that of normal body temperature.108 Normal body temperature may 
therefore become a noxious stimulus, resulting in the experience of 
spontaneous pain. 
Stimulus evoked pain 
In neuropathic pain states, the nervous system is hypersensitive to normal 
sensory input. A number of changes following nerve injury seem to facilitate this 
response, with the dorsal horn of the spinal cord an important area of neuronal 
plasticity and sensitization. In particular, the balance between inhibitory and 
excitatory nerve activity is profoundly altered at this level.  
Sensory inflow to the dorsal horn is altered after peripheral nerve damage 
resulting in the eventual death of inhibitory interneurones.109 These 
interneurones inhibit pain transmission by modulating presynaptic input, and 
regulate postsynaptic transmission through effects on the neurotransmitters 
GABA and glycine.97 Death of these interneurones would result in loss of GABA 
and glycine control, a process that produces evoked neuropathic pain 
symptoms in animal models.110 Descending inhibitory pain pathways are also 
disrupted by nerve injury. These pathways extend from areas of the brain 
involved in pain processing (anterior cingulate gyrus, amygdala and 
hypothalamus), through the brainstem to the spinal cord, and help to modulate 
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pain signals via the neurotransmitters serotonin, noradrenaline and endogenous 
opioids.97 Following nerve injury, there is loss of this inhibitory effect, which may 
transform from inhibition to facilitation.111 Other inhibitory processes are also 
affected by nerve injury. There is reduced expression and sensitivity of opioid 
receptors in primary afferent neurons and the dorsal horn of the spinal cord.97 
Brain derived neurotrophic factor (BDNF) released by microglia causes 
alterations in chloride ion transport across membranes in the dorsal horn. 
Consequently the normal inhibitory effects of GABA receptor activation no 
longer result in membrane hyperpolarization.112 
Concurrent increase in excitatory transmission occurs, as a result of presynaptic 
alterations in the synthesis of neurotransmitters and changes in receptor 
density, and postsynaptic phosphorylation of NMDA receptors facilitate onward 
pain signaling. In particular, there is marked up-regulation of α2δ subunit voltage 
gated calcium channels in the dorsal horn and elsewhere (including the dorsal 
root ganglion) in response to nerve injury.97, 113 This structure appears to be 
involved in new excitatory synapse formation mediated via thrombospondin (an 
astrocyte secreted protein that promotes new synapse formation in the CNS), 
and is the target for the anti-neuropathic drugs gabapentin and pregabalin.114 
A further example of a stimulus evoked symptom in neuropathic pain is 
allodynia, whereby a normally non-noxious stimulus (such as light touch) 
produces pain.2 Following peripheral nerve injury, Aβ fibres, normally 
responsible for touch sensation, transfer their inputs to pain circuits in the spinal 
cord.97 This may occur as a result of structural changes in the dorsal horn of the 
spinal cord. Aβ fibres normally terminate in laminae III – V of the dorsal horn, 
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with pain signaling Aδ and C fibres terminating in levels I and II. Peripheral 
nerve injury promotes the expression of genes associated with nerve 
regeneration in order to aid the reconnection of separated axons.97 This 
tendency towards nerve growth was thought to be responsible for sprouting of 
uninjured Aβ axons into neighbouring dorsal horn laminae, which are normally 
responsible for pain transmission, with Aβ inputs to the spinal cord therefore 
resulting in onward pain transmission.115, 116 Subsequent studies however 
showed that the Cholera toxin used to demonstrate the effects of ‘sprouting’ of 
Aβ axons into neighbouring dorsal horn laminae, is also taken up and 
transported by injured C fibres. This probably accounts for the novel labeling in 
lamina II of the dorsal horn seen after nerve injury, rather than aberrant nerve 
growth into adjacent areas.117, 118 
Immune system responses to nerve injury, may also be responsible for the 
nervous system hypersensitivity seen in neuropathic pain.119 Microglial cells are 
activated in the dorsal horn following nerve injury, and release immune 
mediators, which contribute to the activation and maintenance of neuropathic 
pain by altering nerve function, producing pain hypersensitivity.97  
A number of processes affecting numerous locations within the pain pathway 
are triggered following nerve injury. It is clear that many of these changes give 
rise to the features of neuropathic pain, however, to what extent do these 
processes differ from nociceptive or inflammatory pain models? 
1.3.3 Central sensitization 
Although it is clear that nerve injury causes changes in the central nervous 
system that facilitate pain transmission, and lead to features such as 
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hyperalgesia and allodynia, confusingly, a similar picture can occur following 
nociceptive pain. This has been termed central sensitization, and is a feature of 
both nociceptive and neuropathic pain.  
In the 1960’s it was discovered that repetitive stimulation of a nerve at a 
constant C-fibre strength resulted in a steady increase in action potential firing 
in the dorsal horn.120 This was one of the first examples of use dependent 
plasticity within normally functioning pain pathways of the central nervous 
system and was termed ‘wind-up’. Subsequently, it was discovered that 
activation of peripheral nociceptors increased synaptic efficacy in dorsal horn 
nociceptors, which long outlasted the initial stimulus.121, 122 Furthermore, not 
only was the conditioning input amplified in this way, but also was non 
stimulated input (both nociceptive and non nociceptive) from other nerve 
fibres.122 This homosynaptic and heterosynaptic potentiation was termed 
‘central sensitization’. The increase in dorsal horn synaptic strength is mediated 
via excitatory amino acids, alteration in ion channel properties, increased 
receptor density and activation of pre and postsynaptic kinases.97 Immune cells 
(microglia), astrocytes and alteration in gene transcription help to maintain the 
sensitized state, where normal inhibitory inputs are reduced, and excitatory 
activity increased.122 
These discoveries raised the possibility that once triggered by a nociceptive 
event, the central nervous system was capable of changing, distorting or 
amplifying pain even when the original noxious stimulus resolved.122 Pain in this 
state is uncoupled from peripheral nociceptive stimuli and becomes centrally 
driven. Rather like the changes in the dorsal horn that occur with neuropathic 
pain, amplification and strengthening of afferent inputs is such that normally 
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innocuous inputs such as Aβ touch sensations can activate pain circuits 
resulting in allodynia.122 A further feature is secondary hyperalgesia, which 
occurs in areas beyond the site of injury.104 
There is evidence that central sensitization occurs following surgery. In the 
immediate postoperative period, patients can experience secondary 
hyperalgesia, with no spread in thermal sensitivity, suggesting initiation of 
central sensitization.123, 124 Researchers have also found evidence of central 
sensitization contributing to chronic pain post hernia repair pain, elicited with 
QST.125 In general, patients with central sensitization may present with dynamic 
tactile allodynia, secondary hyperalgesia and temporal summation.122 As we 
have seen, these are also features of neuropathic pain, unsurprising 
considering it is also driven by a process of central sensitization, all be it with 
the trigger of nerve injury rather than the barrage of peripheral nociceptive 
afferent that also occur following surgery. Central sensitization, even if it is 
initiated by nociceptive pain, can no longer be termed ‘nociceptive pain’, as it 
may occur in the absence of noxious stimuli.122 Neither can it be called 
‘neuropathic pain’ which requires a demonstrable disease or lesion of the 
somatosensory nervous system, despite the overlap in symptoms such as 
allodynia and hyperalgesia. Rather it reflects a maladaptive central nervous 
system response, which can be driven by both nociceptive and neuropathic 
pain resulting in a state of induced pain hypersensitivity.122 
Central sensitization has been implicated in the development of chronic pain 
following surgery. For example, there appears to be a relationship between the 
extent of secondary hyperalgesia experienced in the immediate postoperative 
setting following abdominal surgery, and the development of chronic pain.126, 127 
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Similarly, signs of central sensitization are found in 51% of patients with chronic 
post surgical pain, compared to 15% of pain free patients.125, 128 
1.3.4 Opioid induced hyperalgesia 
Like central sensitization, opioid induced hyperalgesia is a further pathological 
state presenting with symptoms that may overlap those of neuropathic pain in 
the postoperative period.  
Both acute and chronic administration of strong opioids appears to trigger 
changes similar to those of central sensitization and neuropathic pain in 
susceptible individuals.129 The NMDA receptor has been implicated in this 
process, with increased receptor activity present after chronic morphine 
administration, and NMDA receptor antagonists attenuating the development of 
opioid induced hyperalgesia.130-132 Other mechanisms that may be involved 
include changes in the descending inhibitory pain pathways of the central 
nervous system towards facilitation rather than inhibition of nociceptive 
signaling.129 Peripheral nerve changes also occur, with the TRPV1 receptor 
likely to play a role in the development of hyperalgesia.129 
The key clinical feature of opioid induced hyperalgesia is a paradoxical increase 
in pain in response to administration of a strong opioid analgesic. In addition, 
the central and peripheral nervous system changes outlined above can result in 
symptoms similar to those found in neuropathic pain, including hyperalgesia 
and allodynia.129 Opioid induced hyperalgesia has been demonstrated in both 
healthy volunteers and also the acute postoperative setting, and therefore 
represents a further confounding factor when diagnosing acute neuropathic 
pain.133, 134 
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1.3.5 The epidemiology of postoperative neuropathic pain 
The evidence reviewed so far suggests that nerve injury, via a number of 
mechanisms, occurs following surgery, and that this nerve injury can trigger a 
number of changes in the nervous system that result in neuropathic pain. What 
is the clinical evidence that neuropathic pain following surgery occurs? 
The existence of chronic pain following surgery has been recognized for many 
years, although there has been increasing recognition of this problem in the last 
15 years, with a resulting proliferation of research articles on this topic (a 
literature search on the topic for a recent systematic review initially returned 
6512 articles).135 Nerve damage has long been implicated in the development 
of this chronic pain following surgery. For example, Blades and Dugan (1944) 
describe pain following thoracic surgery for wounds inflicted during the second 
world war as ‘intercostal pain’ and identify nerve damage at the time of 
operation as the likely causative agent.136 Despite such early recognition of the 
problem, there are comparatively few research articles describing the 
prevalence specifically of chronic neuropathic pain following surgery. Using the 
example of thoracic surgery (thoracotomy or video assisted thoracoscopy), prior 
to 2007 (when the research on this area presented in this thesis was 
undertaken), only 2 studies had estimated the prevalence of probable or definite 
chronic neuropathic pain following surgery (according to subsequently 
published diagnostic criteria).66, 137, 138 A further 14 studies either used sufficient 
pain descriptors or screening tools which allowed an estimate of the prevalence 
of ‘possible’ neuropathic pain.135 A subsequent systematic review in 2013, 
which also included research on sternotomy patients, identified 45 papers which 
allowed an estimate of the prevalence of possible, probable or definite 
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neuropathic pain after thoracic surgery.135 It is clear that in a relatively short 
period of time, interest in this topic has accelerated. 
Assessing the true prevalence of neuropathic pain following surgery is 
challenging. Firstly, there are no universally agreed diagnostic criteria for 
neuropathic pain, and a variety of methods have been used in published 
studies. These include diagnosis by an experienced pain physician, neuropathic 
screening tools (of which there are a number), or the use of objective tests such 
as QST. Secondly, a variety of time points have been used to assess 
prevalence ranging from 6 weeks to 35 years.135  
In their comprehensive systematic review on this topic, Haroutiunian et al., 
(2013) describe the prevalence of chronic neuropathic pain following thoracic 
surgery, breast surgery, groin hernia repair, and total hip or knee arthroplasty 
(THA/TKA).135 They graded papers according to whether or not the diagnostic 
criteria in each paper met recently published standards, or whether neuropathic 
pain was diagnosed by other methods, and gave a prevalence for each.138 The 
results of this review are presented in figure 1.1.135 
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Figure 1.1 Results of a systematic review of studies investigating the prevalence of chronic 
postoperative neuropathic pain following different types of surgery (from Haroutiunian et al, 2013) 
N = number of studies included, n = number of patients, NeuP = neuropathic pain, PPSP = 
Persistent Post Surgical Pain, TKA = total knee arthroplasty, THA = total hip arthroplasty, 
Probability grading system = neuropathic pain diagnosed using a method consistent with a 
published diagnostic consensus statement138, Other methods = Other methods of neuropathic pain 
diagnosis (e.g. neuropathic pain screening tools). 
 
From this study, it is clear that surgery around the chest wall results in a high 
prevalence of chronic neuropathic pain. For thoracic surgery, of the 34.5% of 
patients who experience chronic postoperative pain, 52-66% have neuropathic 
pain. The picture is similar for breast surgery (chronic pain prevalence 31%), 
where 68-74% of those with pain have neuropathic pain.135 Pain is less 
common in areas where major peripheral nerve damage is more unlikely, such 
as following knee or hip arthroplasty (19.8%) and also less likely to be 
neuropathic (6-9%).  
Interestingly, figure 1 demonstrates that the prevalence of neuropathic pain 
using both strict methods of diagnosis (including objective signs of nerve 
damage) and more descriptive methods is similar for chest wall surgery, but 
differs for groin and orthopaedic surgery.135 For the latter two, using descriptive 
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methods of diagnosing neuropathic pain seems to elicit a much greater 
prevalence than using a diagnostic method with more objective criteria.135 One 
possible explanation for this would be that the descriptive method of diagnosis 
is eliciting people whose pain is maintained by central sensitization as well as 
those with neuropathic pain. 
Neuropathic pain as a component of chronic postsurgical pain has been 
described following a number of other procedures not included in the above 
systematic review. These include craniotomy (25%), amputation (>80%) and 
caesarean section (53%).139-141 
Interestingly, it is clear from the epidemiological data that not everyone with 
postoperative nerve damage goes on to develop chronic neuropathic pain. 
Evidence of sensory dysfunction following surgery can be surprisingly prevalent 
in the pain free population. Aasvang and Kehlet (2010) demonstrated 20% of 
pain free post hernia repair patients had sensory dysfunction.128 Sensory 
dysfunction was even more common in pain free individuals following thoracic 
and breast surgery (43% and 37% respectively).61, 142 This may present an 
additional confounding factor when trying to accurately estimate postoperative 
neuropathic pain prevalence, and is perhaps evidence of a genetic susceptibility 
to developing neuropathic pain. 
The natural history of postoperative neuropathic pain is not well described. In a 
retrospective questionnaire survey of women undergoing breast surgery over a 
5 year period in Aberdeen, Smith et al., (1999) discovered that 58% of women 
with pain reported declining symptoms, 9% had increasing pain symptoms and 
33% had variable symptoms.143 Although attempts were made to limit the 
30 
 
analysis to those with neuropathic pain, the results are limited by the varying 
time interval between surgery and receiving the questionnaire (time since 
surgery was not reported). Interestingly, in a follow-up study using the same 
cohort of patients 7-12 years after their original surgery, of those reporting 
chronic pain in the original study, 52% continued to have pain, with the 
symptoms resolving in 48%.144 This suggests that although for some people 
postoperative neuropathic pain resolves with time, for a significant proportion it 
continues to be a problem many years after the original surgery. One study 
investigating the prevalence of painful phantom breast pain following 
mastectomy suggests neuropathic pain may increase with time (from 12.7% at 
1 year to 17.4% at 6 years).3 In contrast, most studies investigating chronic 
postsurgical pain of all causes (without determining the nature of the pain) tend 
to report a decline in pain symptoms with time.145-148 
Although there is considerable research into the prevalence of chronic 
neuropathic pain following surgery, there is very little published data describing 
the onset of postoperative neuropathic pain, in particular whether neuropathic 
pain occurs in the acute postoperative pain setting.  
 
1.4 Acute postoperative neuropathic pain 
The temporal onset of neuropathic pain following surgery is poorly described. 
Traditionally, acute postoperative pain has been considered to be nociceptive in 
origin. However, there is both preclinical and clinical evidence that neuropathic 
pain may play a role in the acute pain experience. 
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1.4.1 Preclinical evidence for acute postoperative neuropathic pain 
The spinal nerve ligation animal model is traditionally considered a neuropathic 
pain model, however it also involves surgery and triggers an inflammatory 
response linked to pain behaviour.149 Experiments using this model have 
demonstrated marked hyperalgesic pain behaviours in the ipsilateral limb of 
affected rats by postoperative day 3, and increased spontaneous and ectopic 
pain fibre discharges, associated with allodynia, by day 7.150, 151 In a rat model 
of thoracic surgery (which includes thoracotomy and rib retraction), 
Buvanendran et al., (2004) demonstrate that rats who go on to develop long 
lasting chronic neuropathic pain behaviour begin to demonstrate signs of 
mechanical and cold allodynia early in the postoperative period.63 This pain 
model was designed to mimic the prolonged rib retraction and subsequent 
intercostal nerve compression that occurs during thoracic surgery, and therefore 
represents a convincing model of surgery with likely peripheral nerve damage.  
Symptoms of neuropathic pain began on day 2 following surgery, with rats 
exhibiting mechanical and cold allodynia.  By day 10 the 50% of rats who 
developed long lasting neuropathic pain following the surgery all had 
established neuropathic pain symptoms.63  
In contrast, animal models of postoperative pain designed to mimic surgery 
without peripheral nerve damage seem less likely to elicit signs of neuropathic 
pain. For example, the skin/muscle incision and retraction (SMIR) model, 
performed on the inner thigh of rats, does not evoke heat hyperalgesia or cold 
allodynia (mechanical allodynia was not possible to assess due to the site of 
surgery).152 
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These animal models suggest that for some individuals, neuropathic pain may 
contribute to their pain experience in the early postoperative period. 
Unfortunately, animal models of pain whilst useful for exploring 
pathophysiological processes are perhaps less reliable when assessing pain 
symptoms.97 Subjective symptoms cannot be assessed directly in animal 
models; instead surrogate markers that rely on motor activity (such as 
withdrawal) are used. In particular, there are no preclinical models that directly 
measure key neuropathic symptoms such as spontaneous pain.97 
Nevertheless, animal models are useful indicators of pain, even though they 
may never replicate the full complexity of the human pain experience. Certainly, 
there is evidence that tactile allodynia measured in rats corresponds with 
neuropathic mechanical hypersensitivity in humans, and that anti-neuropathic 
medications reduce these symptoms in rats just as they do in humans.97, 153-155 
1.4.2 Clinical evidence for acute postoperative neuropathic pain 
Acute neuropathic pain has been described following a number of different 
clinical conditions. For example, in a longitudinal study of pain symptoms in 73 
patients following spinal cord injury, Sidall et al., (2003) report that over 50% 
had symptoms of ‘at level’ or ‘below level’ neuropathic pain beginning in the first 
2 weeks following injury.39 In an earlier study in spinal cord injury, the authors 
report that 78% of patients had developed allodynia by 2 weeks following 
injury.156 Neither study measured symptoms or signs at a time point earlier than 
2 weeks.   
The picture is less clear in other medical examples of neuropathic pain. Herpes 
zoster infection can cause the classical neuropathic pain associated with post 
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herpetic neuralgia (PHN). Patients with herpes zoster infection typically 
experience a prodrome of dermatomal pain symptoms before the characteristic 
rash appears.157 The prodromal pain qualities may include the paraesthesias 
and dysaesthesias present in neuropathic pain.157 Some patients may go on to 
develop a continuum of pain symptoms through the acute phase, subsequently 
developing post herpetic neuralgia.158 Patients who experience pain in the first 
30 days following rash have been described as suffering from ‘acute herpetic 
neuralgia’.159 However, controversy exists over whether or not acute herpetic 
neuralgia and chronic post herpetic neuralgia have the same underlying 
pathophysiological drivers, and it may be that the acute pain owes much of its 
experience to a post-infective inflammatory process.157 Nevertheless, studies 
investigating the treatment of acute herpetic pain have shown responsiveness 
to the anti-neuropathic agent gabapentin, supporting the role of neuropathic 
pain in the acute pain experience.160 
Traumatic injury to peripheral nerves also causes neuropathic pain, and there 
are case reports of military personnel injured in battle experiencing acute 
neuropathic pain.161 In a study of 50 army casualties, Mercer et al (2009) found 
that 28% of patients had neuropathic pain in the first week following injury, with 
a further casualty developing neuropathic pain during the second week 
following injury.162 
It seems from these examples that neuropathic pain can develop during the 
acute phase following injury or disease to the nervous system. Unfortunately, 
few potential causes of neuropathic pain are planned, or have definitive starting 
points (for example diabetic peripheral neuropathy), which makes examining the 
time course of neuropathic pain difficult, particularly determining when 
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neuropathic symptoms and signs begin. Surgery is one exception to this, 
therefore making it an ideal population to study. It is clear that some procedures 
have a high prevalence of chronic postoperative neuropathic pain and 
demonstrable nerve injury, and the onset of injury is known about.  
Pain experts have commentated on the existence of acute postoperative 
neuropathic pain, however there is a paucity of data to support this.163-165 In a 
retrospective survey of 408 patients who received mastectomy for breast 
cancer, Smith et al., (1999) enquired about onset of symptoms of post-
mastectomy pain syndrome (considered by them to be a neuropathic pain 
experience) via postal questionnaire.143 Thirty percent of those patients 
surveyed remembered immediate onset of post-mastectomy pain, 25% had 
onset within a month of surgery and 15% had an onset between 1-3 months 
following surgery.143 Only 24% reported onset of symptoms outside the acute 
post-operative time period. Unfortunately, this result may be biased by a 
number of factors. Firstly, the pain experienced immediately following the 
operation may have been nociceptive or inflammatory pain rather than 
neuropathic post-mastectomy pain. Secondly, the retrospective nature of the 
survey meant that some patients were being asked to recall details that 
occurred 6 years ago, potentially introducing further inaccuracies. Lastly, many 
women received adjuvant treatment for their cancer (such as chemotherapy and 
radiotherapy), which has also been shown to cause neuropathic pain, making 
the assumption of a surgical cause for symptoms potentially unsound. 
Nevertheless, this early report raises the suggestion that some patients may 
experience neuropathic pain early in the postoperative period.  
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Interestingly, the severity or intensity of acute postoperative pain has been 
shown to be a risk factor for the development of chronic postoperative pain. In a 
retrospective survey of women who had breast surgery, Tasmuth et al., (1996) 
discovered that those with chronic pain following surgery remembered more 
severe acute pain following their surgical procedure compared to those who did 
not go on to develop chronic pain.166 A prospective study in thoracic surgery 
patients confirmed this finding, with results that suggested a predictive 
relationship between pain at 24 and 48 hours following surgery, and the 
development of long term pain.167 Moving beyond the first 48 hours following 
surgery, in a prospective case series of patients having inguinal hernia repair, 
Callesen et al., (1999) discovered that those with high pain scores 1 week 
following surgery had a higher risk of suffering moderate or severe pain 12 
months later.168 Similar findings exist for non-surgical trauma, such as serious 
injury and childbirth.169, 170 These findings are interesting, as we know from 
population based studies that neuropathic pain tends to be more severe, or of 
greater intensity than nociceptive pain.45 Coupled with the knowledge that a 
significant proportion of chronic postoperative pain patients have neuropathic 
pain, it would seem logical to hypothesize that the more intense pain 
experienced by some people in the acute postoperative period may indicate the 
development of acute neuropathic pain, which subsequently becomes chronic. 
Further evidence for the existence of acute postoperative neuropathic pain may 
come from examining the response of postoperative pain to analgesics 
specifically designed to target neuropathic pain. Although published data is 
lacking, it would seem likely that gabapentin is not an effective drug in the 
treatment of nociceptive pain.53 However, it does seem to have an analgesic 
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effect on acute postoperative pain. A single dose of gabapentin for established 
moderate or severe postoperative pain is superior to placebo, although has a 
number needed to treat to reduce pain by 50% (NNT) of 11 (compared to a 
NNT of 4 in neuropathic pain).171 When used in conjunction with other analgesic 
agents in the postoperative period, systematic reviews and meta-analyses show 
that the gabapentinoids have a significant opioid sparing effect.172, 173 The fact 
that these drugs do not appear effective in nociceptive pain, yet do have an 
effect on acute postoperative pain suggests that at the very least the acute 
postoperative pain experience may be one of mixed nociceptive/neuropathic 
pain, or that a minority (reflected by the NNT of 11) may experience significant 
neuropathic pain that responds to these analgesics. 
So, there is mounting evidence to support the hypothesis that some people may 
experience acute postoperative neuropathic pain. There is however, very little 
published data describing this problem. 
Hayes et al., (2002) conducted a prospective survey of patients referred to an 
acute pain service over a 2 ½ year period.174 Patients considered to have 
unexpectedly high levels of pain intensity were investigated for the possibility of 
acute neuropathic pain. During the survey period, 4888 patients were seen by 
the acute pain service, and 51 (1%) identified as suffering from neuropathic 
pain.174 The survey reported that neuropathic pain occurred immediately after 
the precipitating event in 24% of cases, with 67% reporting delayed onset and 
the remaining patients unsure of onset time.174 Of the 51 patients identified with 
neuropathic pain, 27.5% resulted from surgery. Interestingly, 41 patients were 
followed up at six months (with 10 lost to follow up) with 78% reporting 
persisting pain.174 Although this study seems to confirm that acute neuropathic 
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pain following surgery occurs, there are a number of confounding factors that 
make estimating the prevalence of this using their methodology potentially 
unreliable. Firstly, only patients who were referred to the acute pain service 
were considered, and then only if they had unexpectedly high pain intensity 
scores were they examined for neuropathic pain symptoms and signs. A 
number of patients would therefore not be recognised, including those with 
‘normal’ pain scores, patients not referred to the acute pain service and those 
patients who had day surgery (and therefore went home). Secondly, some 
patients (notably lower limb amputation patients) were excluded from the survey 
because of other ongoing research. Thirdly, the authors diagnosed neuropathic 
pain without using a validated method. Fourthly, patients with pre-existing 
neuropathic pain were not excluded from the study, potentially skewing results. 
Lastly, it is not clear at what time point following the initiating event patients 
were assessed. Data describing the onset of symptoms appears to be based on 
patient recollection rather than objective assessment. There are therefore a 
number of methodological flaws that confound accurate prevalence data for 
acute neuropathic pain following surgery. 
1.5 Summary of research problem 
The preceding evidence demonstrates that nerve damage occurs as a 
consequence of surgery, and that a significant proportion of patients seem to 
develop chronic neuropathic pain as a result of this. The time course describing 
the onset of neuropathic pain is not well described. Although animal studies and 
human case reports described the phenomenon of acute neuropathic pain, 
there is no accurate measure of the prevalence of this condition. Indeed, it is 
not clear if a neuropathic component to the acute pain experience can be 
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reliably distinguished from the nociceptive pain barrage that is likely to 
predominate following surgery. Investigating acute neuropathic pain is 
important, as evidence shows that despite advances in the treatment of pain 
over the last century, acute pain remains poorly treated and is a risk factor for 
the development of long-term pain problems. Neuropathic pain is commonly 
treated with specific medications such as anticonvulsants and antidepressants, 
and identifying neuropathic pain in the immediate post-operative setting may 
allow targeted treatment using these medications to help reduce the burden of 
poorly controlled pain.  
The aim of this thesis is to investigate the diagnosis and prevalence of acute 
neuropathic pain following surgery. 
1.5.1 Aims and objectives 
In order to accurately assess the prevalence of acute neuropathic pain, it is 
necessary to consider how neuropathic pain is diagnosed and measured. The 
second chapter of this thesis will review the methods of diagnosing neuropathic 
pain, with the specific aim of evaluating the modern psychometric properties of 
the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) 
neuropathic pain screening tool.  
Further aims of this thesis are to estimate the prevalence of acute neuropathic 
pain, in a population of thoracic surgery patients thought likely to be at risk of 
developing this problem. An additional aim is to assess whether patients with 
acute neuropathic pain are at risk of developing chronic neuropathic pain 3 
months after surgery. 
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Additional objectives of this thesis are to explore how, in the face of a paucity of 
published data on the subject, acute neuropathic pain is diagnosed by acute 
pain specialists, with the specific aim of achieving an expert consensus on the 
symptoms and signs considered important in this diagnosis.  
A final aim is to confirm this consensus opinion by clinical investigation of post-
operative patients. This is presented as a pilot study for a matched cohort 
evaluation of neuropathic symptoms and signs in two groups of acute pain 
patients, with the specific aim of assessing the odds of developing neuropathic 
symptoms and signs in patients with poorly controlled acute post operative pain 
(despite the use of strong opioids) compared to those with well controlled acute 
post-operative pain. 
. 
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2 The diagnosis and assessment of neuropathic pain 
 
The term ‘neuropathic pain’ has been in common usage amongst clinicians and 
in pain research for over twenty years, however for much of this time 
controversy has existed surrounding the correct definition and diagnostic criteria 
for this condition. Indeed the term ‘neuropathic pain’ is essentially a clinical 
description, and lacks formal diagnostic criteria. Confusingly, even the definition 
of neuropathic pain has changed between the research presented in this thesis 
beginning and ending. Clearly, such lack of consensus makes research in the 
area of neuropathic pain prevalence complicated.  
The development of neuropathic pain screening tools has allowed a 
reproducible way of estimating the prevalence of neuropathic pain in the 
research and clinical setting. This chapter will therefore review how neuropathic 
pain is diagnosed and examine the properties of neuropathic screening tools.  
It was hypothesized that one such screening tool, the Leeds Assessment of 
Neuropathic Symptoms and Signs (LANSS) (appendix 1) would demonstrate 
unidimensionality and interval level measurement properties when examined 
using modern psychometric techniques. The specific aims of the research 
presented in this chapter were to analyse LANSS data collected from a cohort 
of chronic pain patients, including those with post surgical pain, using Rasch 
analysis to investigate scale unidimensionality, fit to the Rasch model and 
differential item functioning. 
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2.1 The definition of neuropathic pain 
The definition of ‘neuropathic pain’ has changed significantly since it first 
emerged as part of a mechanism based classification of pain. In 1994 The 
International Association for the Study of Pain (IASP) published the second 
edition of it’s internationally recognized taxonomy of pain, including a definition 
of neuropathic pain as: 
“Pain initiated or caused by a primary lesion or dysfunction of the nervous 
system”2 
This definition of neuropathic pain has been criticized for a lack of specificity, 
particularly the inclusion of ‘dysfunction’ within the definition.175, 176 For example, 
it could be argued that the process of central sensitization seen after tissue 
injury, (but not specifically linked to nerve damage) could be regarded as a 
dysfunctional response of the nervous system, blurring the definition of 
neuropathic pain with other mechanisms of pain generation.175 Complex 
Regional Pain Syndrome (CRPS) type 1 was a further example of diagnostic 
confusion, as the symptoms and signs of this condition indicate nerve 
dysfunction, in the absence of a nerve lesion. Whilst some clinicians describe 
this as a neuropathic pain condition, others felt strongly that it was not.176  
The 1994 IASP definition of neuropathic pain was therefore felt to lack both 
diagnostic specificity and anatomic precision.138 In particular, as understanding 
of the pathophysiology of processes such as central sensitization improved, it 
was felt that neuropathic pain needed to be distinguished from secondary 
nervous system changes arising from nociceptive pain.138 Furthermore, it was 
felt necessary to have a definition of neuropathic pain, which helped eliminate 
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other pain generators that commonly occur in patients with nerve lesions (such 
as spasticity).138 
As a result of these concerns, the Special Interest Group on Neuropathic Pain 
(NeupSIG) subgroup of the International Association for the Study of Pain, 
published a consensus document in 2008 setting out a revised definition of 
neuropathic pain and a diagnostic grading system.138 The revised definition of 
neuropathic pain was: 
“Pain arising as a direct consequence of a lesion or disease affecting the 
somatosensory nervous system” 138 
In this definition, the controversial term ‘dysfunction’ is replaced with the word 
‘disease’ in order to exclude nervous system changes that occur as a result of 
normal nociceptive pain processing. The reference to ‘nervous system’ in the 
original definition, was replaced with ‘somatosensory nervous system’ in order 
to exclude pain that arises as a secondary consequence of nerve damage, such 
as spasticity or muscle rigidity. This definition was subsequently adopted in 
guidelines on neuropathic pain assessment, and later replaced the 1994 
definition of neuropathic pain in the IASP taxonomy of pain in 2011.177-180 
This new definition of neuropathic pain has aroused criticism over the restrictive 
nature of limiting this condition to lesions or diseases of the somatosensory 
nervous system, and in particular the exclusion of CRPS as a neuropathic pain 
condition under the new guidelines.181-183 Furthermore, the need to demonstrate 
a lesion or disease of the nervous system is regarded by some as impractical 
for conditions where pain is the primary symptom and specific nerve lesions are 
less obviously demonstrated with imaging or neurological tests. 184, 185 
44 
 
Examples of conditions that fall into this category include postsurgical pain and 
cancer pain, and it has been argued that for many clinicians the diagnosis of the 
type of pain (nociceptive or neuropathic) precedes the diagnosis of the 
lesion.185 
The definition of neuropathic pain has therefore undergone subtle change in the 
last five years. However, the definition is simply a description of a clinical 
condition and does not in itself provide a method for diagnosing neuropathic 
pain. As pain is a subjective experience there has been a lack of objective gold 
standard criteria for diagnosing the underlying pain mechanism. For many years 
a diagnosis of neuropathic pain was made based on clinical information and an 
understanding of pain classification, with little specific diagnostic guidance 
available. Increasing recognition that common groups of symptoms and signs 
may have discriminant diagnostic value, led to the development of screening 
tools to aid the bedside diagnosis of neuropathic pain and provide a 
reproducible method for diagnosing pain mechanisms in research projects.  
In an attempt to establish further diagnostic clarity, the 2008, revised definition 
of neuropathic pain also proposed a method of grading the diagnosis of 
neuropathic pain according to history, examination and the presence of 
confirmatory neurological testing.138 The certainty of diagnosis would be 
subsequently graded possible, probable or definite.  
Unsurprisingly, as the definition of neuropathic pain has evolved over the last 
twenty years, so have the methods for diagnosing this condition. In the 
continued absence of a gold standard characteristic or test for the diagnosis of 
neuropathic pain, it is important to examine common approaches to identify this 
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condition in order to choose a suitable method to use in assessing acute 
neuropathic pain. 
2.2 Clinical features of neuropathic pain 
Pain resulting from nerve injury or disease has distinct clinical characteristics 
that help to distinguish it from pain syndromes in which the nervous system 
remains unaltered (nociceptive pain). Broadly, these characteristics are 
commonly divided into positive and negative symptoms and signs. A key 
negative feature is pain arising in an area of sensory deficit. The sensory deficit 
arises as a result of damage to the peripheral or central somatosensory nervous 
system and may manifest itself for example as a reduced perception of noxious 
or heat stimuli. Some experts believe this in itself is the most important feature 
of neuropathic pain, while others stress the need for pain and sensory 
abnormalities to be linked to a neurological condition. Positive somatosensory 
features are also common, and include spontaneous and evoked symptoms 
and signs. Spontaneous pains occur without a stimulus and can be continuous 
or paroxysmal, the latter often being described as shooting or electric shock like 
in nature. Some patients describe paresthesias such as tingling or unpleasant 
sensations under the skin (‘ants crawling’). Evoked pains occur as a result of a 
stimulus and are typically reported as an area of increased sensitivity to heat, 
cold or mechanical factors. Allodynia refers to pain evoked by a normally non-
painful stimulus (such as lightly touching the skin). Hyperalgesia is an increased 
sensitivity to a normally painful stimulus. Hyperpathia is a further example of 
evoked pain, whereby a repetitive mildly painful stimulus results in progressive 
aggravation of pain symptoms. 
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It is important to note that not all patients with neuropathic pain will present with 
all the characteristics presented above. Similarly no single symptom or sign is 
absolutely diagnostic of neuropathic pain. However, the subjective pain 
experience, and the description of symptoms and signs used by patients is so 
distinct in neuropathic pain states that they have been examined as a method of 
aiding neuropathic pain diagnosis. 
2.2.1 Verbal descriptors of neuropathic pain 
In most languages, there are a multitude of adjectives available to describe a 
particular pain experience. Following the development of early pain 
questionnaires, in particular the McGill Pain Questionnaire, it became apparent 
that verbal descriptors used by patients might have diagnostic properties. In 
1976, Dubuisson and Melzack demonstrated that patients with different types of 
pain described their symptoms using a distinctive constellation of adjectives.186 
Using the McGill Pain Questionnaire, they examined 95 patients with 8 different 
pain diagnoses, including two commonly considered to be neuropathic; 
phantom pain and post herpetic neuralgia. Their results showed a high degree 
of uniformity in the words used to describe particular pain conditions, and that 
the descriptors differed significantly between diagnoses, such that 77% of 
patients could be correctly classified into a specific pain syndrome solely on the 
basis of verbal description. For example, patients with phantom limb pain 
tended to describe their pain as ‘throbbing’, ‘stabbing’, ‘sharp’, ‘cramping’, 
‘burning’ and ‘aching’.186 In contrast, those with arthritis described their pain as 
‘gnawing’ and ‘aching’.186  
A subsequent study by Masson et al., (1989) also used the McGill Pain 
Questionnaire to examine the differences in verbal descriptors between a group 
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of patients with diabetic peripheral neuropathy and a second group with painful 
legs or feet of varying aetiologies.187 They found significant differences between 
the neuropathic pain and control group, with discriminant analysis able to 
correctly classify 91% of patients according to their questionnaire response.  
Boureau et al., (1990) also investigated the role of verbal descriptors, 
specifically examining their diagnostic properties in neuropathic pain.188 Using a 
French reconstructed version of the McGill Pain Questionnaire, they compared 
verbal descriptors chosen by 100 patients with diagnosed neuropathic pain, 
with a control group of 100 patients with chronic benign pain. They 
demonstrated a significant difference in sensory descriptors between the two 
groups, with the six most commonly used adjectives amongst the neuropathic 
pain patients being: electric shock, burning, cold, pricking, tingling and itching. 
They conclude that ‘verbal description is one more index that may lead the 
clinician to a correct diagnosis’.188  
Mackey et al., (2012) developed a two factor model describing two groups of 
McGill Pain Questionnaire sensory descriptors that were common amongst 
patients with diabetic peripheral neuropathy and post herpetic neuralgia.189 
Factor 1 (dubbed ‘stabbing pain’) was characterized by the sensory descriptors 
stabbing, sharp and shooting. Factor 2 (dubbed ‘heavy pain’) included the 
descriptors heavy, gnawing and aching. They proposed these two common sets 
of descriptors reflected distinctive pain sensations common to neuropathic pain, 
but mediated by different mechanisms (such as Aδ and C fibre pain 
transmission).189 
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However, not all studies of verbal descriptors in neuropathic pain agree with 
these results. Atkinson et al., (1982), using the same questionnaire, failed to 
demonstrate that pain descriptors had discriminant properties amongst a group 
of 126 chronic pain patients. They noted that the McGill Pain Questionnaire was 
unable to discriminate between underlying pain mechanism, including 
differentiating neuropathic from bone or visceral pain. They also commented 
that as affective disturbance increased, pain language become more diffuse.190 
Similarly, in a study investigating verbal descriptors in three groups of patients 
with ‘definite’, ‘possible’ or ‘unlikely’ neuropathic pain, researchers found that 
pain descriptors (including the McGill Pain Questionnaire) could not distinguish 
between the three clinical categories, with considerable overlap between 
patients with definite or possible neuropathic pain, and those with unlikely 
neuropathic pain diagnoses.191 
Nevertheless, there is some evidence that sensory and affective pain 
descriptors may predict response to particular analgesic medication. Gilron et 
al., (2013), as secondary analysis of data from a randomized control trial 
examining the effects or morphine and gabapentin in diabetic neuropathy and 
post herpetic neuralgia, discovered a differential effect of these drugs on pain 
descriptors.192 For example, the severity of throbbing, shooting and aching pain 
improved preferentially with morphine, and tiring-exhausting and sickening pain 
with gabapentin.192 Similarly, Carroll et al., (2010) found that pain descriptors 
predicted response to intravenous lidocaine pain treatment.193 
The recognition that verbal descriptors may have discriminatory properties, and 
therefore provide an aid to diagnosing neuropathic pain led to the development 
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of a number of screening tools and neuropathic pain assessment scales. These 
tools arose through recognition that patients often presented with a mixed 
nociceptive/neuropathic picture (for example back pain and radicular leg pain) 
and that identifying a significant neuropathic component to their pain would 
have important implications for treatment. 
2.2.2 Neuropathic pain screening tools 
Since 2001, five neuropathic screening tools have been published and validated 
in the medical literature: The Leeds Assessment of Neuropathic Symptoms and 
Signs (LANSS and S-LANSS [appendix 1 and 2]), The Douleur Neuropathique 
en 4 Questions (DN4 and DN4Interview), The Neuropathic Pain Questionnaire 
(NPQ), ID Pain and painDETECT.36, 194-198 The common aim of these screening 
tools is to identify individuals who may have a significant neuropathic 
component to their pain experience. All the tools are different, however they are 
all based on pain description with or without the use of simple bedside sensory 
testing. Each screening questionnaire was developed in a broadly similar 
manner. An initial selection of items thought to be discriminatory was devised, 
based on published literature, questionnaires and expert opinion. A comparison 
was subsequently made of the frequency of descriptors used in neuropathic 
and non-neuropathic pain populations, with the aim of identifying the most 
discriminant items. These were then incorporated into a questionnaire that was 
validated in a second sample of pain patients, allowing an estimation of 
sensitivity and specificity based on a “gold standard” diagnosis.  
Two of the screening tools, the LANSS and DN4 are administered by a clinician 
and include questions related to both pain quality and items of sensory 
examination.194, 195 Versions of each tool have subsequently been validated as 
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self-administered questionnaires (S-LANSS and DN4 Interview). The remaining 
questionnaires, the ID Pain, NPQ and painDETECT are self-administered and 
contain only items related to the symptoms of neuropathic pain.  
The majority of screening tools were validated in patients with peripheral 
neuropathic pain of mixed aetiologies, with the DN4 also including patients with 
central neuropathic pain.195 The LANSS and ID Pain also included patients with 
complex regional pain syndrome type 1.194, 198 The “gold standard” used to 
validate the questionnaires was diagnosis by a pain clinician, with some studies 
(DN4) requiring demonstrable nerve lesions.  
Each questionnaire differs in the number and phraseology of questions used. 
The LANSS includes 5 questions phrased in a specific manner related to 
symptoms and 2 examination items, with each question receiving a different 
“weighting” in the total score. In contrast the DN4 has 7 symptom questions, 
and although these are more specific (each question asking about a specific 
descriptor rather than a group of related descriptors), the way in which the 
question is phrased to the patient is not specified, and the answers are not 
weighted differently. The NPQ has 10 items related to sensations and 2 further 
items related to affect, with responses rated on a visual analogue scale (VAS), 
similarly the painDETECT grades the response to 7 sensory descriptor items 0: 
hardly noticed to 5: very strongly, with a further 2 items related to spatial and 
temporal pain characteristics. The ID Pain comprises 6 items with dichotomous 
answers, and includes one item asking if the pain is limited to a particular joint. 
Both the DN4 and painDETECT were initially developed and validated in 
languages other than English (French and German respectively). 
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Understandably, the initial reported sensitivity and specificity of each tool differs, 
and these are presented in table 2.1. What is interesting however, is that 
despite differences in the development and validation of these tools there are a 
number of verbal descriptors identified by each process that are common 
across all tools. Items related to paraesthesias or dysaesthesias (pricking, 
tingling or pins and needles), electric shocks, hot or burning pain and items 
related to the symptoms/signs of allodynia and numbness are present across all 
5 questionnaires suggesting these represent the core symptoms of neuropathic 
pain, and providing compelling evidence for the validity of using symptoms as 
diagnostic indicators.185, 199 A number of these questionnaires have been 
validated in different languages, suggesting that pain qualities have a biological 
basis that is common despite different cultures. 185 
Screening Tool Sensitivity (%) Specificity (%) 
LANSS 85 80 
DN4 83 90 
NPQ 66 74 
painDETECT 85 80 
ID-Pain n/a n/a 
 
Table 2.1 Diagnostic sensitivity and specificity of the common neuropathic pain screening tools 
 
It is important to note that screening tools fail to identify 10-20% of patients with 
clinician diagnosed neuropathic pain. The development of the tools involved an 
inevitable overlap of the symptoms included in the questionnaire and those 
LANSS = Leeds Assessment of Neuropathic Symptoms and Signs, DN4 = Douleur 
Neuropathique en 4 questions, NPQ = Neuropathic Pain Questionnaire. 
52 
 
sought by the ‘gold standard’ clinician diagnosis by which they were compared, 
introducing a possible element of bias and inevitable questions about their 
validity. Nevertheless, tools that used demonstrable nerve lesions as part of the 
gold standard diagnostic process (DN4) show similar sensitivity and specificity 
to those that do not (LANSS).194, 195  
The role of screening tools has been questioned in light of the recent change in 
definition and consensus statement on the grading of neuropathic pain, with 
emphasis placed on the need for diagnostic tests confirming a nerve lesion to 
label a patient with ‘definite’ neuropathic pain.138 Nevertheless, screening tools 
are considered to play a role in the clinical and research arenas by a number of 
subsequently published international guidelines. The consensus of opinion from 
these publications seems to be that on an individual patient level, screening 
tools have a valuable role in allowing the non-specialist to identify a patient who 
may have neuropathic pain, which can steer the clinician towards confirming the 
diagnosis with a more in depth examination and investigations. 177-179  
Although screening tools are not replacements for clinical judgment in 
neuropathic pain diagnosis, their ease of use by both healthcare professionals 
(including non-specialists and nurses) and patients make them attractive for use 
in assessing neuropathic pain at a population level. One reported strength of 
screening tools is as a standardized case identification tool in epidemiological 
studies, particularly as they are suited to use face to face, via telephone, post or 
internet.199 However, guidelines on the assessment of neuropathic pain do 
indicate there is a lack of validation studies for use of screening tools in this 
context.179 Nevertheless, two separate epidemiological studies using different 
screening tools, in different European countries demonstrated remarkably 
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similar results when estimating the prevalence of neuropathic pain in the 
general population. Torrance et al., (2006) in a survey of 6000 members of the 
general public using the S-LANSS questionnaire reported a prevalence of pain 
with neuropathic characteristics of 8.2%.42 In a subsequent French study of 
30000 people using the DN4 interview, the reported prevalence of neuropathic 
pain characteristics was 6.9%.43 Although screening tools were not validated for 
use in this manner, the similarity in results would suggest they may be reliable 
to use in epidemiological studies.185 Screening tools have also been used to 
estimate the prevalence of neuropathic pain characteristics in a number of 
specific disease conditions including diabetes, back pain and Parkinson’s 
disease.36, 200, 201 
During the research presented in this thesis the definition of neuropathic pain 
has changed, and a system of grading neuropathic pain diagnosis has been 
introduced in order to bring clarity to research in this area. However, a number 
of issues remain unchanged: there remains no gold standard for diagnosing 
neuropathic pain, and there are a number of practical difficulties in using a more 
traditional approach where neurological signs are considered more important 
than pain descriptors. From the evidence presented, verbal descriptors do seem 
to have diagnostic qualities in distinguishing neuropathic from nociceptive pain, 
and the subsequent development of screening tools based on this observation 
has provided a useful research tool. Screening tools seem particularly useful in 
estimating the prevalence of neuropathic pain characteristics in population 
based studies, and represent a reproducible and standardized method of 
assessment, in a field where the diagnostic goal posts have shifted significantly 
in the last five years.  
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Throughout this thesis one such screening tool, the LANSS and it’s self report 
version the S-LANSS are used to assess neuropathic pain characteristics in the 
post surgical population, therefore it is useful to consider this tool in more detail. 
2.3 The LANSS and S-LANSS screening tools 
The LANSS was the first screening tool to be developed with the aim of 
distinguishing neuropathic from nociceptive pain. It was developed by a two-
stage process involving the initial step of identifying discriminatory factors and 
building a questionnaire, followed by a second study testing the scale on 
patients. 
The first stage in the development of the questionnaire was identifying six 
groups of symptoms thought to be of discriminatory value by reviewing 
published research and expert opinion in this area. The six symptom groups 
represented continuous deep pain, paroxysmal pain, evoked pain, autonomic 
dysfunction, thermal pain quality and dysaesthesias. In contrast to subsequently 
developed screening tools (such as the DN4), questions were constructed to 
reflect the essence of these symptom groups and therefore contained more 
than 1 descriptor. Questions were thought to be a more sensitive way of 
obtaining sensory information compared with the use of descriptors alone. The 
inclusion of an autonomic dysfunction group (and the subsequent use of CRPS 
patients in the study) could perhaps be considered a confounding factor in light 
of the recent neuropathic pain definition change, however the exclusion of 
CRPS as a neuropathic pain entity by IASP could at best be described as 
controversial, with much opinion still regarding CRPS as a neuropathic pain 
process.  
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In addition to verbal descriptor groups, limited bedside sensory testing was also 
identified as a possible discriminatory factor, and included in the initial phase of 
study design in the form of testing for allodynia using cotton wool and pin-prick 
testing for hyperalgesia or hypoalgesia. 
Once the groups of descriptors and sensory testing were identified, 30 
neuropathic pain patients and 30 nociceptive pain patients were recruited to 
assess the presence of these factors. The neuropathic pain group comprised a 
number of neuropathic pain diagnoses including post-surgical, peripheral 
neuropathy, post herpetic neuralgia and phantom limb pain. In contrast, the 
nociceptive group comprised predominantly those with low back pain and 
arthropathies, a fact criticized in subsequent comment on the LANSS scale 
development, with concerns that low back pain often has a mixed pain picture 
that may have confounded the tool development. However, the diagnostic 
groups used in this stage of the LANSS development were rigorously assessed 
by chronic pain experts, using history, examination and available imaging and 
neurophysiological testing, an approach still deemed the gold standard in 
diagnosing neuropathic pain. 
Each of the 60 patients was asked to rate whether the descriptors described 
their pain (with a yes/no response). Non-parametric testing revealed a number 
of descriptors significantly associated with neuropathic pain across the five 
symptoms categories identified in the prior literature search, and also in the 
results of the examination testing with light touch and pin-prick. The one group 
of pain symptoms, which had a similar distribution across both groups, was 
related to ‘continuous deep pain’. This group of symptoms was not included in 
the final scale design. 
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Logistic regression modeling was then used to identify the combination of items 
that would best predict the presence of neuropathic pain. The co-efficient 
resulting from this method reflected the odds ratio of a person with neuropathic 
pain answering positively for a given item, and this information was used in the 
final scale design to give a weighting to each question, reflecting the 
contribution of that item to an overall diagnosis of neuropathic pain within the 
model. For example, the odds ratio for the dysaesthesia group of symptoms 
was 5.24, hence in the final scale the question related to this group of 
symptoms was given a weighting of 5 if answered positively. Using this 
approach, the final scale has a maximum score of 24. A cut off point of 12 was 
identified as having the optimum positive and negative predictive values (83% 
sensitivity and 87% specificity). In applying the scale retrospectively to the 
responses from the 60 initial patients, the median score in the neuropathic 
group was 17, and in the nociceptive group 4. Interestingly, 4 patients in the 
nociceptive group were misclassified as neuropathic. All these patients had 
sensory dysfunction in the area of pain (although none had allodynia). Sensory 
dysfunction in the nociceptive group led one commentator to question whether 
these patients actually had neuropathic pain, and to question the underlying 
diagnosis and therefore the basis for the scale construction.202 This was refuted 
in further commentary suggesting that altered sensory perception in nociceptive 
pain of musculoskeletal origin is not unusual, and to suggest this must be 
neuropathic is “nonsense”.203  
Once the LANSS scale was constructed, a further 20 neuropathic and 20 
nociceptive pain patients were recruited to examine the validity and reliability.  
Each patient received the screening questionnaire twice, by both the 
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investigator and also an independent clinician in order to examine inter-rater 
agreement. In this cohort, the LANSS reported 85% sensitivity and 80% 
specificity, with good internal consistency between items and good agreement 
between the ratings of the investigator and clinician. Cronbach’s alpha was 
0.74. 
One criticism of the LANSS was the exclusive use of neuropathic pain patients 
with peripheral nerve injury to develop and validate the tool, with concerns that 
the performance of the tool in identifying patients with central neuropathic pain 
(such as post-stroke pain or spinal cord injury) may be impaired.202 
Nevertheless, subsequent publications recommended the LANSS for use in this 
context, and other authors describe cohorts of spinal cord injury patients with 
neuropathic pain and confirmatory high LANSS scores.204, 205 However, in a 
Swedish study examining the accuracy of screening tools in this population, the 
LANSS did not perform as well as the original validation study (sensitivity 
35.7%, specificity 100%, agreement 55%).206 
The LANSS has been tested and validated in a number of other settings, 
including diverse diseases, cultural and language groups. The LANSS has been 
translated into Spanish, with a sensitivity of 91% and specificity of 89%.207 
Similarly, Turkish versions of the LANSS returned sensitivity of 70-90% and 
specificity of 94-97%.208, 209 An Ethiopian version returned sensitivity of 85% 
and specificity of 42% (although the results may be influenced by the study 
population, which entirely comprised patients with leprosy).210 A Chinese 
version of the LANSS returned 80% sensitivity and 97% specificity.211 In a 
population with head and neck cancer, Potter et al., showed a sensitivity of 79% 
and a specificity of 100%.212 The LANSS has been used to estimate the 
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prevalence of neuropathic pain in a variety of conditions including back pain, 
Parkinson’s disease, trauma, musculoskeletal pain, and leg ulcers.162, 201, 213-216 
The relative consistency in diagnostic accuracy across several settings 
suggests the initial validation study of the LANSS is likely to represent an 
accurate reflection of sensitivity and specificity, especially if examining patients 
who are likely to have peripheral neuropathic pain. 
The LANSS pain scale has subsequently been modified into a self-report 
version, dubbed the S-LANSS.196 The use of examination items (pin prick, and 
light touch) and the intention for the screening tools to be healthcare worker 
administered hampered the use of the LANSS for large scale epidemiological 
research both in the clinical setting and also by survey. The S-LANSS 
(appendix 2) was designed to overcome this problem by removing the need for 
clinical examination and by ensuring the patients could complete it themselves.  
Of the 5 original symptom questions from the LANSS, only question 4 (related 
to symptoms of electric shocks and spontaneous pain) remained unchanged. 
The other 4 questions underwent subtle alterations in the S-LANSS version, 
although the essence of the questions remained the same, with the same 
symptoms groupings as the original LANSS.  The 2 LANSS examination items 
were altered to prompt the patient to examine the painful area themselves (with 
a finger), attempting to elicit allodynia and/or hyper or hypoalgesia in common 
with the original LANSS questions. Scoring and cut off points for the diagnosis 
of neuropathic pain in the S-LANSS remained identical to the LANSS. A body 
map, to indicate pain site and a 0-11 numerical rating scale of pain intensity 
were added. 
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The new scale was initially validated in both a clinic setting, and then in a postal 
validation study. In the clinical validation study, 200 patients were diagnosed 
with either neuropathic (n=100) or nociceptive (n=100) pain by an experienced 
pain physician using history, examination and investigations. The patients then 
completed the S-LANSS unaided and also by interview. The sensitivity and 
specificity of the unaided S-LANSS was 74% and 76% respectively, and the S-
LANSS completed by interview 74% and 83%. Cronbach’s alpha was 0.76 and 
0.81 for the self completed and interview completed scores. The validity of the 
S-LANSS was further confirmed by comparison with the NPS, and examining 
the relationship between each S-LANSS item and the total score/clinical 
diagnosis 
The S-LANSS was also validated in a postal survey setting against a proxy gold 
standard of a simultaneously completed NPS. A mixture of general practice and 
pain clinic patients returned 174 completed surveys, and the S-LANSS 
demonstrated to perform in a similar way to the clinic validation study when 
compared to the NPS. Cronbach’s alpha for the postal survey group was 0.8. 
Like the LANSS, the S-LANSS failed to correctly classify 20-25% of patients, an 
important limitation for a screening tool aimed at gathering epidemiological 
data. The reliance on a gold standard comparator of diagnosis by an 
experienced pain clinician potentially adds further diagnostic variance and 
therefore influences the validity of the scale, although at the time of 
development there was an absence of consistent, clear and testable definitions 
of neuropathic pain. To compound this problem, postal survey results were 
themselves compared to a tool not validated as a screening tool for neuropathic 
pain (the NPS).  
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The potential variability in the gold standard comparator for the S-LANSS has 
been cited as one possible reason why subsequent studies have demonstrated 
lower sensitivity and specificity than the original validation cohort. In a study of 
community-based patients in North America, Weingarten et al., (2007) 
compared a postal, self-completed S-LANSS and telephone interview S-LANSS 
with clinical assessment.217 The sensitivity and specificity for the self-completed 
S-LANSS was 57% and 69% respectively, and for the interview S-LANSS 52% 
and 78%. Both values are significantly less than the initial S-LANSS validation 
study. The authors demonstrated that the self-examination items, to test for 
altered sensation, only demonstrated modest agreement with clinical 
examination (sensitivity 61-80% and specificity 58-71% depending on the item 
and method of applying the questionnaire).217 In addition, the calculated odds 
ratios for each item, from which the item weighting was derived, differed from 
the original LANSS odds ratios that were used in the questionnaire 
development.  
Although the results of this study question the validity of using the S-LANSS as 
an epidemiological tool to assess the prevalence of neuropathic disorders, the 
study was not without potential confounding factors. Firstly, a number of 
patients deemed to have neuropathic pain by clinical assessment also had 
significant nociceptive pain. Patients were assigned to the neuropathic pain 
group if any of their pain component was neuropathic, so some patients may 
have had sensory disturbance suggestive of neuropathic pain but overriding 
nociceptive pain experience and verbal descriptors. The S-LANSS would tend 
towards classifying these patients as having predominantly nociceptive pain, 
whereas in the study having even a minor contribution of neuropathic pain in 
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the overall pain experience would lead them to be classified in the neuropathic 
category at clinical examination. Clearly, this would adversely affect the 
sensitivity and specificity of the questionnaire. A further confounding factor was 
the length of time taken between assessment methods. The delay between 
mailed questionnaire and clinical assessment was 15 months, during which 
symptoms and signs may have changed significantly, indeed 10 subjects had 
resolution of their pain completely by the time of their clinical assessment. Such 
factors may explain the differences between the reported sensitivity and 
specificity in this study and both the original validation study and further 
validation performed on a Turkish version of the questionnaire, which reported 
similar sensitivity (72%) and specificity (80%) to the original results.218 
The validity of the S-LANSS has been further examined by comparison with 
other screening tools and measures of neuropathic pain. In a cohort of breast 
cancer survivors, the total ID Pain score was significantly associated with the 
total S-LANSS score (r=0.54, P <0.001).219 Similarly, there was a moderate to 
high correlation between total scores in a modified painDetect questionnaire 
and the S-LANSS in osteoarthritis patients (r=0.73, P<0.0001).220 Lastly, in an 
observational study of patients with radicular leg pain, the S-LANSS was 
compared with the DN4, with again moderate to good correlation in total scores 
(r=0.62, P,0.001), although only fair agreement on neuropathic pain diagnosis 
suggesting incongruent cut off points.221 Two independent studies using the S-
LANSS and DN4 interview to estimate the prevalence of neuropathic pain in the 
general population in the UK and France respectively provided remarkably 
similar estimates (8.2% and 6.9%), adding to the argument for the validity of 
these tools.42, 43 
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One advantage of the S-LANSS was the high completion rates (95-99% for 
each question in the original validation study), supporting the acceptability of 
the questionnaire in postal research. Indeed the S-LANSS has been used 
extensively in investigating the prevalence of neuropathic pain in a number of 
diverse conditions including: pelvic pain, sarcoma, metastatic bone disease, 
dental surgery, ischaemic pain and the general population.42, 222-227  
A further attribute of the S-LANSS is the correlation of the total score with 
clinician certainty of a neuropathic pain component in a mixed picture of pain.228 
Clinical scenarios rarely produce pain of ‘pure’ nociceptive or neuropathic pain, 
rather they are often a mixed picture (such as the diabetic with peripheral 
neuropathy and ulcers, or the back pain patient with radicular leg symptoms). 
This has led to the suggestion that pain can be more or less neuropathic, a 
construct supported by a study comparing S-LANSS scores with clinical 
certainty of a neuropathic component being unlikely, possible or definite.228  
If screening tools such as the S-LANSS support the concept that pain can be 
more or less neuropathic, the natural suggestion would be to question whether 
or not screening tools are sensitive to changes in the degree of neuropathic 
pain a patient may experience with treatment. Indeed, a number of clinical trials 
have used the LANSS screening tool as an outcome measure, and have 
demonstrated corresponding reductions in LANSS and pain intensity scores in 
treatment groups compared to controls.229-233 
The LANSS based screening tools offer a number of potential attributes to 
examining the prevalence of acute neuropathic pain in the post-surgical 
population. However, although these screening tools have been validated in 
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chronic pain patients, their modern psychometric properties have not been fully 
examined. The use of the LANSS as an outcome measure, although appears to 
have some face validity, has not been formally assessed. The fact that the 
LANSS has been used in this way, despite being designed as a screening tool, 
suggests a need for an outcome tool that reflects not simply change in pain 
intensity, but also change in neuropathic pain in response to treatment. 
Pain is not directly measurable unlike many attributes in the physical sciences 
(for example length or weight). When a property is directly measureable, such 
as length, devising a measurement tool is relatively straightforward. The meter 
can be used to measure any structure, and remains unaffected by the item it is 
measuring, i.e. the interval between scale points on the meter does not vary 
with the item measured, thus the meter is an interval level measurement tool. In 
contrast, pain is a ‘latent trait’ that cannot be measured directly, and is normally 
assessed by the use of ordinal scales. The LANSS and the VAS would be 
examples of an ordinal scale; pain scores can be ranked but the distance 
between each point on the scale does not necessarily reflect equidistant steps 
in the underlying trait.234 Furthermore, the level of pain required to reach a 
particular step on the scale may vary between subjects. 
Ordinal scales are useful to determine if a patient has improved or worsened 
with treatment, and can separate patients into groups based on the magnitude 
of pain, and data from ordinal scales can be subjected to non-parametric 
statistics to aid interpretation of results. However, the type of analysis common 
to medical outcome studies often involves calculation of change scores, % 
improvement, effect sizes and minimum clinically important difference. Strictly 
speaking, this requires interval level scales that are capable of parametric 
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analysis.235 Ordinal scales on the other hand do not support the mathematical 
operations needed to calculate means and standard deviations.236 
Modern psychometric approaches to scale design and analysis are able to 
create interval level measurement of underlying latent traits, based on the 
theory that the important indication of a measurement structure is in the 
relationship between variables, not the physical values themselves. The 
practical realization of this theory of conjoint mechanism takes the form of 
Rasch analysis. Rasch analysis is the testing of a scale against a mathematical 
model that formalizes the axioms of conjoint measurement, and is capable of 
transforming ordinal scales into interval level measurement providing the data fit 
the Rasch model to an acceptable degree.237 
For example, a neuropathic pain scale that satisfied the expectations of the 
Rasch model could be used to calculate the effect of treatment on an interval 
scale. This would have important implications for research and clinical practice. 
The LANSS was developed as a neuropathic pain screening tool, however it 
may have properties that allow it to discriminate the magnitude of neuropathic 
pain experienced by a patient, and it appears to demonstrate change in relation 
to neuropathic pain treatment. No existing neuropathic pain tools have been 
developed to Rasch model standards, such that they can be used as interval 
level measurement tools. In order to explore this gap in knowledge about the 
properties of the LANSS tool, which may have implications for the way the tool 
can be used, and the statistics applied to data collected using it, the LANSS 
was investigated to see if it could satisfy Rasch model expectations and be 
transformed into an interval level measurement scale both in a general pain 
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population and more specifically in a cohort of patients with chronic 
postoperative pain.  
2.4 Methods 
This study used data collected by a group of researchers in Belgium who 
performed a multicentre observational survey on 2480 pain patients with the 
aim of examining how neuropathic pain conditions are diagnosed and managed 
in daily practice.238 As part of this study, 177 general practitioners and 97 
specialists were asked to complete a LANSS questionnaire on consecutive 
patients presenting with chronic pain (>3 months duration) of any cause. Data 
on the possible underlying cause of pain, and demographic details were also 
recorded as part of the study. Clinicians were able to choose more than one 
diagnostic category if more than one pain generator were present, or there was 
diagnostic uncertainty. The frequency of different underlying diagnostic groups 
is presented in table 2.2. 
The Belgian study was supported by the pharmaceutical company Pfizer who 
kindly granted full access to the original data. LANSS data from this study were 
formatted in SPSS prior to exporting as an ASCII file to RUMM2020 Rasch 
analysis software (RUMM Laboratory Pty Ltd.) for analysis. Rasch analysis was 
performed on both a random representative sample of all LANSS patients 
(n=400), and analysis of individual underlying disease diagnoses where the 
number available for analysis was greater than 150 (following exclusion of 
extreme scores). These groups comprised postsurgical pain, diabetic 
neuropathy, osteoarthritis, post-traumatic injury and low back pain. 
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Rasch analysis of the LANSS data included a number of investigations 
including fit to the Rasch model, scale reliability, scale multi-dimensionality and 
differential item functioning. 
 
 
 
 
 
 
 
 
 
 
2.4.1 Fit to the Rasch Model 
Each LANSS question has only two response options (yes or no), therefore the 
dichotomous Rasch model was chosen to compare the difference between the 
observed responses (from the LANSS data) and those expected by the Rasch 
mathematical model. These differences, termed fit statistics are based on chi-
Diagnosis Number of patients 
Diabetic neuropathy 253 
Cancer 75 
Low back pain 781 
Osteoporosis 184 
Multiple Sclerosis 38 
Thalamic syndrome 11 
Post-herpetic neuralgia 163 
Post traumatic injury 326 
CRPS 178 
Alcohol abuse 85 
Syringomyelia 11 
Other 499 
Post-surgical lesion 232 
Carpal tunnel 91 
Osteoarthritis 590 
Post CVA 76 
Table 2.2 Frequency of underlying causes for chronic pain recorded by Hans et al., (2007) and 
used in the Rasch analysis of LANSS data. 
CRPS = Complex Regional Pain Syndrome, CVA = cerebrovascular accident 
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square calculations. RUMM2020 chi-square statistics compare the difference in 
observed and expected values across groups with different ability levels (‘ability’ 
in the case of the LANSS refers to different levels of neuropathic pain).237 For a 
given LANSS question, a number of chi-square values are calculated across 
ability groups, and then summed to give an overall statistic for that item.237 
Residual statistics describe the standardized sum of all differences between 
observed and expected values summed over all persons.237 Invariance across 
the trait is examined using a sum of the individual item chi-square values. This 
is termed the item-trait interaction fit statistic.237 The data are also examined for 
aberrant response patterns from individuals, which may raise questions about 
the construct validity of the scale in a particular population. This analysis is 
termed person fit statistics, and is reported as a residual in a similar manner to 
item fit. 
With perfect fit to the Rasch model, item and person residuals would have a 
mean of 0 and a standard deviation of 1. The chi-square item-trait interaction 
should be non-significant. For each individual item, fit residuals should lie 
between +/- 2.5 and chi-square results should be non-significant. 
2.4.2 Scale Reliability 
RUMM2020 reports a statistic termed the person separation index. This is an 
estimate of the internal consistency reliability of the scale, and as such indicates 
the power of the scale to discriminate among respondents. This statistic is 
analogous to Cronbach’s alpha (using the calculated logit value instead of the 
raw score). The interpretation of the person separation index is the same as 
Cronbach’s alpha, with a value of 0.7 regarded as the minimum acceptable to 
differentiate between two groups, and 0.9 to allow use on an individual level.239 
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2.4.3 Scale Multi-Dimensionality 
The LANSS was examined to ensure that the scale is measuring only one latent 
construct (in this case, assumed to be neuropathic pain). This was by two 
methods, firstly through a confirmatory factor analysis based upon a tetrachoric 
correlation, and secondly via a method recommended by Smith (2002) for use 
within Rasch analysis.240 
Confirmatory factor analysis was used initially to test the construct validity of the 
scale, as with only seven LANSS questions, principal component analysis of the 
residuals is likely to be underpowered. The latter test is based on the 
assumption that once the Rasch factor has been removed, there should be no 
relationship (other than random ones) between the LANSS questions. The test 
recommended by Smith (2002) involves using t-tests to compare person-
locations based on different subsets of items located on the same scale.240 If 
less than 5% of the t-test comparisons are significant, the scale is considered 
unidimensional. 
2.4.4 Differential Item Functioning (DIF) 
A key aspect of a measurement scale is invariance across different populations 
being measured. Differential Item Functioning occurs when different groups 
within a sample have a tendency to respond to scale questions in a different 
manner, for example, if women answered questions on the LANSS scale very 
differently to men, or younger persons answered differently to older persons. 
For the LANSS to demonstrate measurement properties, the response to a 
question should only depend on the level of neuropathic pain, irrespective of 
gender or age group. The LANSS was tested for DIF within RUMM2020 across 
gender and three age groups (0-35, 36-70, 71-99). 
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2.5 Results 
2.5.1 Unidimensionality and Fit to the Rasch Model 
Confirmatory factor analysis (CFA) on a random sample of 400 cases was 
performed by Professor Tennant, co-author of a research paper based on this 
work.241 CFA indicated a strong unidimensional construct with a Root Mean 
Square Error of Approximation of 0.00; Comparative fit index (CFI) and Tucker-
Lewis index  (TLI) of 1.0.  
Data were then analyzed for fit to the Rasch model. Both the random sample of 
400 cases across diagnostic categories was analyzed, and also individual 
diagnostic categories with >150 respondents. Individuals with extreme scores 
(representing the maximum and minimum score on the LANSS scale) were 
excluded from the analysis (as there is no variation in their responses), hence 
the final number used in the calculation differs from the original number of 
respondents in that diagnostic category. 
Summary Rasch statistics are presented in table 2.3. The Person Separation 
Index was 0.7 across all groups, indicating the scale has reliability consistent 
with use at the group level. Only two diagnostic categories, diabetic neuropathy 
and chronic post-surgical pain demonstrated acceptable fit to the Rasch model 
(demonstrated by non-significant Chi-square interaction statistics). Data from 
these two groups were further examined for unidimensionality, DIF and local 
dependency. 
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Further tests of unidimensionality were performed in the two groups that fit the 
Rasch model to an acceptable degree. Independent t-tests were used to 
compare person locations that had been estimated using two different subsets 
of items from the final scale. The three highest positive loading items on the first 
residual component were compared with the four highest negative loading items 
(with both sets calibrated on the same metric scale). For the diabetic 
neuropathy population, 170 t-test comparisons were made, and 173 
comparisons in the post-surgical pain group. None of these were significant, 
further supporting the unidimensionality of the scale in this group. 
2.5.2 Differential Item Functioning (DIF) 
No LANSS questions demonstrated evidence of uniform or non-uniform DIF 
(following Bonferroni adjustment) between gender or age groups, in both the 
diabetic neuropathy and post-surgical pain cohorts. The LANSS scale items are 
measuring the same construct across these person factors. 
2.5.3 Local Dependency 
Local dependency occurs when an individual’s response to one question on the 
scale will influence their response to another different question on the scale. 
RUMM2020 searches for positive correlations among item residuals, to 
determine if local dependency exists. For the LANSS groups, no question had 
correlations greater than 0.3 in both groups analyzed, indicating an absence of 
local dependency. 
2.5.4 Item-Person Threshold Distributions 
As the diabetic neuropathy and post-surgical pain groups of LANSS data fit the 
Rasch model to an acceptable degree, it was possible to create a distribution 
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map comparing LANSS question difficulty with distributions of person ‘ability’ on 
the same logit scale. These are termed item-person threshold distribution maps 
and are presented in figures 2.1 and 2.2 for diabetic neuropathy and post-
surgical pain respectively. In both groups the item difficulties are spread through 
the middle of the ability range, with some evidence of a floor and ceiling effect 
(meaning the scale is less discriminating at lower and higher levels of 
neuropathic pain). 
The raw scores for the LANSS scale were transformed into interval scale scores 
and are presented in table 2.4. 
 
 
 Interval score (logits) 
LANSS raw score Diabetic neuropathy 
 
Post-surgical pain 
 
0 -2.66 -2.56 
1 -1.73 -1.64 
2 -0.98 -0.92 
3 -0.36 -0.32 
4 0.23 0.25 
5 0.90 0.87 
6 1.78 1.67 
7 2.88 2.68 
 
Table 2.4 Rasch transformed interval scale scores (in logits) for diabetic neuropathy and post-
surgical pain patients. 
LANSS = Leeds Assessment of Neuropathic Symptoms and Signs  
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Figure 2.1 Rasch analysis item person threshold map for diabetic neuropathy pain patients. 
 
 
 
Figure 2.2 Rasch analysis item person threshold map for Post-surgical pain patients 
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2.6 Discussion 
Item response theory, and in particular Rasch analysis is being increasingly 
used to develop and evaluate outcome measures within medicine. No previous 
study has sought to investigate the modern psychometric measurement 
properties of a neuropathic pain screening tool such as the LANSS using item 
response theory or Rasch analysis. This is an important gap in knowledge, as 
this scale has already been used as an outcome measure in published studies. 
Although the LANSS based scales seem to be able to differentiate pain that is 
more or less neuropathic, and show response to treatment effect, they were not 
designed to be used in this way and have not been formally validated in this 
context. Rasch analysis provides a way of assessing the validity of using the 
LANSS as a measurement tool. 
Analysis of the LANSS data shows that for patients with diabetic neuropathy 
and chronic post-surgical pain, the LANSS fits the Rasch measurement model 
to an acceptable degree. The scale measures a single construct (neuropathic 
pain), and does not vary across gender or age group. LANSS raw scores could 
therefore be transformed into interval level measurement for these groups. 
There are a number of limitations to this interpretation. Importantly, the reliability 
of the LANSS only allows statistical interpretation at the group level, and cannot 
be reliably used to measure change in individuals. The LANSS has a relatively 
low number of questions for a measurement scale (7), and this is likely to 
contribute to its poor discriminatory properties at either end of the neuropathic 
pain spectrum. Classical tests of reliability are not well suited to non-normal 
distributions found in population screening tools, where the emphasis is on a 
cut point, not the fact that large numbers of people are well below this 
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level.242Screening tools need the test information function to be maximized at 
the cut point, which explains the poor levels of precision (when transformed to 
an interval measure) at the margins of the scale. 
Neither should the LANSS be used as a generalized measurement tool across 
pain diagnostic groups, and the analysis shows the LANSS does not fit the 
Rasch model to an acceptable degree when used across all pain diagnostic 
categories. This may reflect the fact that the analysis included pain diagnoses 
that are more associated with nociceptive pain (such as osteoarthritis and low 
back pain). Assuming the construct the LANSS is measuring is neuropathic 
pain, it is not surprising that it failed to demonstrate measurement properties in 
these groups. In contrast diabetic neuropathy is regarded as neuropathic pain, 
and the LANSS shows measurement properties in this group. The fact that the 
LANSS also demonstrates measurement properties in patients with chronic 
post-surgical pain lends further weight to the hypothesis that this condition is 
commonly a neuropathic pain state. 
To date, only one other scale assessing the quality of pain has been assessed 
with item response theory. The Pain Quality Assessment Scale (PQAS) is a 
revised version of the Neuropathic Pain Scale (NPS), to which were added 
questions to allow assessment of non-neuropathic pain.243 Although this scale 
was designed as a measurement tool across pain categories, it demonstrated a 
number of issues when examined with item response theory. These included 
variability in the precision of the subscales and a lack of interval 
scaling/redundant items for the 0 to 10 response levels.244  
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Despite its weaknesses, the LANSS therefore is the only neuropathic pain tool 
to have demonstrated neuropathic pain measurement properties in a cohort of 
patients with chronic post-surgical pain. The psychometric properties of the 
LANSS elicited by the Rasch analysis lend support to its use to further assess 
neuropathic pain following surgery, during the immediate post-operative period.
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3 The prevalence of acute & chronic neuropathic pain 
following thoracic surgery 
 
3.1 Introduction 
From the evidence presented in Chapter 1, there are basic science and clinical 
reasons to suggest that a proportion of postoperative patients experience a 
significant neuropathic component to their acute pain experience. The 
epidemiology of this acute postoperative neuropathic pain is poorly described, 
with only one prospective audit published on the topic.174 This study had a 
number of potential methodological flaws including a failure to exclude patients 
with pre-existing neuropathic pain, only evaluating patients with poorly 
controlled pain and a failure to use a validated method of neuropathic pain 
assessment.   
It was hypothesized that some patients experience a significant neuropathic 
component to their acute post surgical pain experience, and that these patients 
would be at risk of developing chronic neuropathic pain following surgery. The 
research presented in this chapter aims to estimate the prevalence of acute 
neuropathic pain following thoracic surgery, and also whether acute neuropathic 
pain is associated with the development of chronic neuropathic pain 3 months 
later. 
Patients undergoing thoracic surgery were chosen as the study population. 
Chronic pain following thoracic surgery is widely reported as a common 
complication; the prevalence is often reported as >50% (table 3.1).  
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Reference N= Surgical approach Chronic pain time point Chronic pain prevalence 
Dajczman et al., (1991)245 56 T 20 months* 54% 
Kalso et al., (1992)246 134 - 30 months* 44% 
Richardson et al., 
(1994)247 
883 T 2 months 22% 
Richardson et al., 
(1994)247 
883 T 12 months 14% 
Landreneau et al., 
(1994)146 
142 V 3-12 months 30% 
Landreneau et al., 
(1994)146 
36 V 13-31 months 22% 
Landreneau et al., 
(1994)146 
97 T 3-12 months 44% 
Landreneau et al., 
(1994)146 
68 T 13-31 months 29% 
Bertrand et al., (1996)248 146 V 25 months 63%# 
Bertrand et al., (1996)248 87 T 33 months 61%# 
Katz et al., (1996)167 23 T 18 months 52% 
Perttunen et al., (1999)249 62 T 12 months 61% 
Obata et al., (1999)250  28 T 3 months 50% 
Obata et al., (1999)250 30 T 3 months 77% 
Obata et al., (1999)250  28 T 6 months 33% 
Obata et al., (1999)250 30 T 6 months 67% 
Passlick et al., (2001)251 60 V 59 months* 32% 
Gotoda et al., (2001)137 85 T 12 months 41% 
Ochroch et al., (2005)252 120 T 3 & 4 months 45% 
Ochroch et al., (2005)252 120 T 6 months 35% 
Ochroch et al., (2005)252 120 T 9 & 12 months 21% 
Maguire et al., (2006)253 482 T 7 months-7years 45% 
Maguire et al., (2006)253 118 V 7 months-7years 41% 
Maguire et al., (2006)253 31 T 3 months 52% 
Pluijms et al., (2006)254 149 T 6-42 months 52% 
Steegers et al., (2008)255 144 T 23 months* 40% 
Steegers et al., (2008)255 60 V 23 months* 47% 
 
Table 3.1 The reported prevalence of chronic post thoracic surgery pain  
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V=Video Assisted Thoracoscopic Surgery, T=Thoracotomy, N = number of patients examined 
Of these patients with chronic pain, 52-66% will have a neuropathic pain 
component.135  
The chest wall is richly innervated with nerve supply, and a number of studies 
have demonstrated objective evidence of nerve damage following both 
thoracotomy and also video assisted thoracic surgery (VATS) procedures.64-66 
Signs of nerve damage seem to be associated with more severe acute pain 
following thoracic surgery.64 In turn, the severity of acute pain seems to predict 
the development of chronic pain after thoracic surgery.167 
With a relatively high prevalence of chronic neuropathic pain and well described 
mechanisms of nerve injury at the time of surgery, thoracic surgery patients 
would appear to be an ideal population to explore the existence of acute 
postoperative neuropathic pain.  
The proportion of patients experiencing acute neuropathic pain in the thoracic 
surgery population is not known. Although acute pain intensity following thoracic 
surgery is associated with the development of chronic pain, it is not known if 
pain character predicts the development of chronic neuropathic pain in this 
population. 
The aim of this study was to determine the incidence of acute and chronic 
neuropathic pain following thoracic surgery. It was hypothesized that the 
occurrence of acute neuropathic pain characteristics following thoracic surgery 
would be associated with significantly higher odds of developing chronic 
neuropathic pain characteristics 3 months later. 
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3.2 Methods 
3.2.1 Study design 
The study was designed as a prospective, observational cohort study. After 
ethics committee approval, adult patients admitted to St James’s University 
Hospital (Leeds, UK) for VATS or thoracotomy were recruited. Patients were 
excluded if they had previously undergone VATS or thoracotomy, had 
previously diagnosed neuropathic pain or were pregnant.  
The primary aim was to assess the proportion of patients who experienced 
acute neuropathic pain characteristics following thoracic surgery. The 
secondary aim was to investigate the incidence of chronic neuropathic pain in 
this cohort 3 months after surgery, and to explore possible links between the 
two.  
Following a review of neuropathic pain assessment tools (outlined in chapter 2), 
the LANSS and S-LANSS neuropathic pain screening tools were chosen. We 
used screening tools rather than clinician assessment alone, to ensure 
consistency and reduce missing data between assessments in the acute and 
follow up periods. In addition, the validity of using the LANSS based screening 
tools in the post-surgical neuropathic pain population was enhanced by the 
Rasch analysis presented in Chapter 2, which demonstrated the tool had some 
measurement properties in this population. 
Following informed consent, a medical researcher performed a baseline pre-
operative LANSS score on the day before scheduled surgery (performing the 
examination items at the expected site of surgery). Patients who had positive 
LANSS scores at this stage were withdrawn from the study. Patient 
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demographics and the operation performed were recorded. During the post-
operative period the medical researcher repeated the LANSS score whilst the 
patient was in hospital. This examination was conducted at least 24 hours after 
regional or local anaesthetic infusion or injection had ceased. Three months 
following their operation, patients were sent an S-LANSS questionnaire by post. 
This self-report version of the LANSS score included a numerical rating scale 
(anchored 0: no pain and 10: severe pain) recording pain intensity. Those failing 
to return the postal questionnaire were telephoned after a further two weeks 
and where possible the S-LANSS was completed by telephone interview.  
3.2.2 Surgical technique 
Patients undergoing thoracotomy were positioned on the appropriate lateral 
side, and a standard posterolateral thoracotomy was performed with division of 
the latissimus dorsi muscle and sparing of serratus anterior muscle.  Division of 
rib was not performed and the ribs were spread using a Holme-Sellars self-
retaining retractor.  Patients undergoing VATS procedures had between one 
and three ports depending on the procedure performed.  If more than one port 
was used, where possible these were placed in the same intercostal space. 
A paravertebral catheter was placed under direct vision at the end of the 
surgical procedure in a number of patients, as outlined in the results 
3.2.3 Sample size calculation 
Initially we aimed to recruit 125 patients to the study. This allowed a loss of 20% 
at follow up to give a final sample size of 100. This sample size allowed 
estimates of acute neuropathic pain within at least 10% of the true population 
incidence (with 95% confidence intervals). Even if acute neuropathic pain in 
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thoracic surgery patients was rare, such as the 3% incidence previously 
described (in all post operative patients), this study sample size would provide a 
good chance of detecting it (95% power) 174. 
If the incidence of acute neuropathic pain was greater than 25% there would be 
adequate power to detect an important association with chronic neuropathic 
pain at 3 months (80% power at 5% significance for a risk ratio of 2). 
3.2.4 Statistical methods 
Pain in patients with a LANSS or S-LANSS score ≥12 was considered to be 
neuropathic. Relative risks and Odds ratios were used to express and quantify 
any association between acute neuropathic pain and chronic neuropathic pain, 
with Fisher’s exact test being used to calculate the significance of any such 
associations in this, and in other, 2x2 contingency tables. Any possible 
relationships between chronic neuropathic pain and other factors (such as the 
pre-operative LANSS score) were investigated using stepwise logistic 
regression analysis with the statistical package STATA. This statistical analysis 
was performed by the statistician Dr Walter Gregory working on behalf of the 
Clinical Trials and Research Unit in Leeds. Relative risks and their associated 
confidence intervals were calculated as described by Altman 256. 
3.3 Results 
3.3.1 Patient characteristics 
115 patients were recruited to the study between October 2007 and September 
2008. Fifteen patients were withdrawn from the study. One patient was 
excluded because of pre-existing neuropathic pain identified by a baseline pre 
operative LANSS score ≥12. One patient was admitted to intensive care 
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following surgery and subsequently died. One patient withdrew consent to 
participate in the study in the post-operative period. Twelve patients were 
recruited but had their operation cancelled, postponed or did not proceed to 
VATS or thoracotomy. The number of patients recruited and completing 
assessments at each stage of the study is presented in figure 3.1. 
Analysis of the data was based on the remaining 100 patients. The average age 
(mean) was 62 (range 17-88). There were 64 males and 36 females in the 
cohort. Data relating to operation type are presented in table 3.2.  
Operation type N= 
Thoracotomy 48 
VATS 49 
VATS & Mini thoracotomy 2 
VATS & thoracotomy 1 
 
Table 3.2 The number of patients receiving VATS and thoracotomy procedures assessed for acute 
neuropathic pain using the LANSS questionnaire. 
VATS = Video Assisted Thoracoscopic Surgery, N = number of patients, LANSS = Leeds 
Assessment of Neuropathic Symptoms and Signs.
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Completed pre-operative 
LANSS 
n=115 
Patients withdrawn 
from study  
n=15 
Completed post-
operative LANSS 
n=100 
Completed   
postal      
S-LANSS 
n=57 
Completed 
telephone 
S-LANSS 
n=30 
Thoracic surgery patients 
recruited to the study 
 n=115 
Figure 3.1 The number of patients recruited and completing each stage 
of the acute neuropathic pain prevalence study. 
n = number of patients, LANSS = Leeds Assessment of Neuropathic 
Symptoms and Signs, S-LANSS = Self report version of the Leeds 
Assessment of Neuropathic Symptoms and Signs 
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There was an even split between thoracotomy and VATS procedures, with a 
small minority having both procedures. 
The reason for operation was recorded, with 65 patients having malignant 
disease. Thirty-one patients had non-small cell lung cancer, 6 had 
mesothelioma, 20 had metastatic cancers. A variety of other pathologies were 
recorded including 2 carcinoid, 1 empyema, 1 interstitial pneumonia, 1 
leiomyosarcoma, 1 pneumothorax and 1 thymoma.  
The different forms of primary post-operative analgesia used are presented 
according to operation type in table 3.3. 
 
Type of 
operation 
Intravenous 
morphine(via 
PCA) 
Thoracic 
paravertebral 
block 
Thoracic 
epidural 
Intercostal 
nerve block 
 
Video assisted 
thoracoscopic 
surgery (VATS) 
33 (67%) 24 (49%) 1 (2%) 4 (8%) 
Thoracotomy 41 (85%) 39 (81%) 5 (10% 7 (12.5%) 
VATS & 
thoracotomy 3 (100%) 2 (66%) 1 (33%) 0 (0%) 
All procedures 77% 65% 7% 11% 
 
Table 3.3  Types of post-operative analgesia used by patients assessed for acute neuropathic pain 
using the LANSS questionnaire (number of patients and percentage of total) 
VATS = Video Assisted Thoracoscopic Surgery, PCA = Patient Controlled Analgesia 
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3.3.2 Prevalence of acute and chronic neuropathic pain 
One hundred patients completed the LANSS score an average (mean) of 3 
days post operation (range 1-6 days). Eight patients (8%) developed acute 
neuropathic pain in the early post-operative period (defined as a LANSS score 
≥12). None of these 100 patients had pre-operative neuropathic pain identified 
by pre-operative LANSS screening.  
Eighty-seven of the 100 patients completing pre and early postoperative LANSS 
assessments subsequently completed postal or telephone S-LANSS 
questionnaires an average (mean) of 110 days following their procedure (range 
86-213 days). One patient died during the three months period following their 
operation and a further 12 patients did not respond to the postal questionnaire 
or telephone contact.  
Of these 87 patients, 19 (22%) had chronic neuropathic pain (defined as an S-
LANSS ≥12). Eighty five patients completed the numerical rating scale (NRS) 
component of the S-LANSS questionnaire, revealing 53 (62%) had some 
degree of chronic pain following their operation. There was a significant 
difference in the NRS scores when comparing those with chronic neuropathic 
pain (S-LANSS ≥12) with those with chronic nociceptive pain (S-LANSS <12) 
following their operation, with those with neuropathic pain having more severe 
pain intensity. The median NRS score for those with nociceptive pain was 1, 
compared to the median NRS score of 5 for those with neuropathic pain (Mann-
Whitney W statistic 2297, p<0.00001). The distribution of NRS scores in the 
neuropathic and nociceptive groups are presented in table 3.4.   
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NRS score 3-month 
S-LANSS<12 
N (%) 
3-month 
S-LANSS ≥12 
N (%) 
 
0 32 (49) 0 (0) 
1 9 (14) 0 (0) 
2 10 (15) 3 (16) 
3 6 (9) 3 (16) 
4 1 (1) 2 (11) 
5 2 (3) 5 (26) 
6 1 (1) 2 (11) 
7 2 (3) 2 (11) 
8 2 (3) 2 (11) 
9 0 (0) 0 (0) 
10 0 (0) 0 (0) 
 
 
Table 3.4 Distribution of numerical rating pain intensity scores (NRS) according to S-LANSS 
category of neuropathic (score ≥12) or nociceptive (score <12) pain. 
S-LANSS = Self report version of the Leeds Assessment of Neuropathic Symptoms and Signs, N = 
number of patients 
 
Interestingly, there is only a weak correlation between the total early post-
operative LANSS score and chronic pain intensity at three-month follow-up 
(r=0.18, p=0.0466), figure 3.2. Spearman’s rank correlation coefficient is non 
significant (0.12).  
Comparing categorical early post-operative LANSS data (dividing patients into 
nociceptive and neuropathic pain groups) also shows a lack of significant 
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difference in pain intensity at three-month follow-up (median of 1 and 3.5 
respectively, W statistic 3196.5 p=0.09). 
Patients with acute neuropathic pain were more likely to have chronic  
neuropathic pain at 3 months than those without acute neuropathic pain (5/8 
(62.5%) vs. 14/79 (18%), relative risk 3.5 (95% C.I. 1.7-7.2). Item one of the 
LANSS questionnaire (“Does your pain feel like strange, unpleasant sensations 
in your skin? Words like pricking, tingling pins and needles might describe these 
sensations”) was particularly predictive of 3 month chronic neuropathic pain, 
with a relative risk of 4.5 (95% C.I. 2.3-8.7), with 70% of patients who answered 
yes to this question developing chronic neuropathic pain compared to 16% of 
those who answered “no”. Relative risks and odds ratios for the univariate 
logistic model prediction of a neuropathic or nociceptive S-LANSS score at 3 
months are presented in table 3.5. In a multivariate logistic regression, the other 
Figure 3.2 Scatter plot showing correlation between early post-operative LANSS score and 3 
month pain intensity score. 
LANSS = Leeds Assessment of Neuropathic Symptoms and Signs, NRS = Numerical Rating 
Scale of pain intensity (0-10) 
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6 components of the LANSS did not add to the predictive capacity of question 
1. 
LANSS 
Item 
LANSS 
Positive post-
operatively  
[n (%)] 
S-LANSS 
Positive at 3 
months 
 [n (%)] 
Relative Risk 
(95% C.I.) 
Odds ratio 
(95% C.I.) 
Total ≥12 8 (8) 19 (22) 3.5 (1.7 – 7.2) 7.7 (1.5-39.7) 
1 11 (11) 25 (29) 4.5 (2.3 – 8.7) 12.6 (2.4-65.6) 
2 8 (8) 5 (6) 3.5 (1.7 – 7.2) 7.7 (1.5-39.7) 
3 26 (26) 36 (41) 1.8 (0.82 – 3.9) 2.2 (0.74-6.4) 
4 20 (20) 22 (25) 2.4 (1.1 – 5.2) 3.4 (1-11.1) 
5 17 (17) 8 (9) 2.2 (1.0 – 4.9) 3.0 (0.89-10.3) 
6 4 (4) 27 (31) 1.2 (0.2 – 6.6) 1.2 (0.12-12.5) 
7 55 (55) 41 (47) 1.8 (0.77 – 4.4) 2.2 (0.72-6.5) 
 
Table 3.5 Numbers (%) of thoracic surgery patients that were LANSS positive post-operatively; 
numbers that were S-LANSS positive at 3 month follow-up; relative risk and odds ratios for 
positive scores at 3 months if positive post-operatively 
n = number of patients, C.I. = confidence interval, LANSS = Leeds Assessment of Neuropathic 
Symptoms and Signs, S-LANSS = Self report version of the Leeds Assessment of Neuropathic 
Symptoms and Signs 
 
Unlike the pain intensity (NRS) measure at 3 months, there was a significant 
correlation between the total early post-operative LANSS score and the 3-
month S-LANSS score (r=0.33, p<0.001) (figure 3.3). 
Three patients who demonstrated acute neuropathic pain characteristics did not 
go on to develop chronic neuropathic pain. One patient with acute neuropathic 
pain characteristics had a NRS score and S-LANSS score of 0 at the three-
month follow-up. Of the other two patients with acute neuropathic pain who did 
not develop chronic neuropathic pain, both answered  “yes” to either item 3 or 
item 6 of the three month S-LANSS, suggesting that they may have had 
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symptoms or signs of allodynia, yet their total S-LANSS scores were 3 and 5. 
This is much lower than the 12 needed to make a diagnosis of chronic 
neuropathic pain. 
 
 
There was no correlation between chronic neuropathic pain and gender, type of 
operation or whether the underlying disease diagnosis was malignant or benign. 
Older patients were more likely to have chronic neuropathic pain (p= 0.04); 
although this was not significant once the post-operative LANSS score was 
included in a multivariate predictive model. Univariate and multivariate logistic 
regression analysis demonstrated no single analgesic technique was 
associated with the subsequent development of chronic neuropathic pain. 
Figure 3.3 Scatter plot showing correlation between total post-operative LANSS score and 3 
month S-LANSS score. 
 LANSS = Leeds Assessment of Neuropathic Symptoms and Signs, S-LANSS = Self 
report version of the Leeds Assessment of Neuropathic Symptoms and Signs. 
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Interestingly, using cut off points other than 12 on the LANSS to define pain as 
nociceptive or neuropathic in origin reduced the correlation between post-
operative LANSS and 3 month S-LANSS score, perhaps confirming this cut off 
point in the early post-operative period as appropriate. 
3.4 Conclusions 
The results of this study demonstrate that 8% of patients undergoing major 
thoracic surgery develop acute neuropathic pain characteristics in the 
immediate post-operative period and that 22% of patients have symptoms of 
predominantly neuropathic pain three months after their operation. Furthermore, 
the study demonstrates the presence of acute neuropathic pain symptoms and 
signs are significantly associated with the development of chronic neuropathic 
pain, suggesting that for some patients who develop neuropathic pain following 
surgery, the process can be identified early in the post-operative period using 
verbal descriptors and simple bedside examination techniques. 
3.4.1 Acute neuropathic pain 
Prior to this research, the prevalence of acute neuropathic pain following 
thoracic surgery was not known. Although Hayes (2002) estimated the 
incidence of acute neuropathic pain as 1-3% of all surgical patients, this study 
only included one case following thoracotomy, and patients were not screened 
for pre-existing neuropathic pain.174 In addition, the authors only investigated 
patients referred to the acute pain service.174 However, similar results were 
reported in a more recent study: Sadler et al., (2012) used the LANSS and DN4 
screening tools to estimate acute neuropathic pain prevalence in a population of 
165 patients undergoing orthopaedic or general surgery, one day after their 
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operation.257 The LANSS identified 5 (3%) patients with neuropathic pain, 
compared to 7 (4%) identified with the DN4 questionnaire.257  
Although both these results differ from the prevalence of acute neuropathic pain 
of 8% in the cohort of patients presented in this thesis, this may in part be 
explained by the difference in surgery type. As discussed previously, thoracic 
surgery is particularly associated with nerve damage, and the prevalence of 
chronic neuropathic pain is significantly higher in this group compared to 
orthopaedic or general surgical patients, so logically, the incidence of acute 
neuropathic pain would be expected to be greater amongst thoracic surgery 
patients.  
In a recent study investigating patients having surgery for iliac crest bone 
harvest, chronic neuropathic pain (at 3 months) was present in 23% of patients 
investigated, a proportion almost identical to that found in our study following 
thoracic surgery.258 This study also collected DN4 data in the early 
postoperative period at 48 hours, and despite using a different screening tool 
described 8 (10%) patients with positive DN4 scores at this stage developing 
chronic neuropathic pain. Unfortunately, the exact prevalence of acute 
neuropathic pain was not reported. However the incidence was at least 10% or 
higher, similar to the 8% reported by our study, supporting the hypothesis that 
acute neuropathic pain is more common in surgery where nerve damage and 
thus chronic neuropathic pain is more likely. 
3.4.2 Chronic neuropathic pain 
This study found that 22% of patients have predominantly neuropathic pain 3 
months after thoracic surgery. At the time the study started recruiting in 2007, 
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little data was available describing the prevalence of chronic neuropathic pain in 
the post thoracic surgery population. 
Gotoda et al., (2001) reported that 28% of post-thoracotomy patients had pain 
with paraesthesia/dysaesthesia, and 11% had allodynia 1year after surgery and 
concluded that “nerve impairment rather than simple nociceptive impact may be 
involved in this syndrome”.137 
Maguire et al., (2006) performed a retrospective survey of 600 thoracic surgery 
patients, enquiring about the presence of 5 symptoms suggestive of 
neuropathic pain.253 Their results suggested that neuropathic pain may be a 
component of the pain experience in a proportion of post thoracic surgery 
patients: of the 45% of patients with chronic pain after their surgery, between 
35% and 83% answered ‘yes’ to each of the five verbal descriptors of 
neuropathic pain.253 However, whilst the results of this study point to 
neuropathic pain playing a role in the chronic pain experience of thoracic 
surgery patients, it did not allow an estimation of the prevalence of this problem, 
and was limited by a number of methodological issues. 
Firstly, the study was retrospective, and failed to exclude pre-existing 
neuropathic pain. Secondly, the time period between surgery and questionnaire 
completion ranged from 7 months to 7 years, making a point estimate of 
prevalence impossible. Lastly, the study did not use a validated method of 
diagnosing neuropathic pain, instead it used the first 5 questions of the S-
LANSS questionnaire (without the 2 self examination items). The validity of 
these questions relies on their use as a weighted overall score, and a positive 
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response to one or more of the questions does not necessarily result in a 
diagnosis of neuropathic pain.  
Similarly, other studies have demonstrated the presence of neuropathic 
descriptors in the post thoracic surgery population, however these are 
interventional rather than epidemiological studies and methodological issues 
prevent accurate estimation of neuropathic pain prevalence.259-261 
Steegers et al., (2008) used a validated questionnaire (PainDETECT) to 
determine the incidence of chronic neuropathic pain following surgery.255 They 
found that of the 40-47% of patients with chronic pain following their surgery, 
53% had at least probable neuropathic pain. Despite the retrospective nature of 
this study, again performed at varying time-points following surgery (6-38 
months), and the use of a different screening tool, the calculated incidence of 
neuropathic pain of 21-25% is remarkably similar to that found in our study 
(22%). 
In a more recent study, Guastella et al., (2011) prospectively investigated 54 
patients undergoing thoracic surgery, assessing them for neuropathic pain 6 
months after their operation.262 Using a combination of verbal descriptors and 
sensory examination (including tests for mechanical and thermal allodynia and 
sensory deficits to touch and pin-prick) allowed the authors to estimate the 
prevalence of probable neuropathic pain according to the recent diagnostic 
grading system proposed by a consensus panel of international experts.138 
Their results show an incidence of neuropathic pain of at least 29% six months 
following thoracotomy. Interestingly, the DN4 screening questionnaire was also 
completed at the time of assessment, and all patients exhibiting positive results 
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with this screening tool also fulfilled the criteria for probable neuropathic pain 
according to the grading system, bar one person in whom sensory loss was not 
demonstrated. Overall, the grading system identified 21 patients with probable 
neuropathic pain, and the DN4 17 patients. Both this, and the similarity of 
results with the study presented in this thesis suggest using screening tools is a 
valid way of estimating neuropathic pain prevalence in this population, although 
in keeping with original validation studies they are likely to underestimate the 
true incidence of neuropathic pain.263 This observation is supported by data 
collected in a systematic review of the neuropathic component of persistent 
post-surgical pain, which showed that by grading neuropathic pain as probable 
or definite (using the consensus grading system) the prevalence of neuropathic 
pain following all types of thoracic surgery (including sternotomy) was 66% of 
those with persistent pain, compared to 52% in studies using questionnaire 
screening tools.135 
3.4.3 Can postoperative pain descriptors predict chronic neuropathic 
pain? 
The results presented in this chapter demonstrate that the presence of 
neuropathic pain descriptors in the immediate post-operative period predict the 
development of chronic neuropathic pain. A LANSS diagnosis of acute 
neuropathic pain results in a relative risk of developing chronic neuropathic pain 
of 3.5 (OR 7.7). Interestingly, answering question 1 positively was particularly 
predictive of developing chronic neuropathic pain, with a relative risk of 4.4 (OR 
12.6). This question, related to the sensation of unpleasant dysaethesias, 
carries a high LANSS weighting in the total score meaning it was particularly 
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associated with a diagnosis of neuropathic pain in the original LANSS validation 
study. 
Whilst other studies have demonstrated that pain intensity following thoracic 
surgery is associated with the development of chronic pain, the predictive 
nature of neuropathic pain descriptors for the development of chronic 
neuropathic pain has not previously been described.167 Hayes et al., (2002) 
noted a strong association between the diagnosis of acute neuropathic pain and 
the presence of persistent pain 6-12 months later, although were not able to say 
if this pain was neuropathic in nature.174 In their study, 78% of those with acute 
neuropathic pain went on to develop chronic post-operative pain.174 
Interestingly, two subsequent studies tend to support the predictive nature of 
neuropathic pain descriptors. Bouhassira et al., (2012) using the DN4 screening 
questionnaire demonstrated that a DN4 diagnosis of neuropathic pain made 
during the first 7 days of herpes zoster infection was an independent predictor 
for the development of post herpetic neuralgia at 3 months (OR 1.78 95% C.I. 
1.03-3.06).264 The authors conclude that pain quality, rather than just pain 
intensity confers greater risk of persistent herpes zoster related pain.264 
In a study of the predictive factors for the development of chronic neuropathic 
pain 3 months after surgery for Iliac crest bone harvest, Martinez et al., (2012) 
found that the DN4 screening tool when performed 48 hours after surgery 
independently predicted the development of chronic neuropathic pain (OR 
1.94).258 The authors conclude that a major finding of their study was the 
predictive nature of neuropathic pain characteristics in the early postoperative 
period.258 Interestingly, the odds ratios for the predictive qualities of the LANSS 
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in our study were much higher than those presented using the DN4 (7.7 vs 
1.94).  
3.4.4 Limitations of the research 
It is important to realize that not all patients with acute neuropathic pain 
characteristics go on to develop chronic neuropathic pain. In the cohort studied, 
three patients with acute neuropathic characteristics did not develop chronic 
neuropathic pain. There are a number of potential reasons for this.  
Firstly, the natural history of acute neuropathic symptoms and signs may be that 
over a third of cases spontaneously resolve in the first three months. For 
example, a painful neuropraxia caused during surgery slowly resolves with time. 
This hypothesis is supported by evidence from longitudinal studies of chronic 
post thoracotomy pain patients, which demonstrate the incidence of pain falling 
with time.146, 250, 252 
Secondly, because of the small number of patients with acute neuropathic pain 
characteristics, confounding factors such as differing medications may have 
influenced the results. For example, it is not clear what effects anti-neuropathic 
pain medications used during the perioperative period have on the development 
of chronic neuropathic pain. In a study of patients undergoing amputation, the 
anti-neuropathic pain medication gabapentin started pre-operatively and 
continued for 30 days post-operatively failed to prevent the development of 
phantom limb pain.265 In contrast a small study showed a promising reduction in 
chronic pain following breast cancer surgery when perioperative gabapentin 
was combined with local anaesthetics, although this study has been criticized 
for methodological flaws.266, 267 Pregabalin has also shown promise in reducing 
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the incidence of chronic neuropathic pain following surgery when given as a 
preventative medication in the peri-operative period. In a study of patients 
having total knee arthroplasty, pregabalin given pre-operatively and for 14 days 
post-operatively appeared to have a significant preventative effect on the 
development of chronic neuropathic pain following surgery, with no patients in 
the treatment group developing chronic neuropathic pain (compared to 8.7% in 
the placebo group).268 The effects of peri-operative gabapentin and pregabalin 
were recently summarized in a meta-analysis that described preventative 
effects of both drugs on the development of chronic post-surgical pain (pooled 
OR 0.52 and 0.09 respectively).269 
Other drugs may have similar properties. In animal models of neuropathic pain 
the antibiotic minocycline, when commenced in advance of traumatic nerve 
injury attenuated the development of chronic neuropathic pain.270 Similar effect 
have been noted with amitriptyline.271 This raises the possibility that 
perioperative medications may influence the development of chronic 
neuropathic pain. 
This study did not specifically screen patients pre-operatively for the presence 
of anti-neuropathic pain medications. However, review of the acute pain notes 
for the three patients who had acute neuropathic pain characteristics but did not 
develop chronic neuropathic pain revealed that one patient was started on 
gabapentin in the postoperative period (4 days following their operation). This 
patient had a 3-month NRS and S-LANSS score of 0. The peri-operative 
administration of these drugs may therefore have been a confounding factor in 
the results of both acute and chronic neuropathic pain prevalence. 
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A further important observation is that the majority of patients who developed 
CNP (74%) did not have neuropathic pain characteristics in the immediate post-
operative period, although they had significantly higher average LANSS scores 
compared to patients who did not develop CNP. It is not clear whether this 
reflects a different pathophysiological process, delayed onset of nerve damage, 
or if it reflects a reduction in the sensitivity of the LANSS score when used in the 
early post-operative period. Interestingly Martinez et al., (2012) reported similar 
results, noting that in 57.5% of patients with chronic neuropathic pain at 3 
months after surgery, neuropathic pain developed between 48 hours and 3 
months after their operation.258 
The S-LANSS contains a numerical rating scale of pain intensity, however in 
contrast, the LANSS screening tool does not. Pain intensity data was therefore 
not collected during the immediate postoperative period. In addition, although 
basic details of analgesic use was recorded, data on the quantities of 
analgesics used was not. Consequently, it is impossible to exclude opioid 
induced hyperalgesia as a potential confounding factor contributing to 
neuropathic pain symptoms in the immediate postoperative period.  
Although the LANSS score has been validated in a mixed population of patients 
with neuropathic pain, it has not been specifically designed for use in the early 
post-operative period and the behaviour of the scale may be affected by the 
intensity of the nociceptive pain experienced following an operation.  
No work has been published validating a screening tool such as the LANSS 
scale in the post-operative period.  The LANSS has however been used in other 
acute pain contexts, such as investigating the neuropathic pain component of 
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acute whiplash injury.272 In addition, further analysis of the results of this study 
showed using cut-off points other than 12 to define nociceptive or neuropathic 
pain (such as 11 or 13) reduced the correlation between the post-operative 
LANSS and three month S-LANSS, suggesting that 12 is an appropriate cut-off 
point assuming that post-operative neuropathic pain predicts the development 
of chronic neuropathic pain.  
Following the publication of a recommended grading system for neuropathic 
pain in 2008, it could be argued that diagnosing neuropathic pain in the acute 
post-operative setting should be done based on the presence of pain in a 
neuroanatomically plausible distribution, and the use of confirmatory diagnostic 
tests (demonstrating negative or positive sensory signs, and a lesion or disease 
explaining neuropathic pain) to give a diagnosis of definite neuropathic pain 
(figure 3.4).138  
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Figure 3.4 Flow chart explaining the consensus grading system for the diagnosis of neuropathic 
pain (from Treede et al., 2008). 
 
 
However, there are a number of difficulties with using this approach in the 
immediate post-operative period. Firstly, patients may have pain in a 
neuroanatomically plausible distribution, although the majority of this is likely to 
be nociceptive from the tissue damage of the operation rather than neuropathic. 
Secondly, the usefulness of sensory testing in the post-surgical pain setting has 
been questioned. In the chronic post-surgical pain setting, quantitative sensory 
testing is unable to differentiate between patients with and without pain after 
hernia repair, mastectomy or mandibular split osteotomy.273-275 The implication 
is that neuropathic pain may not develop, even after significant sensory 
abnormalities. Similar results have been demonstrated in patients following 
Pain is categorized as unlikely, possible, probable or definitely neuropathic 
according to a hierarchy of signs and tests. 
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thoracic surgery. Quantitative sensory testing of thermal and mechanical stimuli 
2 years after VATS surgery showed no significant differences between those 
patients with pain, and pain-free patients.276 Similarly, nerve injury judged by 
QST is common in both pain and pain free patients following thoracotomy.67 If 
quantitative sensory testing is unable to differentiate patients in the chronic pain 
setting, it is less likely to do so in the acute post-operative period when there is 
also a significant nociceptive component present. Sensory testing alone 
appears to be less predictive of the development of chronic neuropathic pain 
than screening tools. Martinez et al., (2012) performed mechanical sensory 
testing 48 hours after surgery for Iliac crest bone harvest and found only one 
variable, area of hyperalgesia, to be weakly predictive of the development of 
chronic neuropathic pain with an odds ratio of 1.02.258 This compared to a 
higher odds ratio of 1.9 when they used a diagnostic screening tool.  
A further objective test of nerve function – nerve conduction studies, when 
performed at the time of operation, failed to predict those who would go on to 
develop chronic pain after thoracic surgery.66 
Diagnosing acute neuropathic pain is therefore challenging. Conventional 
approaches to assessing nerve damage do not seem to correlate with the 
development of chronic neuropathic pain as might be expected, and the most 
predictive tools appear to be screening questionnaires that to a greater or 
lesser extent rely on verbal descriptors of pain quality. 
Despite this, more work is needed to develop a validated tool to aid the 
diagnosis of neuropathic pain in the immediate postoperative period. Both the 
face validity and construct validity of using tools such as the LANSS is 
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questionable. The LANSS was validated in a mixed population of chronic pain 
patients, and did not include patients in the immediate post-operative period. In 
addition, some of the items of the LANSS tool appear to lack face validity when 
used in this context. For example, question 2, asks whether the skin in the area 
of pain looks different from normal. This would be an expected finding following 
surgery where an inflammatory healing process is occurring.  
Because of concerns about the validity of using screening tools such as the 
LANSS in the immediate post-operative period, and the difficulties of using 
other confirmatory tests for neuropathic pain in this context, further investigation 
of methods for diagnosing acute neuropathic pain are warranted. In the face of 
uncertainty about the best way to diagnose acute neuropathic pain, it was 
hypothesized that acute pain specialists are likely to be diagnosing neuropathic 
pain in clinical practice, and therefore investigating what criteria are being 
currently used would be useful. The results of a Delphi survey investigating this 
are presented in Chapter 4.
105 
 
4 Diagnosing postoperative neuropathic pain: a Delphi 
survey of experts 
 
4.1 Introduction 
The previous chapters of this thesis have explained the challenging nature of 
diagnosing neuropathic pain, a clinical condition that has a definition, but no 
universally accepted diagnostic criteria. Such challenges are compounded in 
the acute postoperative period by a concurrent nociceptive pain component, 
perioperative interventions that may alter sensory thresholds and symptoms 
and signs associated with tissue healing after surgical trauma. Consequently, 
the face validity of using existing tools to aid the diagnosis of neuropathic pain 
in this context may be questioned.  
It was hypothesized that despite a paucity of research data, acute pain 
specialists are likely to be diagnosing acute neuropathic pain regularly in the 
clinical setting. They are likely to be using judgment (based on knowledge and 
experience) rather than research data alone to achieve this. The specific aim of 
the research presented in this chapter was to obtain an expert agreed list of 
pain characteristics or investigations that are considered important in the 
diagnosis of a significant neuropathic pain component to acute postoperative 
pain. This was performed using the Delphi consensus technique, a method of 
eliciting and aggregating knowledge and judgments in a transparent and 
structured way. 
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4.2 Consensus methods in qualitative research 
Consensus methods are a means of approaching a problem where conflicting 
or absent scientific evidence exists.277 They are, in essence a way of 
collaborative problem solving, with the aim of determining the extent to which a 
group of individuals agree about a given issue or topic. This type of 
methodology can allow a broader spectrum of information to be considered than 
is commonly used in more quantitative approaches (such as meta-analysis), 
and can be particularly useful where published information is inadequate. 
Broadly, there are three common approaches to building consensus: the 
nominal group technique, the consensus development conference and the 
Delphi process.277 
4.2.1 Consensus conference 
Consensus conferences tend to be organized when agreement on an important 
topic is needed. The process has been used extensively by the US National 
Institutes of Health and also by other countries including the UK and Canada to 
reach consensus on topics such as the treatment of stroke and renal failure.278, 
279
 A select group of experts are chosen to hear evidence presented by various 
interest groups or other experts on the topic, and are allowed to ask questions. 
This group then retires to deliberate amongst themselves, in a manner similar to 
that of a jury in a trial, with a chairperson responsible for controlling the 
discussion. Although consensus is encouraged, members may hold minority or 
alternative views, and a vote may be used to reach judgment on a decision.279, 
280
 Although face to face discussions of this nature can aid group understanding 
of a topic, organizing conferences can be logistically challenging, expensive 
and prone to bias by strong willed individuals within the chosen expert group.280 
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In order to overcome some of the disadvantages of the consensus conference 
process, other consensus development methods, such as the nominal group 
technique, use a much more structured format of group discussion. 
4.2.2 Nominal group technique 
The nominal group technique uses a meeting involving a group of experts to 
rate, discuss, and then re-rate a series of questions about a specific issue. A 
facilitator who asks experts to take turns in contributing their views on the topic 
in question leads the meeting. There may be group discussion surrounding the 
issues identified, and the experts then rank each idea. The rankings are 
presented to the group, followed by further discussion and re-ranking in order to 
try and gain a consensus of opinions.280 
This method has been used widely to solve problems in areas ranging from 
education and industry to social services and healthcare, and has a number of 
features that make it an attractive method for generating ideas and consensus 
opinions.281 Ideas can be generated in a short space of time, and consensus 
achieved in a single meeting. The method encourages equal participation from 
panelists and the process of reaching consensus is transparent to all those 
participating.280 In particular, nominal group techniques seek to prevent too 
much focus on a particular idea, at the expense of exploring the problem 
thoroughly.282 Each person in the panel is more likely to work on the problem in 
hand, rather than leaving the generation of ideas to other panelists.282 As the 
facilitator controls the discussion closely, and each participant has the 
opportunity to express their views in turn, the risk of the discussion being 
dominated by a few vocal members is reduced. Unfortunately, although the 
nominal group technique has been modified to allow the first round to be 
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performed by postal questionnaire, ultimately a face to face meeting of expert 
panelists is required, which can lead to logistical difficulties where experts may 
be geographically spread across regions or even globally. 
4.2.3 Delphi consensus method 
The Delphi consensus method offers a potential solution to the logistical 
problems of holding a face-to-face meeting of experts in a particular field. 
Developed in the 1950’s by the RAND corporation in America, the Delphi 
process was originally used by the US government to try and predict the impact 
of technology on inter-continental warfare at the time of the cold war.280 This 
was an area where at the time, lack of scientific information made traditional 
forecasting methods unreliable. Based on the assumption that individual 
statistical predications would be more accurate than the conclusions of 
unstructured group opinions, a consensus method was developed that required 
experts to give their opinion on the probability, intensity and frequency of enemy 
attacks and the number of atomic weapons needed to destroy specific 
targets.280 The aggregated views of the group were fed back to participants, 
and the process repeated until consensus emerged. The term ‘Delphi’ was 
coined by Abraham Kaplan, a philosopher working at the time for the RAND 
corporation, after the Greek oracle said to have the power to predict the 
future.277  
The Delphi process is similar to that of the nominal group technique, the main 
difference being the use of surveys rather than conference meetings to gather 
expert opinion (with subsequent anonymity of expert views). The ‘classical’ 
Delphi involves a preliminary survey round where participants are asked broad, 
open-ended questions on a specific topic. This is used to generate ideas and 
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opinions, which may not be elicited by other means of information gathering 
(such as literature reviews), and in the healthcare setting can reflect clinical 
experience as well as knowledge of scientific research on the topic. These 
ideas and opinions are grouped together into common themes that are typically 
formed into a series of statements in the form of a questionnaire. The 
questionnaire is sent out to the panel of experts as round 2 of the Delphi 
process. The experts are asked to rate the degree to which they agree or 
disagree with the statements in the questionnaire. The questionnaires from 
round 2 are analyzed and the average level of agreement for the group as a 
whole is calculated for each statement or question. This is then used as 
feedback to individual experts in round 3. In round 3, the same questionnaire is 
sent back to panelists, this time with the addition of the overall group score for 
each statement or question and a reminder of the individual experts previous 
score. The experts have the opportunity to change their individual scores in light 
of the group result. The re-rated questionnaires are then analyzed for the 
degree of consensus achieved. In theory the process can be repeated until a 
predetermined level of consensus is achieved or diminishing changes mean 
opinions and scores are likely to remain the same. 
A number of different forms of Delphi surveys have evolved since the early 
development of the classic Delphi approach. These include the ‘modified 
Delphi’, whereby the first round is often replaced by face-to-face meetings or 
focus groups and the ‘Policy Delphi’, which uses expert agreement to define 
future policy on a given topic.283, 284 Further modifications of the classical Delphi 
have capitalized on the technological revolution of the latter part of the 20th 
century, resulting in the e-Delphi (administered by email or online rather than by 
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post), the online Delphi (questionnaires completed and submitted online) and 
the technological Delphi (similar to the consensus conference, but making use 
of electronic devices to allow voting and instant feedback of group scores on a 
topic).280 The proliferation of modified techniques has led to concerns that the 
credibility of the original Delphi process is being threatened.280 
A further threat comes from the (somewhat ironic) lack of consensus over 
Delphi methodology, and absence of universal guidelines. With few established 
rules to guide the design of Delphi studies, a confusing variety of formats and 
variations exist.285 Beyond the generally accepted criteria that the Delphi 
process should give feedback to participants, and have at least two rounds, 
most other aspects of methodology including the size and composition of the 
expert panel and definition of consensus, are subject to variation in the 
literature, both in health related research and also outside of medicine.279, 286, 287 
Perhaps the most important consideration in the Delphi process is the choice 
and identification of the expert panel. The use of credible ‘experts’ in the 
appropriate field is cited by many as an important factor in consensus 
development methods.277, 281, 282 However, the definition of ‘expert’ may vary 
depending on the issue being studied, and may include an experienced 
clinician, research scientist or patient with experience of a disease.288 As such, 
an expert can be defined as a group of informed individuals, who are specialists 
or who have knowledge about a specific subject. 283, 289, 290 
The exact composition of a panel of experts may vary considerably, although 
broadly can be defined as homogenous or heterogeneous with regards to 
factors such as demographics, education, job, experience, geographical 
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location etc. Heterogeneity probably leads to better performance and enhances 
the credibility of the consensus process, although some evidence suggests 
heterogeneity may cause conflict and difficulty reaching a common 
conclusion.282, 288  
The size of the expert panel can vary dramatically from single figures to 
thousands of individuals.280, 291 Although large panel sizes have been advocated 
by some as a means of ensuring reliable results, there is little empirical 
evidence to support such a proposition.282, 288, 292 Large panel sizes can be 
difficult to co-ordinate, and participation may become more unequal.293 In 
addition, they may be prone to higher rates of attrition between Delphi 
rounds.294 Theoretical studies investigating the optimum panel size suggest 
there is little improvement in group validity by increasing panel sizes beyond 10 
individuals.295, 296 Supporting this theoretical view of consensus methodology is 
a study by Richardson (1972) that demonstrated improvement in the reliability 
of ratings with up to 10 group participants, beyond which it began to level off.297 
In studies of group decision making, the effect of size is slight and few effects 
have been found in studies comparing 6 and 12 person groups.298-301 The 
conclusion of the Health Technology Assessment review of consensus 
methodology in 1998 was that with a group size less than 6, reliability declines 
rapidly, and with a group size over 12, improvements in reliability are subject to 
diminishing returns.282 A recent systematic review of healthcare Delphi studies 
reported an average panel size of 17 (range 3-418).302 
A further area of Delphi methodology that varies from study to study is the 
definition of consensus. However, before considering the definition of 
consensus, it is necessary to summarize the results of each round. This 
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typically takes the form of aggregating individual judgments in some way. One 
of the most common methods of achieving this is by calculating the median and 
interquartile range of the panelist scores. This has the advantage of being 
independent of extreme values and less sensitive to skew in the distribution of 
responses, as long as the panel is greater than 8 and the distribution is not 
markedly bimodal.279 Once the frequency and distribution of responses for each 
item or question have been calculated, the next step is to determine which, if 
any, have achieved consensus. 
For most, consensus represents collective agreement, or put more formally “a 
condition of homogeneity or consistency of opinion among the panelists”.280, 303 
The point at which consensus is reached however, and the statistics applied to 
this aspect of Delphi studies varies considerably.  In their systematic review of 
Delphi studies, Boulkedid et al., (2011) reported 5 main methods of achieving 
consensus.302 Thirty five percent of studies used median scores above a 
predefined threshold combined with a high level of agreement among panel 
members. In 16% of studies, only a median score above a certain predefined 
level was used. In 15% of studies, the proportion of experts who rated the item 
highly had to be greater than a predefined threshold (e.g. 75% of experts rating 
the item greater than 7/10). Thirteen percent of studies used RAND UCLA 
criteria, and 3% used interpercentile range  and interpercentile range adjusted 
symmetry. Other statistics used to gauge agreement, include the kappa 
statistic, intra-class correlation coefficients and Cronbach’s alpha.279, 303 There 
remains however no agreed standard method for determining group consensus, 
and arbitrary consensus standards are common.280 
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4.3 Methods 
A three round, internet based Delphi survey of acute pain experts was 
designed. After review by the Leeds ethics committee, the project was not 
judged to need formal ethics committee review by an NHS research ethics 
committee. 
4.3.1 Choice of experts 
Experts with clinical or research experience of diagnosing and treating acute 
neuropathic pain in the immediate postoperative period were sought to 
participate in the Delphi expert panel from two main sources. Firstly, from the 
membership of the British Pain Society’s Acute Pain Special Interest Group, 
whose aim is to provide a forum for members of the British Pain Society with a 
special interest in acute pain. Secondly, by a literature search of national and 
international authors who had previously published research on the subject of 
acute neuropathic pain. Potential participants identified by these two means 
were emailed an invitation to participate in the Delphi survey. The email 
contained a web-link to an online information page explaining the objectives of 
the survey and Delphi process (appendix 3). From this page, participants could 
access round 1 of the Delphi survey via a web-link.  
All rounds of the Delphi were conducted via a secure internet email survey 
system (http://www.defgo.net). 
4.3.2 Round 1 
Those acute pain experts who read the information web page and decided to 
participate in the Delphi survey were taken via a web-link to the first round 
Delphi questionnaire. In keeping with classical Delphi methodology, the round 1 
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questionnaire was designed to generate ideas around the topic of acute 
neuropathic pain. Specifically, participants were asked open questions to 
develop an initial list of symptoms, signs and investigations considered useful or 
important in diagnosing acute neuropathic pain. Additionally, barriers to the 
diagnosis of acute neuropathic pain were explored, as were the degree to which 
anti-neuropathic pain medications were used in the postoperative setting. The 
questions included in the round 1 survey are presented in appendix 4. 
Participants completing round 1 were asked to leave contact email details if 
they wished to become a panelist in further Delphic rounds. 
The symptoms, signs and investigations identified in round 1 were collated and 
grouped together under common headings. From this information, plus that 
obtained from a literature search on the topic, a new questionnaire was 
designed and distributed as round 2 of the Delphi process to panel members 
from round 1 who agreed to continue to participate by leaving their email 
contact details. 
4.3.3 Round 2 
A copy of the round 2 questionnaire is included as appendix 5. The 
questionnaire asked panelists to rate the importance of each acute neuropathic 
pain diagnostic parameter on a numerical likert scale (anchored 1 “not 
important” to 10 “very important”). Rather than asking participants to rank the 
items in order of importance, the importance of each item was judged 
independently of the others (so all items could potentially be rated as very 
important). As in round 1, each panelist completed the questionnaire online, via 
a web-link sent in an email. 
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The results of round 2 were aggregated and summarized as the median of the 
attributed weights and inter-quartile range (IQR) for each item. All statistical 
calculations were performed using IBM SPSS Statistics Version 20 (SPSS Inc., 
Chicago, IL, USA). These values were fed back to individual panelists during 
round 3. 
4.3.4 Round 3 
In round 3, the same questionnaire as round 2 was used with the addition of the 
group median and IQR results clearly stated for each item. In addition, each 
participant was reminded of his or her initial score for the item (from round 2). 
Each panelist was given the opportunity to change their round 2 score in light of 
the group median and IQR result, on the same 1 to 10 numerical rating scale. 
Following round 3, revised median and IQR results were calculated. 
Questionnaire items were considered important if the median score was ≥7. 
Expert agreement or consensus was defined as an IQR ≤3. Cronbach’s alpha 
was used to investigate internal consistency among panellists and also for 
parameters considered important and achieving agreement. Internal 
consistency was also calculated for non-important items. 
4.4 Results 
4.4.1 Round 1 
Thirty-four specialists who received the invitation email opened the round 1 
survey via a web-link in the online information page. Twenty-four participants 
answered 1 or more of the survey questions, with 14 leaving contact details, 
indicating they would like to participate further in the Delphi process. Of the 14 
leaving contact details 13 were based in the UK, with 1 person from Australia. 
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Five specialists had > 10 years experience as consultants, 1 had 5-10 years 
experience and 2 reported 1-5 years experience (6 left the question 
unanswered). 
The symptoms, signs and investigations identified by participants in the round 1 
survey, in conjunction with those identified by literature search, were collated 
and grouped under common categories. Round 1 of the Delphi process 
generated a number of items that may be useful in identifying acute neuropathic 
pain, and are presented in table 4.1.  
Fifty percent (n=7) of respondents used current screening tools in the diagnosis 
of acute neuropathic pain. Examples given included the LANSS, PainDetect 
and locally developed questionnaires. 
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A number of obstacles to identifying acute neuropathic pain were identified, 
including distinguishing it from nociceptive post-operative pain, lack of 
awareness of the problem, cross cultural communication difficulties and lack of 
agreed diagnostic criteria. 
Sixty seven percent (n=8) used anti-neuropathic pain medications in the 
immediate post-operative period, with 55% (n=6) using them on a weekly basis. 
60% (n=6) used anticonvulsants, 40% (n=4) used antidepressants, 30% (n=3) 
used NMDA receptor antagonists. 
4.4.2 Round 2 
Using the symptoms, signs and investigations identified in round 1, a round 2 
questionnaire was developed and sent to the 14 participants who agreed to 
continue with the Delphi process. The participants were asked to rate the 
importance of each symptom, sign or investigation on a numerical rating scale. 
10 panelists completed the round 2 questionnaire and the results are presented 
in table 4.2. 
4.4.3 Round 3 
The 10 panelists completing round 2 of the Delphi process were emailed a link 
to the round 3 questionnaire, and asked to consider changing their rating for 
each pain characteristic in light of the group median and IQR results. Two 
panelists changed their results in light of the group results and the recalculated 
aggregate results are presented in table 4.2. Items achieving consensus 
following the 3 Delphi rounds are presented in table 4.3. 
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 Round 2 Round 3 
ANP 
Identifier 
Valid 
(n=)  
Missing 
(n=) 
Median IQR Range Median IQR 
Pins & needles 9 1 9 3.5 4-10 9 3.5 
Dysaesthesias 9 1 9 2.5 7-10 9 2.5 
Good response to 
antineuropathics 
10 0 9 1.5 7-10 9 1.25 
Burning 10 0 8.5 3 6-10 8.5 3 
Allodynia 10 0 8.5 2.25 7-10 8 2.25 
Hyperalgesia 10 0 8.5 2.25 6-10 8.5 2.25 
Shooting 10 0 8 2.25 7-10 8 2.25 
Unpleasant 
sensations 
9 1 8 3.5 6-10 8 3.5 
Difficult to 
manage 
10 0 8 3 4-10 7.5 1.5 
Screening tools 10 0 8 4.25 5-10 8 5 
Lancinating 10 0 7.5 4 3-10 7.5 4 
Hyperpathia 10 0 7.5 4.25 5-10 7.5 4.25 
Autonomic 
features 
10 0 7.5 4.25 3-10 7.5 4.25 
Poor response to 
opioids 
10 0 7.5 1 6-9 8 1.25 
Spontaneous 9 1 7 2.5 4-10 7 2.5 
Stabbing 10 0 7 5.5 2-10 7 5.5 
Colour 10 0 7 5.75 1-10 7 5.75 
Response to IV 
lignocaine 
10 0 7 3.5 5-10 7 3.5 
Paroxysmal 8 2 6 2.75 2-9 6 2.5 
Sharp 10 0 5 5.5 1-10 4.5 5.5 
QST 9 1 5 3.5 1-10 5 4.5 
Radiology 9 1 5 2.5 0-7 5 2 
Nerve conduction 9 1 5 2 4-10 5 3 
Pulsing 9 1 3 3.5 1-6 3 2 
        
Table 4.2 Aggregate rating responses of importance for individual neuropathic pain symptoms, 
signs and investigations, expressed on a 0-10 numerical rating scale from participants in Delphi 
rounds 2 and 3. 
QST = Quantitative Sensory Testing, n = number of responses, IQR = Interquartile range, ANP = 
Acute Neuropathic Pain 
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Important Not Important 
Spontaneous Paroxysmal 
Shooting Pulsing 
Burning Radiology 
Dysaesthesia Nerve Conduction 
Allodynia  
Hyperalgesia  
Difficult to manage pain  
Poor response to opioids  
Good response to antineuropathics  
 
Table 4.3 Neuropathic pain symptoms, signs and investigations achieving consensus after 3 
Delphi rounds. 
 
Cronbach’s Alpha for the 9 items considered important and achieving 
consensus was 0.664. If item “spontaneous” was deleted, Cronbach’s Alpha 
rises to 0.798. This item correlates poorly with the composite scores from the 
other items (corrected item-total correlation -0.303). Cronbach’s Alpha for the 4 
items considered not important and achieving consensus was 0.0. If item 
“Nerve conduction studies” was deleted, Cronbach’s Alpha rises to 0.525. 
Cronbach’s Alpha was also used for evaluating internal consistency among 
experts. Cronbach’s Alpha for round 2 was 0.658 rising to 0.705 after round 3. 
The individual panelist-group correlations are presented in table 4.4. The 
panelist-group correlation increased in 7 out of 10 instances following round 3, 
corresponding to the higher Cronbach’s Alpha observed. 
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Panelist-group correlation 
Panelist Round 2 Round 3 
A 0.552 0.616 
B 0.278 0.775 
C -0.041 -0.019 
D 0.564 0.565 
E 0.090 0.1 
F 0.260 0.233 
G 0.646 0.686 
H 0.245 0.269 
I -0.057 -0.079 
J 0.574 0.550 
 
Table 4.4 Panelist-group correlations for Delphi rounds 2 and 3 
 
4.5 Conclusion 
This three round Delphi survey of acute pain specialists has identified a number 
of acute pain characteristics that may be important in aiding the diagnosis of 
acute neuropathic pain in the post-operative period. Importantly, it informs how 
specialists are diagnosing this problem in the absence of diagnostic criteria or 
robust research in this area. 
Twenty-four items were identified by the first round “brainstorming” phase of the 
Delphi process, and agreement was achieved among specialists for 14 items, 
with 9 of these items identified as important. Although the majority of panelists 
did not change their scores between round 2 and 3, an improvement in 
Cronbach’s alpha suggests an increase in homogeneity of opinion between 
Delphi rounds. 
One interesting result of the Delphi process was the high level of consensus 
amongst panelists that response to medication plays an important role in 
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diagnosing neuropathic pain in the acute setting. The two items with the highest 
level of agreement (lowest IQR) were ‘poor response to opioid analgesics’ and 
‘good response to anti-neuropathic analgesics’. This contrasts markedly with 
the diagnosis of neuropathic pain in the chronic setting, where a prospective 
diagnosis of neuropathic pain is made on the basis of history, examination and 
investigation before appropriate drug therapy is used. Certainly, the empirical 
use of anti-neuropathic medications as a diagnostic (as well as therapeutic) aid 
in the acute post-operative setting probably reflects a pragmatic approach in 
light of the practical difficulties of using more established neuropathic pain 
diagnostic techniques. Using a poor response to opioids as a diagnostic aid is 
another interesting finding, and runs counter to the evidence of opioid efficacy 
in the chronic neuropathic pain population, where the NNT is less than more 
established anti-neuropathic treatments (such as gabapentin).46 
Other symptoms achieving consensus as important items include the presence 
of dysaesthesias. Interestingly, question 1 of the LANSS relates to the presence 
of dysaesthesias, and was shown in chapter 3 to be the LANSS item most 
predictive of developing chronic neuropathic pain after surgery if present in the 
immediate post-operative period. 
What is less clear is the role of autonomic symptoms or signs (such as colour 
change or swelling). Although the presence of these forms a part of existing 
neuropathic pain tools, the face validity of such items would appear to be 
lacking in the face of the normal inflammatory response to surgery, which can 
produce similar changes. Although the median scores of these items in the 
Delphi were relatively high, the range of results indicated little expert 
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consensus, with some clearly feeling these items are unimportant, and unwilling 
to change their minds. 
Relying on confirmatory tests to aid the diagnosis of neuropathic pain may also 
be confounded by perioperative interventions (such as the use of local 
anaesthetics) and the availability of equipment (such as QST or 
electromyography), and the expert panel agreed that neither nerve conduction 
studies nor radiological investigations were useful diagnostic aids in a clinical 
setting. 
It is important to note that although items with a median score <7 are 
considered not important in this study, care should be taken in inferring these 
items are not useful. There was a lack of internal consistency amongst the 4 
items agreed to be not important. This may reflect the fact that the default 
definition of ‘not important’ actually contains a spectrum of responses ranging 
from those with a very low median score (such as ‘pulsing’ median=3) to those 
with borderline important scores (‘paroxysmal’ median=6). There is subsequent 
low correlation and covariance between the individual results.  
The Delphi technique has a number of attractions when seeking to acquire 
agreement in areas of uncertainty or where there is lack of empirical evidence, 
and it has been previously used to facilitate the development of diagnostic 
criteria in the healthcare setting.279, 303-306 It is important however, to understand 
the limitations and criticisms that can limit the usefulness of this type of 
consensus exercise. 
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4.5.1 Study limitations 
There has been much debate over the validity of the Delphi technique since it 
was conceptualized in the post second world war period. Some commentators 
have argued that it fails to meet the standards required for scientific 
methodology, particularly in those studies with poor questionnaire design, 
reliability testing and selection of experts, with others describing it as a method 
of “last resort”.277, 307 
The expert panel chosen to participate in the Delphi technique is often cited as 
critical to the success of a project.280 As the exact composition of the panel will 
affect the results obtained, the potential for bias in this aspect of Delphi 
methodology is considerable.  
For this study, invitations to participate were sent to two groups: researchers 
who had published on the subject of acute neuropathic pain, and members of 
the British Pain Society Acute Pain Special Interest Group (SIG). Whilst authors 
of research in the area of acute neuropathic pain could be expected to be well 
informed on the topic, there is no guarantee that members of the Acute Pain 
SIG have knowledge on the topic. Furthermore, the BPS is a multidisciplinary 
society, therefore the panel invitation may be sent to doctors or nurses of 
varying experience and qualifications, and is no guarantee of expertise or 
familiarity with the topic in question. 
Some Delphi studies have been able to apply rigorous selection criteria to 
expert panels. Keeney et al., (2011) cite examples from outside medicine, which 
required panelists to be academics with a record of published research on the 
topic in question in major journals.280 While this may be practical in some 
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academic areas, the paucity of published research on the topic of acute 
neuropathic pain means this approach would not have been feasible.  
One approach to improve the knowledge of the expert panel may have been to 
include background research reading as part of the Delphi exercise. This may 
have helped inform the panel about published research in this area, however, 
Raine et al., (2004) found that although providing a literature review improved 
concordance, if clinical experience and beliefs were not consistent with 
research evidence, then experience and beliefs seemed to take precedence.308  
The adoption of the Acute Pain SIG membership as panel members presented 
a number of advantages. Membership implies a degree of active interest in 
acute pain, and members were easily contacted via the British Pain Society 
secretariat. The background hypothesis of the study was that clinicians working 
in the field of acute pain would have practical experience of diagnosing 
neuropathic pain in the acute post-operative period (as there is a paucity of 
published criteria to aid diagnosis), thus the most important pre-requisite for 
panel membership would be practical experience in the field of acute pain. 
Although data were incomplete, our results show a range of experience levels 
with half the original panelists having at least 5 years experience in acute pain.  
In addition to the composition of the expert panel, size and rate of attrition are 
also considered important. Although 24 individuals answered at least one 
question in round 1, only 14 left contact details indicating a willingness to 
continue with the Delphi process and then only 10 completed round 2. The 
number of participants in the Delphi process should probably be at least 12, 
with less than six considered unreliable.279 Less is known about acceptable 
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rates of attrition, with published studies varying between 8% and 100%.280 
Some commentators have recommended a 70% response rate as necessary to 
maintain methodological rigor, although this is based on opinion rather than 
research in the area.309, 310 Nevertheless, high attrition rates may result in bias 
and a potentially unrepresentative small sample.280 
Anonymity is cited as a key feature of the Delphi method, providing the 
opportunity for each panel member to present and react to ideas without bias 
attributed to knowledge of the identities of other participants.289 True anonymity 
requires both the researcher and panelists to be blind to the source of 
questionnaire responses.311 Although Delphi panel members in the presented 
study were blind to the composition of the panel, the researcher aggregating the 
results and designing the subsequent questionnaire was not blind to the panel 
membership, introducing the potential for bias. This is a common pragmatic 
approach to performing Delphi studies, and has led to some authors dubbing 
the process “quasi-anonymity”.283, 312 It is not known what effect a lack of full 
anonymity has on Delphi findings.313 Interestingly, anonymity has been cited as 
a weakness of the Delphi process, with concerns that some respondents do not 
engage with the process responsibly. In addition, the first round “brainstorming” 
process may be limited by the inability of participants to interact in the idea-
generating phase. 
A variety of techniques have been used to define consensus within the context 
of a Delphi study, with no guidelines or widespread agreement on the optimal 
methodology. This study used pre-determined levels of consensus based on 
the inter-quartile range, an approach common to other Delphi survey on 
diagnostic criteria.304 Although the use of pre-determined levels of consensus 
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may be criticized, some authors have suggested it may reduce researcher bias 
by removing the temptation to manipulate results.314 
Perhaps the most important limitation of the Delphi technique lies in the 
interpretation of a study’s results. In particular, it is important not to equate 
consensus with validity: the existence of consensus does not mean the “correct” 
answer has been found.277 Indeed, there is a danger that the process will 
identify collective bias or ignorance rather than wisdom.277 Delphi is a means of 
identifying medical opinion, but is no substitute for conventional medical 
research. It can however, help to identify areas in which further research should 
focus. Pill (1971) recommends consensus results should be matched with 
observable events wherever possible.315 
This Delphi survey identified items of possible diagnostic value in the area of 
acute post-operative neuropathic pain. Some of these items differ significantly 
to those found in conventional chronic neuropathic pain screening tools and 
diagnostic aids. The next stage of research presented in this thesis is to move 
towards confirmation of these results through observational study. 
129 
 
5 Are patients with poorly controlled postoperative 
pain more likely to have neuropathic symptoms and 
signs?  
 
5.1 Introduction 
The previous chapter reporting the results of a Delphi survey of diagnostic 
indicators of acute postoperative neuropathic pain suggested that two factors 
not used in the diagnosis of chronic neuropathic pain were considered useful in 
a clinical acute pain setting: difficult to control pain, and pain poorly responsive 
to opioids. 
The validity of using these observations as useful diagnostic indicators of 
neuropathic pain is unclear, and arguments for and against this hypothesis can 
be made. For example, in a chronic pain setting, neuropathic pain responds 
well to opioids, which demonstrate a NNT lower than many established anti-
neuropathic medications.46 However, at a molecular level, raised levels of 
cholecystokinin (CCK), a hormonal peptide known to reduce the anti-
nociceptive effects of opioids, occur within days of nerve injury and may be a 
mechanism for a poor response of neuropathic pain to strong opioids in the 
postoperative period.316 In addition, there is evidence of reduced opioid binding 
sites in the dorsal horn of the spinal cord in the first two weeks after nerve 
injury.317 
If patients with poorly controlled pain, which is not responsive to opioids are 
considered more likely to have acute neuropathic pain, they should also 
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demonstrate the presence of other symptoms and signs suggestive of 
neuropathic pain. This chapter presents a pilot study designed to evaluate 
neuropathic symptoms in patients with difficult to control pain after surgery, 
referred to the acute pain service.  
It was hypothesized that patients with poorly controlled post-operative pain, 
unresponsive to opioids, have higher odds of developing other neuropathic 
symptoms, as suggested by expert opinion.  
This chapter presents the results of a pilot cohort study. The specific aims of 
this pilot study were to report on the research processes that would be used in 
a larger study, including recruitment, questionnaire design, case matching 
methods and sample size calculation.  
In a cohort study, exposure is identified before the outcome. Not only does this 
provide the potential to examine causality, but is particularly useful for 
examining rare exposures.318 The disadvantages of cohort studies include the 
tendency to need large sample sizes that can result in costly or lengthy 
investigations, hence the usefulness of a pilot study that will allow accurate 
sample size calculations.318  
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5.2 Methods 
Study outline 
This pilot study was designed as a matched cohort investigation. Matched 
cohort studies have cases and controls relating to the exposure of interest (in 
this study difficult to control pain, poorly responsive to opioids), rather than the 
outcome of interest (occurrence of neuropathic symptoms). 
This investigation sought to identify cases of patients following surgery with 
difficult to control pain, which has responded poorly to a standard analgesic 
regime based on opioids. Controls were identified from the postoperative 
population with well-controlled pain. Both groups were investigated with a 
questionnaire designed to elicit other neuropathic pain symptoms and signs 
based on the results of the previously presented Delphi survey and existing 
neuropathic pain screening tools. If difficult to control pain, that responds poorly 
to opioid analgesics is an indicator of acute neuropathic pain, the odds of 
developing other neuropathic symptoms and signs should be higher in this 
group compared to those with well controlled postoperative pain. 
The study protocol was reviewed by the South West Regional Ethics Committee 
who deemed full ethics approval was not required for this questionnaire project. 
5.2.1 Selection of cases and controls 
Cases were identified from patients who received surgery at the Royal Cornwall 
Hospitals NHS Trust, and who were referred to the acute pain service with 
difficult to control postoperative pain, despite standard analgesic treatment with 
strong opioid analgesics (see appendix 6 ‘Criteria for referral to the Acute Pain 
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Service’ and appendix 7 ‘Opioid treatment guidelines for the management of 
severe pain’). 
Difficult to control post-operative pain was defined as a pain score ≥4/10 on a 
numerical rating scale of pain intensity anchored 0 (no pain) and 10 (worst 
possible pain). This has been shown to correlate with moderate to severe pain 
in the post-operative period.319 Standard analgesic treatment was defined as 
the use of oral, intravenous, intramuscular or subcutaneous strong opioid 
treatment (morphine or it’s equivalent), in standard acute pain service protocol 
doses. 
Patients were excluded if they were under the age of 18, pregnant, unable or 
unwilling to complete the study questionnaire. Additional exclusions aimed to 
reduce the number of patients with poorly controlled pain from other causes, 
and included: analgesia not given as prescribed, known pre-existing 
neuropathic pain, known pre-existing strong opioid use, and the use of epidural 
analgesia. Initially, recruitment was confined to the period 24-96 hours post 
surgery and patients with nerve plexus or peripheral nerve blocks were 
excluded.  
This protocol was modified after 6 months. The recruitment timeframe of 24-96 
hours postoperatively was extended to include patients after discharge from the 
recovery ward and up to 3 months after surgery. This would allow inclusion of 
patients referred to the acute pain service because of difficult to control pain 
during the rehabilitation phase of their recovery whilst still inpatients in the 
hospital. Patients who had received nerve blocks as part of their anaesthetic 
were also included (as discussed in the results section and conclusion). 
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A summary of the initial study design is presented in figure 5.1. 
 
Study Population 
Patients 24-96hours following 
surgery* 
Cases 
NRS ≥4 despite strong 
opioid treatment 
Controls 
NRS ≤3, matched by 
surgery type 
Disease 
Presence of 
neuropathic 
symptom/sign 
No Disease 
No neuropathic 
symptoms/signs 
Disease 
Presence of 
neuropathic 
symptom/sign 
No Disease 
No neuropathic 
symptoms/signs 
 
Figure 5.1 Study design for the matched cohort pilot evaluation of neuropathic 
symptoms and signs in patients with well controlled postoperative pain compared 
to those with poorly controlled postoperative pain. 
 NRS = Numerical Rating Scale of pain intensity (0-10) 
* Following a protocol change after 6 months, this was extended to include 
patients within 3 months of surgery. 
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Controls were matched by surgery type. Matching cases to controls provides a 
way of controlling for known confounding variables. Although there is a paucity 
of research identifying risk factors for the development of acute neuropathic 
pain, there is good evidence that chronic neuropathic pain is more common 
following certain surgical procedures.135 In the acute pain setting, surgery type 
is also likely to influence the development of neuropathic pain. In chapter 3, the 
incidence of acute neuropathic pain in the thoracic surgery population was 8%, 
twice that reported by patients undergoing elective general or orthopaedic 
surgery.257 In their study of all patients referred to the acute pain service, Hayes 
et al., (2002) found that nearly half of all acute neuropathic pain diagnoses 
came from the traumatic injury population.174 Type of surgery is therefore likely 
to be a significant confounding variable, and controls were therefore matched 
by surgical type. Ideally, control patients would be matched to the exact surgical 
procedure performed for each case. However, pragmatically, because of the 
individual nature of many operation types, particularly those performed for 
emergency or trauma reasons, this was not likely to be feasible. Instead, 
operations were coded according to operation site (e.g. upper limb), specialty 
(e.g. orthopaedic), and minor or major classification. Operation codes used are 
presented in table 5.1.  
Patients with well-controlled pain, described as a pain intensity score of 3 or 
less on the same (0-10) numerical pain scale used to identify cases, were 
asked to complete the same questionnaire. The same exclusion criteria were 
applied to this group of patients. Patients in the control group were recruited at 
random having been initially identified by surgery type. 
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Operation Example Code 
Upper abdominal minor Laparoscopic cholecystectomy 1 
Upper abdominal major laparoscopic Nissen fundoplication 2 
Upper abdominal major open Pancreatectomy 3 
Lower abdominal minor  Appendicectomy 4 
Lower abdominal major laparoscopic Hemicolectomy 5 
Lower abdominal major open Anterior resection 6 
Gynaecological minor Hysteroscopy 7 
Gynaecological major laparoscopic Laparoscopic oophorectomy 8 
Gynaecological major open Hysterectomy 9 
Urology minor Cystoscopy 10 
Urology major Nephrectomy 11 
Abdominal wall Hernia repair 12 
Orthopaedic upper limb minor K-wire to hand fracture 13 
Orthopaedic upper limb major Shoulder decompression 14 
Orthopaedic lower limb minor Knee arthroscopy 15 
Orthopaedic lower limb major Fractured femur 16 
Orthopaedic pelvic Fixation of pelvic fracture 17 
Thoracic minor Rigid bronchoscopy 18 
Thoracic major Thoracotomy 19 
Cardiothoracic sternotomy  20 
Breast minor Augmentation/reduction 21 
Breast major Mastectomy 22 
Plastics minor Split skin graft 23 
Plastics major Reconstruction surgery 24 
Maxillo-facial/ENT minor Tonsillectomy 25 
Maxillo-facial/ENT major Neck dissection 26 
Spinal minor Discectomy 27 
Spinal major Fusion 28 
Vascular abdominal major Open aneurysm repair 29 
Vascular lower limb minor Varicose veins 30 
Vascular lower limb major Amputation 31 
Vascular upper limb minor Fistula formation 32 
Vascular upper limb major Amputation 33 
 
Table 5.1 Operation codes and examples used when matching controls with cases in the matched 
cohort evaluation study. 
ENT = Ear Nose and Throat surgery 
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5.2.2 Questionnaire design 
From the Delphi survey presented in chapter 4, expert consensus concluded 
that 9 items were important in diagnosing acute neuropathic pain (table 14). 
The questionnaire design sought to incorporate 6 of these items: spontaneous, 
shooting, burning, dysaesthesia, allodynia and hyperalgesia. Where possible, 
questions relating to these symptoms were based on those already used in 
existing screening questionnaires, with known face validity and acceptability. 
The final questionnaire used is presented in appendix 8. 
Question 1 is based on S-LANSS item 4, and is designed to elicit spontaneous 
pain. 
Question 2 is based on S-LANSS item 5, and relates to the symptom of burning 
pain. 
Question 3 investigates the presence of shooting pains. 
Question 4 is designed to elicit the symptom of dysaesthesia, and is based on 
item 1 of the LANSS questionnaire. 
Questions 5 to 8 are self examination items designed to elicit allodynia, 
hyperalgesia or sensory loss, adapted to the post-operative setting. 
Additional data collection included analgesia used since the operation, planned 
analgesic use, operation type, number of hours or days post-surgery, 
demographic data and 0-10 numerical rating of pain intensity. 
5.2.3 Statistical methods 
Odds ratios for each questionnaire item were calculated. Odds ratios were 
estimated using conditional maximum likelihood estimates, and Fisher’s exact 
137 
 
test of statistical significance (to account for the relatively low sample sizes). 
Demographic and treatment variables were examined for statistically significant 
differences. Fisher’s exact test was used for categorical variables, and Mann 
Whiney U tests for continuous variables. Sample size calculations were 
performed for a prevalence of acute neuropathic pain of 8% (based on the 
findings presented in chapter 3), and for a range of neuropathic pain prevalence 
rates and odds ratios based on the results of the pilot study. Sample size 
calculations were performed based on the methods described by Wang et al., 
(2002).320 Statistical advice and analysis was provided by Sarah Marley 
(statistical consultant). 
 
5.3 Results 
5.3.1 Study recruitment 
In the 10-month period from July 2012 to May 2013, 24 cases were identified 
from referrals to the acute pain team at the Royal Cornwall Hospital, Truro. 
Twenty-one matched controls were identified by operation type. During the first 
six months of recruitment, only 8 cases were identified. In order to improve 
recruitment, the time period for recruiting cases was extended beyond 96 hours 
after surgery, and the exclusion criteria of peripheral nerve block was removed. 
Following changes to the protocol, in the four months from February to May 
2013, a further 16 patients were recruited. No patients were recruited beyond 5 
days after surgery. 
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5.3.2 Matched case controls 
Details of the operations received by patients recruited to the pilot study are 
presented in table 5.2. Seventy one percent (n=15) of cases were major lower 
limb orthopaedic, 14% (n=3) were laparoscopic gynaecological cases, 10% 
(n=2) were major upper limb orthopaedic and 5% (n=1) were major 
laparoscopic lower gastro-intestinal surgery. 
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Case operation Control operation Operation code 
Revision total knee 
replacement 
Revision total knee 
replacement 
16 
Revision total knee 
replacement 
Revision total hip 
replacement 
16 
Total knee replacement Total knee replacement 16 
Total knee replacement Total knee replacement 16 
Total knee replacement Total knee replacement 16 
Total knee replacement Total knee replacement 16 
Total hip replacement Total hip replacement 16 
Total hip replacement Revision total hip 
replacement 
16 
Dynamic hip screws Hip hemiarthroplasty 16 
Revision total hip 
replacement 
Revision total hip 
replacement 
16 
Resection of tibia Femoral osteotomy 16 
External fixation of ankle 
fracture 
Open fixation of ankle 
fracture 
16 
Femoral nail Open fixation of femoral 
fracture 
16 
Tibial nail Revision total hip 
replacement 
16 
Ankle fusion Patello-femoral replacement 16 
Arthroscopic subacromial 
decompression of shoulder 
Arthroscopic rotator cuff 
repair 
14 
Arthroscopic subacromial 
decompression of shoulder 
Arthroscopic rotator cuff 
repair 
14 
Laparoscopic hysterectomy Laparoscopic hysterectomy 8 
Laparoscopic hysterectomy 
& oophorectomy 
Laparoscopic hysterectomy 8 
Laparoscopic oophorectomy 
and vaginal repair 
Laparoscopic cystectomy 8 
Laparoscopic ileocaecal 
resection 
Laparoscopic hemicolectomy 5 
 
Table 5.2 Operation details of the cases recruited to the matched cohort study, and their controls. 
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5.3.3 Questionnaire design 
Analysis of the pilot data demonstrates some inconsistent responses to the 
examination items (questions 5 to 8). Patients answering ‘yes’ to question 5 
(“The painful area feels no different from the non-painful area”) should in theory 
answer ‘no’ to questions 6 to 8, which seek to elicit hyperalgesia, allodynia, or 
numbness.  
The pilot data shows that 11 (46%) patients in the case group and 2 (8%) 
patients in the control group answered ‘yes’ to question 5, and then ‘yes’ to at 
least one other examination question eliciting different sensations to normal.  
Incomplete data were present for 2 cases and 2 controls. All missing data 
related to one or more examination items. The two reasons given for incomplete 
data collection were an inability to examine the operative site (for example 
presence of a plaster cast), or the patient unwilling to touch the skin over the 
operated area. 
5.3.4 Odds ratio calculations for individual questionnaire items 
There is evidence (at the 5% level) that, compared to controls:  Cases have a 
greater odds of suffering pain that comes on suddenly in bursts for no apparent 
reason, even when completely still (Q1); Odds ratio (OR) = 9.16; 95% 
Confidence Interval (CI) = (1.83, 64.38); p-value = 0.0036.  Cases have a 
greater odds of experiencing pain feeling like strange unpleasant sensations in 
the skin (Q4); OR = 14.11; 95% CI = (1.62, 686.69); p-value = 0.0089.  Cases 
have a greater odds of feeling discomfort like pins & needles, pricking or 
burning that is different from the non-painful area (Q6); OR = Inf; 95% CI = 
(1.68, Inf); p-value = 0.0086.  Cases have a greater odds of the painful area 
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being more sensitive on examination than a non-painful area, (but not more 
sensitive than the patient had expected after surgery) (Q7); OR = 27.03; 95% CI 
= (4.35, 317.75); p-value < 0.0001.  All of the other questions (except for Q5) 
have odds ratios greater than 1, but the results do not reach statistical 
significance. Results for each questionnaire item are presented in table 5.3. 
Questionnaire 
Item 
Cases* 
(N=) 
Controls* 
(N=) 
Odds Ratio 95% C.I. P Value 
1 13 3 9.16 1.83-64.38 0.0036§ 
2 7 2 4.58 0.72-51.74 0.13 
3 9 3 4.34 0.85-30.09 0.0855 
4 9 1 14.11 1.62-686.69 0.0089§ 
5 10 14 0.49 0.1-2.12 0.3332 
6 7 0 Infinity 1.68-Infinity 0.0086§ 
7 16 2 27.03 4.35-317.75 <0.0001§ 
8 9 5 2.35 0.54-11.46 0.3264 
 
Table 5.3 The number of patients answering each questionnaire item positively in the case and 
control groups of the matched cohort study, and the calculated odds ratios. 
Number of patients answering item “yes”, § Statistically significant result (p=<0.05), N = number of 
patients, C.I. = confidence interval 
 
 
5.3.5 Summary statistics for demographic and treatment variables 
Statistically significant differences were observed between cases and controls 
for the following variables: pain score (median cases=7, median controls=2; 
p<0.0001), number of hours post-operatively the assessment was performed 
(median cases=24, median controls=10; p=0.0083), current PCA morphine 
usage (cases=10(47.6%), controls=2(9.5%); p=0.0148), nerve block current 
usage (cases=7(33.3%), controls=0; p=0.0086). Results are presented in full in 
table 5.4. 
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Characteristic Statistic Case Control p-value 
Sex Male, n (%) 5 (23.8) 11 (52.4) 0.1109 
 Female, n (%) 15 (71.4) 10 (47.6) - 
Unknown, n (%) 1 (4.8) 0 (0) - 
Age  Median 55.5 72 0.1001 
Mean 54.35 65.14 - 
Pain Score Median 7 2 <0.0001§ 
Mean 7.43 2.29 - 
Emergency Yes, n (%) 4 (19) 1 (4.8) 0.3433 
No, n (%) 17 (81) 20 (95.2) - 
Hours Post-op Median 24 10 0.0083§ 
Mean 29.71 21.43 - 
Paracetamol Current, n (%) 20 (95.2) 20 (95.2) ~1 
NSAIDs Current, n (%) 11 (52.4) 5 (23.8) 0.1109 
PCA morphine Current, n (%) 10 (47.6) 2 (9.5) 0.0148§ 
PCA fentanyl Current, n (%) 2 (9.5) 1 (4.8) ~1 
Oramorph/Oxycodone Current, n (%) 9 (42.9) 11 (52.4) 0.7579 
Tramadol Current, n (%) 6 (28.6) 1 (4.8) 0.0931 
I.M./S.C. Morphine Current, n (%) 4 (19) 1 (4.8) 0.3433 
I.V. Morphine bolus Current, n (%) 0 (0) 0 (0) ~1 
Ketamine Current, n (%) 0 (0) 0 (0) ~1 
Gabapentin Current, n (%) 0 (0) 0 (0) ~1 
Pregabalin Current, n (%) 1 (4.8) 0 (0) ~1 
TCA Current, n (%) 1 (4.8) 0 (0) ~1 
Nerve block  Current, n (%) 7 (33.3) 0 (0) 0.0086§ 
Regional anaes Catheter Current, n (%) 1 (4.8) 0 (0) ~1 
 
Table 5.4 Summary statistics for demographic and treatment variables of patients recruited to the 
matched cohort study 
§ p<0.05, PCA (patient controlled analgesia), I.M (intramuscular), S.C. (subcutaneous), I.V 
(intravenous), TCA (tricyclic antidepressant, n= number of patients 
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5.3.6 Sample size calculations 
Sample size calculations are provided for testing the equality of the odds of 
experiencing post-operative neuropathic pain for case and control patients. 
Three estimates of the prevalence of neuropathic pain in control subjects (8%, 
10% and 14%), and three estimates of the odds ratio between cases and 
controls (3, 6 and 9) are given in table 5.5. These are based on the prevalence 
of acute neuropathic pain found in thoracic surgery patients (8%), the 
prevalence of patients answering “yes” to question 1 of the pilot study (14%) 
and a figure of 10% to reflect a conservative midpoint between the two.  A 90% 
power and 5% significance level are assumed throughout. 
 
Control 
Prevalence 
Case 
Prevalence 
OR Power Alpha N (per group) N (total) 
8% 21% 3 90% 5% 171 342 
10% 25% 3 90% 5% 143 286 
14% 33% 3 90% 5% 112 224 
8% 34% 6 90% 5% 59 118 
10% 40% 6 90% 5% 50 100 
14% 49% 6 90% 5% 40 80 
8% 44% 9 90% 5% 38 76 
10% 50% 9 90% 5% 33 66 
14% 59% 9 90% 5% 27 54 
 
Table 5.5 Sample size calculations for a fully powered matched cohort investigation of 
postoperative neuropathic symptoms and signs, based on the results of the pilot investigation. 
OR = odds ratio, N = number of patients 
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5.4 Discussion 
This pilot study reports on a number of research processes important to the 
success of the main case control cohort study. In addition, it gives an initial 
assessment of the primary outcome of the study: to determine if neuropathic 
symptoms and signs are more common in patients with poorly controlled post-
operative pain that is unresponsive to opioids. 
Preliminary analysis of the pilot data show that the odds of patients developing 
neuropathic symptoms and signs are much higher amongst patients with poorly 
controlled post-operative pain that is unresponsive to opioids, compared to 
those with well-controlled pain. In particular, questions 1, 4, 6 and 7 
demonstrate statistically significant differences between the two groups with 
odds ratios between 9 and infinity. This points towards confirmation of the 
results of the Delphi survey indicating that poorly controlled post-operative pain 
unresponsive to opioids is an important indicator of acute neuropathic pain. 
Questions 1 and 4 refer to the presence of spontaneous pain and 
dysaesthesias, and questions 6 and 7 refer to the examination items testing for 
sensory abnormalities such as allodynia and hyperalgesia.  
Interestingly, in this small sample, the prevalence of each neuropathic symptom 
or sign in the control group tended to be higher than would be expected by the 
previously published prevalence studies of acute neuropathic pain. More than 
9% of control patients answered “yes” to five of the 7 neuropathic questionnaire 
items, compared to 3-8% of patients in other studies.174, 257, 321 This suggests 
that in our control group the prevalence of neuropathic symptoms may be 
higher than previously reported, however, importantly the distinction must be 
made between the reporting of one neuropathic sensory descriptor and the 
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diagnosis of neuropathic pain. No single descriptor is pathognomic of 
neuropathic pain, and validated screening tools rely on identifying a cluster of 
characteristic symptoms/signs for their accuracy. In fact, if the prevalence of 
individual neuropathic symptoms in the control group is compared to the 
answers for each individual question of the LANSS (performed post-operatively 
in thoracic surgery patients) in Chapter 3, the results are not too dissimilar 
(table 5.6)  
 
Pain descriptor Control prevalence Thoracic surgery prevalence 
Dysaesthesias 14% 11% 
Spontaneous  14% 20% 
Burning 10% 17% 
Allodynia 0% 4% 
 
Table 5.6 Comparison of neuropathic symptom prevalence in the control group of the matched 
cohort investigation, and thoracic surgery population (from data presented in Chapter 3) 
 
Recruitment was initially disappointing, and threatened the viability of both the 
pilot and main study. After discussion with the acute pain team, two main 
barriers to recruitment were identified: the 24-96 hours post-operation time 
period for eligibility, and the exclusion of patients who had received nerve 
plexus or peripheral nerve blocks at the time of operation. These criteria were 
originally included to reduce the inclusion of patients with poorly controlled pain 
for reasons other than a significant neuropathic component to their pain. 
Without these criteria, there was concern that patients who had received a local 
anaesthetic nerve block would be recruited in the transition period between the 
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nerve block wearing off and the establishment of other forms of analgesia. 
However, local anaesthetic nerve blocks are a common form of analgesia in our 
institution, and after discussion with the acute pain team, it was felt that a 
significant number of patients were being excluded from recruitment because 
they had received this form of analgesia. In addition, it was felt that the inclusion 
criteria “Standard opioid therapy used” meant patients would not be recruited 
before they had failed a trial of opioid therapy.  
Additionally, the decision was made to extend the timeframe of recruitment to 
that of a common definition of acute pain – pain of less than 3 months duration. 
This would allow the acute pain team to recruit patients with delayed poor pain 
control after their operation, presenting whilst still inpatients after their surgery. 
Martinez et al., (2012) demonstrated that in the iliac crest bone harvest model, a 
proportion of patients develop neuropathic pain between 48 hours and 1 month 
after surgery.258 The extended recruitment period would potentially allow 
inclusion of these patients.  
Following these changes to the protocol, the rate of recruitment more than 
doubled. However, only 24 cases were identified during the 10-month 
recruitment period. This recruitment rate suggests a multicentre final study 
would be needed to ensure adequate case numbers within a reasonable 
timeframe. A multicentre study may improve the generalisability and validity of 
the final results by including a broader range of surgical procedures and 
approaches. In addition, the ability to compare data collected from different 
sites can improve the detection of errors or problems compared to single centre 
studies.322 Multicentre studies do however require strict adherence to research 
protocols in order for the results to be meaningful. For example, in this case, a 
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multicentre cohort study would need strict inclusion criteria to ensure that each 
case has had an adequate trial of strong opioids, as acute pain service 
protocols and practice differ across hospitals. 
This pilot study also demonstrated some potential problems with the 
questionnaire design. The examination items demonstrated inconsistencies in 
the way the questions were answered, with some patients reporting the site of 
pain feeling no different to a non operated area, then going on to report signs of 
sensory dysfunction. The most likely explanation for this result is that the 
questionnaire wording is sufficiently ambiguous to confuse those administering 
and completing the assessment. The questions were originally adapted from 
the LANSS and S-LANSS screening tools, however in the original form, patients 
have a choice of reporting the painful site as feeling normal or abnormal, they 
are not given the option of choosing both responses as in the pilot 
questionnaire.  
A perhaps less likely explanation, although one that should be considered, is 
that both the operated site and the “non-painful area” patients are asked to use 
as a comparator, are exhibiting sensory changes in the post-operative period. 
As discussed in the initial chapter of this thesis, the process of central 
sensitization can be initiated by surgery, and can cause areas of secondary 
hyperalgesia extending beyond the site of surgical injury.104, 123 Patients with 
central sensitization may also present with areas of allodynia and temporal 
summation, and in theory this may account for the seemingly inconsistent 
responses of some patients to the examination items of the questionnaire, 
particularly if these areas are remote to the original site of surgery.122 
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In this pilot study, cases were matched with controls undergoing similar surgery. 
Type of surgery was considered likely to be a confounding risk factor for the 
development of acute neuropathic pain, and frequency matching can ensure 
that cases and controls have the same distribution of operation types. This 
helps to remove any potential bias in the odds ratio estimates due to this 
confounding factor. Frequency matching can also add to the efficiency of the 
final study if an analysis stratified by operation type is performed.  
Rather than matching by exact operation type, controls were identified by site, 
approach and major/minor surgical category. This was felt to be a pragmatic 
approach to recruiting controls, as many operations, particularly emergency or 
trauma cases require individualistic surgery that may not be repeated frequently 
enough to allow realistic control matching.  
The disadvantage of matching controls in this way is the degree to which the 
confounding risk is eliminated from subsequent analysis. For example, can we 
assume that patients having a total knee replacement have a similar surgical 
risk of developing acute neuropathic pain to those undergoing total hip 
replacement? There is little direct evidence in the acute setting to show that this 
is not the case. In the chronic post-surgical pain setting the prevalence of 
neuropathic pain following knee and hip arthroplasty is similar (3.6% vs. 5.2%), 
and systematic reviews have combined the results of both procedures when 
reporting overall prevalence rates.135, 268, 323 However, other surgical sites may 
show greater differences between exact operations, depending on the proximity 
of neural structures. For example, inguinal hernia repair and appendicectomy 
could be matched together, although operations in the groin are known to have 
a high incidence of chronic neuropathic pain.135 In this pilot study, 38% of cases 
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had an exact match with operation type therefore although surgery as a 
confounding factor is likely to be reduced, it may not be removed completely. 
Whilst there was no statistically significant difference in age or gender between 
the two cohorts in this pilot study, there were some important differences, which 
may have influenced the final results. There was a significant difference in the 
timing of assessments between the case and control groups, (mean of 30 and 
21 hours respectively). The inclusion criteria for the study were changed from a 
relatively tight post-operative window (24-96 hours following surgery) to include 
patients from the immediate post-operative period to 3 months after surgery. 
Although this may have improved recruitment, it has introduced another 
possible confounding factor. Theoretically, a case presenting with poorly 
controlled pain 2 months after surgery could be matched with a control from 2 
hours after their operation. This may influence the results as it seems a 
proportion of patients develop neuropathic pain sometime between the 
immediate postoperative period and 3 month follow-up.258, 321 Although the 
differences in the cases and controls in the pilot study are not this extreme, it 
may be that in light of the revised inclusion criteria, patients should be matched 
according to time following surgery, particularly if there are significant outliers. 
Whilst this may seem attractive this does however present a potential problem 
for recruiting controls, as patients with well-controlled pain will be at home and 
therefore impossible to identify and recruit. 
A further change in the protocol allowed patients to be recruited if they had 
received a peripheral nerve block. Interestingly, there was a significant 
difference in nerve block use between the case and control groups in the pilot 
study (33% vs. 0%). There are two potential issues with this result. The first is 
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that patients are being recruited in the transition period between the block 
wearing off and establishment of alternative analgesic techniques. The second 
is that neuropathic symptoms may be related to the block itself, for example a 
temporary neuropraxia from the injection at the time of operation. This remains 
a further limitation of the pilot study results. 
The results of this pilot study point towards confirmation that patients with poorly 
controlled post-operative pain are more likely to experience pain symptoms and 
signs suggestive of neuropathic pain. However the study sample size is small 
and further investigation is needed with a fully powered study for these results 
to be confirmed. 
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6 General discussion and conclusion 
 
Over the last thirty years there has been huge progress in the understanding of 
neuropathic pain, both in basic science and pathophysiology and in areas of 
diagnosis and treatment. Yet neuropathic pain is still thought of principally as a 
chronic disorder, with little focus on investigating neuropathic pain around the 
time of onset, in the acute phase. Perhaps this has been because many 
disease processes leading to neuropathic pain lack a definitive starting point, 
with insidious onset of symptoms, such as in diabetic peripheral neuropathy, the 
norm. 
Surgery, in contrast, does have a definitive point of onset and offers the 
opportunity to study disease processes such as the development of pain from 
the initial putative cause. Chronic neuropathic pain is increasingly recognized 
as a major complication of surgery, with many studies reporting the prevalence 
of this problem ranging from less than 5% to greater than 50% after a variety of 
surgical procedures.135 Yet little is known about the period between surgery and 
the development of chronic neuropathic pain i.e. the acute postoperative phase. 
This is surprising, as anecdotally, the existence of neuropathic pain in the acute 
postoperative period has been well documented over many years. In the 1970’s 
and 1980’s phantom limb pain following amputation, now considered a 
neuropathic pain condition, was reported to occur in the immediate 
postoperative period in up to 84% of patients.324, 325 In the 1990’s bodies such 
as The National Health and Medical Research Council (NHMRC) of Australia 
and the authors of review articles sought to highlight the issue of acute 
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neuropathic pain.326, 327 However, not until 2002 was the first estimate of the 
prevalence of this problem published following a prospective audit of patients 
referred to an acute pain service.174 Since then there has been comment on the 
problem, and case reports, but overall no further research investigating this 
area prior to the publication of the research presented in this thesis.163, 165, 328  
Identification of acute neuropathic pain following surgery is important, as we 
know that despite advances in drug development and delivery, a third of 
patients still suffer moderate to severe acute pain following surgery, a 
proportion largely unchanged since the 1950’s. Neuropathic pain is largely 
treated differently to nociceptive pain, and responds to medication such as the 
tricyclic antidepressants and gabapentinoids. It may be that a proportion of the 
one third of patients with poorly controlled postoperative pain have a 
neuropathic component that is unrecognized and undertreated. Identifying 
these patients opens new avenues for improving their pain management. 
Additionally, as acute neuropathic pain seems to be predictive of chronic 
neuropathic pain, it offers the opportunity to identify ‘at risk’ patients early in the 
disease process and explore disease-modifying interventions. 
The concept of acute postoperative neuropathic pain has been lent credence by 
developments in our understanding of the basic science of pain 
pathophysiology. Following nerve injury, a cascade of complex neurobiological 
events occurs that may result in neuropathic pain. Many of these changes to 
the central and peripheral nervous system begin rapidly following nerve injury. 
For example, in animal models of spinal nerve ligation injury, dramatic up 
regulation of Nav1.8 sodium channel proteins are apparent in distal nerves by 
day 2 following injury.329 Similar rapid up regulation of Nav1.3 sodium channels 
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occurs after nerve ligation, transection or constriction.329 Both these sodium 
channels have been implicated in the development of neuropathic pain, and 
may be responsible for features such as ‘spontaneous’ pain.329  
Another process implicated in the development of neuropathic pain is the 
activation of neuroimmune cells such as microglia following nerve injury. 
Microglia appear to have an important role in signaling to neurons in the dorsal 
horn, causing modulation of nociceptive processing. In particular, they may 
have a role in the development of hyperalgesia and allodynia after nerve 
injury.330 Microglia show signs of activation 24 hours following nerve injury, with 
a peak in the proliferation of cells at 3 days, suggesting neuropathic symptoms 
may be possible within this timeframe following nerve injury.330 Other changes 
to the central nervous system may also promote the early experience of 
neuropathic pain after surgery. Following nerve damage, the somatosensory 
cortex becomes reorganized, with inputs from the transected nerve expanding 
to three times the normal size within 1-2 days.331 Cortical reorganization has 
been implicated in the development of phantom limb pain following amputation, 
which is known to occur in the immediate postoperative period.332 
The focus of this thesis has been to expand scientific knowledge in the field of 
acute neuropathic pain following surgery. The research presented in this thesis 
has demonstrated that an existing screening tool for neuropathic pain (the 
LANSS) has important measurement properties in the chronic postoperative 
pain population.241 It has estimated the previously unknown prevalence of acute 
neuropathic pain in thoracic surgery patients using this screening tool, and 
demonstrated a link with the development of chronic neuropathic pain 3 months 
later.321 It has also explored how best to diagnose this problem, using 
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consensus methodology to gauge expert opinion and testing this in a clinical 
study with resulting identification of key diagnostic indicators of acute 
neuropathic pain.333 
One of the key findings of the research presented in this thesis has been to give 
a plausible estimate of the prevalence of acute neuropathic pain in an at risk 
surgical population. Eight percent of thoracic surgery patients demonstrated 
pain of predominantly neuropathic origin using the LANSS questionnaire. 
Importantly, patients with pre-existing neuropathic pain were excluded from the 
study, so a direct causal link with surgery was established. The figure of 8% is 
interesting as evidence suggests that gabapentin, a drug used to manage 
neuropathic pain, and unlikely to be helpful in nociceptive pain, has an NNT of 
11 when used in the postoperative period. It may be that the one in eleven 
patients benefitting from gabapentin in this scenario are experiencing a 
significant neuropathic component to their acute pain experience. In common 
with previous findings, this study also demonstrated a link between acute 
neuropathic pain and the development of chronic neuropathic pain. However, 
the LANSS screening tool, although demonstrated measurement level 
properties in the chronic postoperative pain population, was not designed to be 
used in the immediate postoperative period. The face validity of the tool in this 
context was questionable and therefore further exploration of factors likely to be 
indicative of acute neuropathic pain was warranted. 
The Delphi survey of acute pain specialists identified some interesting 
neuropathic pain discriminators that are not typically used in the diagnosis of 
chronic neuropathic pain, but may be helpful in the acute pain setting. Pain that 
is poorly controlled by opioids has some scientific basis for indicating 
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neuropathic pain, as nerve damage is known to alter the balance of hormones 
and receptors in the central nervous system that could impair the 
antinociceptive effects of opioids. Cholecystokinin (CCK) levels in the central 
nervous system are raised within days of nerve injury and contribute to an 
impaired opioid response.316 Opioid binding sites in the dorsal horn of the spinal 
cord are reduced within weeks of nerve injury.317 
The pilot study presented in chapter 5 indicates that this hypothesis may well be 
true, demonstrating that neuropathic symptoms and signs seem to be much 
more common in patients with poorly controlled postoperative pain that does 
not respond well to opioids. 
The field of neuropathic pain has seen significant change in the last 5 years, 
which has made research in this area challenging. For example, during the 
course of the research published in this thesis, the accepted definition of 
neuropathic pain has changed from “pain caused by damage or disruption of 
the nervous system” to “pain caused by a lesion or disease of the 
somatosensory nervous system”.2 Such changes are often controversial, and in 
this case led to confusion over whether or not to include conditions such as 
CRPS as neuropathic pain states. The implication for the research presented in 
this thesis was that the LANSS screening tool was validated using a cohort of 
patients that included those with CRPS.194 The LANSS and self-report version 
(S-LANSS) were used as screening tools to estimate the prevalence of acute 
and chronic neuropathic pain in the thoracic surgery population in chapter 3, 
although this study was performed prior to the change in neuropathic pain 
definition. 
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Not only has the definition of neuropathic pain changed during the course of this 
thesis, but also diagnostic criteria. A grading system for neuropathic pain was 
published by a body of experts in 2008, and was rapidly adopted by both the 
European Federation of Neurological Societies (EFNS) and the International 
Association for the Study of Pain (IASP).138, 179 This grading system proposed 
three levels of diagnostic certainty for neuropathic pain based on four criteria. If 
patients have pain in a neuro-anatomically plausible distribution, and a history 
of a relevant lesion or disease they have “possible” neuropathic pain. If they 
also demonstrate either confirmatory tests of positive (hyperalgesia, allodynia) 
and negative (hypoalgesia, hypoaesthesia) signs in the innervation territory of 
the damaged nerve, or confirmatory diagnostic tests (such as MRI or nerve 
conduction studies), they have “probable” neuropathic pain. If they have all 
these criteria they have “definite” neuropathic pain.138  
One problem with this grading system is a lack of clarity about which or how 
many sensory abnormalities are required to fulfill the criteria of neuropathic pain 
diagnosis. Further unanswered questions surround the role of verbal descriptors 
of neuropathic pain, which have played an important part in the development of 
neuropathic screening tools over the last ten years, yet do not play a part in the 
new grading system.  
Using the new grading system to diagnose acute neuropathic pain would be 
challenging. Sensory abnormalities around operative wounds are common, with 
positive signs (such as hyperalgesia) resulting from peripheral sensitization of 
nociceptors, and negative signs (such as hypoaesthesia) resulting from local 
anaesthetic use. Similarly, the logistics, availability and reliability of confirmatory 
tests such as EMG, nerve conduction studies and MRI are questionable in a 
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clinical setting. Although nerve conduction studies at the time of operation 
revealed nerve damage is common during thoracic surgery, there is no 
correlation with sensory abnormalities or pain 3 months later.66 Similar 
questions have been raised regarding the predictive qualities of MRI scanning. 
In patients with known lumbar disc herniation and sciatica, MRI findings do not 
correlate with pain symptoms at 1 year follow up.334 
In contrast to this approach to diagnosing neuropathic pain, one feature of the 
research presented in this thesis has been the value of verbal descriptors of 
neuropathic pain in the acute postoperative setting. The verbal description of 
dysaesthesia for example, scored very highly for importance (median 9/10) 
when acute pain experts are asked what they consider to be useful in the 
diagnosis of acute neuropathic pain. The presence of dysaesthesia in the 
immediate postoperative period was more predictive of the development of 
chronic neuropathic pain than any other symptom or sign of the LANSS, or 
indeed the total LANSS score in thoracic surgery patients (odds ratio 12.6 
versus 7.7 for a positive LANSS score). Similarly, the verbal description of 
dysaesthesia is far more common in patients with poorly controlled 
postoperative pain (that responds poorly to opioids) compared to those with 
well-controlled pain (odds ratio 14).  
Other verbal descriptors identified in this thesis as potentially useful indicators 
of acute neuropathic pain include spontaneous, burning and shooting pain. 
Patients with spontaneous pain have a significant odds ratio (3.4) for the 
development of chronic neuropathic pain, and spontaneous pain is more likely 
to be present in patients with poorly controlled pain in the postoperative period 
(odds ratio 9.16). There is a trend towards burning and shooting pain being 
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more common in patients with poorly controlled postoperative pain, although 
the odds ratios (4 for both) were non-significant. Similarly, the predictive 
qualities of burning pain for the development of chronic neuropathic pain were 
non-significant (odds ratio 3). 
The usefulness of verbal descriptors may extend beyond their diagnostic 
qualities, with limited evidence that they may predict response to analgesic 
medication.192 
In contrast to the results of verbal descriptors of pain, the limited bedside 
examination items examined in this thesis demonstrated less clear evidence of 
usefulness. Whilst the presence of allodynia and hyperalgesia were much more 
common in patients with poorly controlled postoperative pain (odds ratio infinity 
and 27 respectively) and were considered important by the consensus panel of 
experts, they had the lowest predictive value for the development of chronic 
neuropathic pain in the thoracic surgery group, with non-significant odds ratios 
of 1.2 and 2.2 respectively.  
Importantly, the LANSS item related to the presence of hyperalgesia can also 
be positive if hypoaesthesia is present (raised or lowered pin-prick threshold), 
and this may be a confounding factor between the study results in this thesis. 
Certainly, other authors have subsequently found that the area of secondary 
hyperalgesia around a wound in the postoperative period is related to the 
development of chronic postoperative pain, whereas hypoaesthesia is not.258 
This may account for the lack of predictive qualities of LANSS item 7 which can 
be scored positively in the presence of both hyperalgesia and hypoaesthesia. 
The results of Martinez et al., (2012) showing hypoaesthesia is not predictive of 
159 
 
the development of chronic postoperative pain is interesting in light of the 
results presented in chapter 5, which also show that the presence of numbness 
(question 8), although more common in the group with poorly controlled pain, is 
not significantly so compared to controls.  
These results are consistent with the finding that evidence of nerve damage 
elicited with quantitative sensory testing is present in both those with chronic 
postoperative pain, and those without pain. QST in this scenario fails to 
differentiate between pain free and pain present patients following hernia repair 
and mastectomy.273, 274 This points towards the observation that chronic 
postoperative pain does not develop in many patients despite significant 
sensory abnormalities. The research presented in chapter 3, showing a lack of 
the predictive value of the LANSS examination items supports this hypothesis 
and demonstrates this is true specifically for the development of chronic 
neuropathic pain. 
The results presented in this thesis suggest that verbal descriptors of 
neuropathic pain may have a useful role to play in the diagnosis of acute 
neuropathic pain, in contrast to the direction of neuropathic pain diagnosis 
taken in recent years by IASP and EFNS. In addition to verbal descriptors, pain 
that is poorly controlled despite the use of strong opioids may indicate a group 
of patients at risk of neuropathic pain in the postoperative period.  
A number of areas of further work are needed to help identify and define acute 
neuropathic pain. The results of the pilot study presented in chapter 5 need to 
be confirmed with a properly powered multi-centered study. Ideally, work should 
focus on developing diagnostic criteria for acute neuropathic pain, and 
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validating these against a gold standard. This would allow accurate 
measurement of the prevalence of acute neuropathic pain across surgery types. 
Unfortunately, the current gold standard for neuropathic pain diagnosis has 
moved away from using verbal descriptors and requires the use of confirmatory 
tests that elicit positive or negative sensory signs or confirm nerve lesion or 
disease. Quantitative sensory testing (QST) has become a popular way of 
detecting sensory abnormalities, typically testing mechanical pain thresholds to 
pinprick and pressure, mechanical detection thresholds to vibration and 
pinprick, hot/cold thresholds, allodynia and pain summation. QST protocols are 
available, and normal values have been described.335 However, little 
information is available to describe normal sensory changes in wounds 
immediately after surgery, or the time course of changes in sensory 
abnormalities. Before complex sensory testing can be used as a confirmatory 
step in the diagnosis of acute neuropathic pain, the ‘normal’ changes that occur 
after surgery need to be described, and this presents a further potential area of 
study although the feasibility of this approach would need to be tested. In 
particular, the acceptability of performing these sorts of examinations in the 
early postoperative period may be questioned, as well as more practical 
concerns such as the risk of introducing infection to wounds and the need to 
remove dressings or even plaster casts. 
The proportion of patients experiencing moderate to severe postoperative pain 
has remained remarkably static at 30% over the last 50 years, despite 
advances in our knowledge and understanding of nociceptive pain physiology 
and developments in the effectiveness and delivery of strong opioid analgesics 
and other forms of analgesia. One reason for this may be that we are under 
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recognizing and treating neuropathic pain in the immediate postoperative 
period. Neuropathic pain on the whole responds well to anti-neuropathic pain 
medications such as Amitriptyline or Gabapentin. If we use medications such as 
gabapentin on everyone in the postoperative period we know that the proportion 
of patients who gain benefit is small compared with more traditional acute pain 
analgesics, and the risk of unpleasant side effects considerable. The answer 
may therefore lie in identifying and treating those with acute neuropathic pain, 
rather than the majority with predominantly nociceptive pain after surgery. The 
difficulty has been identifying this small proportion of patients in the face of 
significant confounding factors, however this thesis has helped to advance 
knowledge in this area with the hope that this knowledge can be used to help 
develop diagnostic criteria or guidelines for acute neuropathic pain in the future 
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Appendix 2: The S-LANSS neuropathic pain screening tool 
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Appendix 3: Acute Neuropathic Pain Survey – Background 
Information 
Background 
This project is a web-based survey of expert opinion regarding the importance 
of different symptoms and signs in diagnosing acute neuropathic pain. 
Diagnosing neuropathic pain in the immediate post-operative period is 
challenging because of concurrent nociceptive pain from tissue damage, and a 
lack of published diagnostic criteria. Establishing a consensus on what 
symptoms and signs are important in diagnosing acute neuropathic pain will 
help inform future studies on the prevalence of this condition. 
Delphic survey methods 
The Delphic technique seeks to obtain consensus on the opinions of experts 
through a series of structured questionnaires. Experts complete the 
questionnaires anonymously, and the responses from each questionnaire are 
fed back in summarized form to the participants. The experts are then able to 
modify their individual responses in light of the group result. The initial 
questionnaire will generate a list of possible symptoms and signs, and in 
subsequent rounds, participants will be asked to rate the importance of these 
symptoms and signs on a 0 to 10 scale. Consensus is usually achieved after 2 
or 3 survey rounds. 
What will happen to the results? 
All individual results will be anonymised before being analysed. Individual 
responses will not be attributable in any report or publication.  The list of 
important symptoms and signs generated by the Delphic survey will be used in 
the design of a prospective observational study investigating the prevalence of 
these symptoms among the surgical population. 
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Appendix 4: Round 1 Delphi questions. 
1. What symptoms are important in the diagnosis of acute neuropathic pain 
in the immediate post-operative period? 
2. What clinical signs are important in the diagnosis of acute neuropathic 
pain in the immediate post-operative period? 
3. What investigations are useful in diagnosing a significant neuropathic 
element to post-operative pain? 
4. Do you use any other clinical tools to help diagnose acute neuropathic 
pain (e.g. screening questionnaires)? 
5. Please specify which tools you use 
6. What are the obstacles to diagnosing acute neuropathic pain in the 
immediate post-operative period? 
7. How long have you been involved in acute pain management at 
consultant level? 
8. Do you use anti-neuropathic pain medication in the immediate post-
operative period? 
9. How often do you use anti-neuropathic pain medication in the immediate 
post-operative period? 
10. How do you decide when to use anti-neuropathic pain medication in the 
immediate post-operative period? 
11. Which type of anti-neuropathic medication do you use in the immediate 
post-operative period? 
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Appendix 5: Round 2 Delphi questions 
1. How important to you are the following symptoms in diagnosing acute 
neuropathic pain (on a 0-10 scale where 0=completely unimportant and 
10=extremely important)? 
• Paroxysmal nature 
• Spontaneous nature 
• Sharp 
• Shooting 
• Pulsing 
• Stabbing 
• Lancinating 
• Burning 
• Pins and needles sensations 
• Dysaesthesias 
 
2. How important to you are the following signs in diagnosing acute 
neuropathic pain (on a 0-10 scale where 0=completely unimportant and 
10=extremely important)? 
• Changes in skin colour 
• Pain in an area of altered skin sensation 
• Allodynia 
• Hyperalgesia 
• Hyperpathia 
• Signs of autonomic dysfunction 
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3. How important to you are the following responses to acute pain 
management in diagnosing acute neuropathic pain (on a 0-10 scale 
where 0=completely unimportant and 10=extremely important)? 
• Difficult to manage pain 
• Poor response to Opioids 
• Good response to trial of anti-neuropathic agents 
• Good response to intravenous lidocaine 
 
4. How useful to you are the following tests in diagnosing acute neuropathic 
pain (on a 0-10 scale where 0=completely useless and 10=extremely 
useful)? 
• Neuropathic pain screening tools (e.g. the LANSS) 
• Quantitative sensory testing 
• Radiographic imaging (e.g. MRI) 
• Nerve conduction studies 
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Appendix 6: Criteria for referral to the Acute Pain Service 
Taken from “The Royal Cornwall Hospital Pain Services Referral Guideline” 
April 2012.  
Pain should be measured using the verbal descriptor or categorical scale: 
S = Sleeping 
0 = No pain 
1 = Mild pain 
2 = Moderate pain 
3 = Severe pain 
Patients whose pain scores are persistently 2 or 3 (moderate or severe) despite 
the regular administration of appropriate analgesia should be referred for 
specialist pain advice. 
Additional Acute Pain Service referral guidelines for post-operative pain: 
• Pain control problem despite the regular administration of appropriate 
analgesia. 
• Pain score regularly 2 or more on MEWS (modified early warning score) 
chart. 
• Pain not controlled with specific mode of analgesia 
(PCA/epidural/intrathecal). 
• Equipment concerns. 
• Unwanted side effects. 
• Medical/healthcare team request advice. 
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Appendix 7: Opioid treatment guidelines for the management of 
severe pain 
Taken from The Royal Cornwall Hospital “Analgesic advice for ward doctors” 
version 1. 
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Appendix 8: Matched cohort study questionnaire 
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